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The specific objective of the work described in this thesis was to 
study aspects of signal transduction in the post mortem brains of persons 
who had suffered from dementia of the Alzheimer type (DAT). There 
already exists much data describing the state of many neurotransmitter 
systems in the disease, but little information was available regarding the 
events that take place subsequent to receptor activation. Such knowledge is 
important in order to assess the potential for neurotransmitter replacement 
therapies in the treatment of Alzheimer's disease, as well giving further 
insight into the neurodegenerative mechanism of this disease.
The levels of the guanine nucleotide binding protein (G protein) a  
subunits, GsH, GsL, Gil, Gi2 and G sa , were measured by western blotting 
utilising highly specific anti-G protein antisera. Similarly, the messenger 
RNA (mRNA) encoding the G protein subunits Goa, Gia and G|3, as well as 
28S ribosomal RNA (28S mRNA), were analysed by northern blotting 
utilising radiolabelled oligonucleotide probes. In addition, the activities of 
the enzymes adenylate cyclase, sodium potassium dependent ATPase and 
choline acetyl transferase were assayed using standard methods.
(i) Effect of post mortem delay on different components of signal 
transduction in rat brain.
Since multiple parameters (e.g. levels of G proteins and their mRNAs, 
adenylate cyclase activity, etc.) were to be measured in post mortem human 
tissue, there was a concern that the delay between death and freezing of the 
tissue (the post mortem delay) would influence the reliability of any 
measurements made. This possibility was investigated by experiments in 
which rats were sacrificed and left at room temperature for 24 hours, or at 
4°C for up to 72 hours. The subsequent analysis of crude membranes 
prepared from the brains of these animals brains showed that no significant
14
degradation of G protein a  subunits, or loss of activity of adenylate cyclase
occurred
or sodium-potassium dependent ATPaseyover these time periods. In 
addition G protein encoding mRNA appeared to be relatively stable for up 
to 72 hours at 4°C, although there was a time dependent increase in 28S 
rRNA breakdown.
(ii) Measurement of G protein levels, and enzyme activities in DAT 
diseased post mortem human brain.
The mean activity of choline acetyl transferase (ChAT), assayed in the 
hippocampus of eight persons who had suffered from DAT, was 
significantly reduced to 34% of that observed in eight age-matched control 
subjects. Similarly, the mean activity of ChAT in DAT diseased frontal 
cortex was 54% of that measured in control subjects.
When adenylate cyclase activity was assayed in the same subjects, 
both the basal and fluoroaluminate stimulated activities were significantly 
reduced in DAT diseased frontal cortex, being 56% and 53% of the mean 
values observed in control subjects. In contrast, no statistically significant 
change was observed in the hippocampus.
A second membrane-bound enzyme, sodium potassium-dependent 
ATPase, was assayed in the same preparations. No statistically significant 
change in the mean activity of this enzyme was detected between DAT 
diseased and control subjects, in either the frontal cortex or hippocampus.
The western blot analysis of G protein levels also revealed no 
statistically significant difference, in either brain region, in the levels of GsH, 
GsL, Gil, Gi2 or Goa, between DAT and control subjects. However the 
mean ratio of GsH to GsL was found to be significantly reduced in DAT 
diseased frontal cortex, to a value of 72% of that observed in controls.
Thus while some components of the signal transduction process are 
preserved in DAT, other key components are significantly altered by the 
disease process.
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None of the parameters measured showed any significant linear 
correlation with either age or post mortem delay. However the activity of 
sodium potassium-dependent ATPase was significantly correlated with the 
length of time the tissue had been stored at -80°C, in both the frontal cortex 
and hippocampus (r = 0.746 and 0.707 respectively).
(iii) Distribution of G protein a  subunits and adenylate cyclase in human 
brain.
The levels of the G protein a  subunits, and the activity of adenylate 
cyclase, were measured in five brain regions obtained from three control 
subjects. Adenylate cyclase, Gil, Gi2 and Goa were similarly distributed 
throughout the brain, each possessing their highest levels in the frontal 
cortex, and lowest in the pons. However the distributions of GsH, and 
especially GsL, were dissimilar to that of the other a  subunits and adenylate 
cyclase. In addition, an extra "Gsa-like" immunoreactive band, which 
migrated slightly more slowly than GsL, was observed in the western blot 
analysis of human neostriatum. It is suggested that this species may be the 
G protein a  subunit, Golfa, which is normally associated with olfactory 
neurons.
Similar experiments demonstrated that GsH, Gil, Gi2, Goa and 
adenylate cyclase were more strongly expressed in cortical grey matter than 
white, with the opposite being true for GsL.
(iv) Analysis of G protein encoding mRNA in post mortem human brain.
The levels of the mRNA encoding the G protein subunits Gsa, G01 
and G{32 were measured, by northern blotting, in the frontal cortex and 
hippocampus of six DAT diseased subjects, and in six age-matched control 
subjects. There was no significant difference, in either brain region, between 
the control and DAT diseased groups, for any of the G protein mRNAs 
measured.
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The degree of intersubject variability was very high, giving an 
average coefficient of variation, or CV, (SD as percentage of mean) of 65%, 
with the highest CV being 92%, observed in the measurement of Gpj mRNA 
levels in the frontal cortex. This compares with an average CV of 
approximately 30%, observed in the measurement of G protein levels, or 
enzyme activities.
The extent of generalised RNA degradation was assessed by 
detecting the breakdown products of 28S rRNA. RNA degradation was 
present in tissue samples from every human subject studied. The extent of 
28S rRNA degradation in each subject was found to be related to the levels 
of G protein mRNA detected. In addition, the degree of RNA degradation 
in human subjects was found to be very variable and unaffected by the 
presence of DAT. RNA degradation (and G protein mRNA levels) were not 
significantly correlated with subject age, post mortem delay or storage time.
The effect that periods of ischemia, and freeze/thawing of tissue, had 
upon RNA integrity was investigated in rat brain. A single cycle of freeze/ 
thawing greatly increased the rate of RNA degradation, while three hours of 
permanent focal forebrain ischemia had little effect upon RNA integrity.
The variable extent of RNA degradation means that great care must 
be taken to ensure the validity of RNA analyses undertaken in human 
postmortem brain, in order to avoid drawing incorrect conclusions from 
such studies.
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I. INTRODUCTION
1. Introductory comments.
The evolution of complex multicellular organisms has necessitated 
the development of mechanisms which allow intercellular communication to 
take place. This is vital for the co-ordination of body functions, as well as in 
mediating a response to external stimuli. Cellular communication is of 
particular importance in the central nervous system which, being comprised 
of fairly simple cell types, relies for its function on the interactions which 
take place between individual cells. The study of these mechanisms has 
revealed that what is an apparently simple process, namely the release of a 
transmitter substance by one cell eliciting a response in another, is 
associated with an array of complex molecular events. The major 
components of such processes, for example neurotransmitter receptors, G 
proteins, and protein kinases, will be described in the following section.
The ubiquitous and important nature of these systems makes it likely 
that they are involved in a variety of disease states. Indeed, there is much 
current interest in the role that such processes play in ailments such as 
diabetes, heart disease and affective disorders of the brain (described in 
Section 3). One disease in which dysfunction of intercellular communication 
has clearly taken place, is dementia of the Alzheimer type (DAT), a severe 
neurological disorder prevalent in later life. The role which different 
neurotransmitters play in the disease, as well as the receptor proteins to 
which they bind, has been extensively studied over the last two decades. It 
has become apparent however that, in many cases, the binding of 
transmitter to a receptor is only the first in a series of events which cause a 
response to occur in the responding cell. These components, distal to the 
activation of receptors, have received relatively little attention in DAT 
which, given their demonstrated involvement in other neurological 
disorders, is a situation which requires to be remedied.
16
Tissue samples from the human subjects used in this study have 
already been used in a variety of other investigations. For example, that of 
Dewar et al. (1990) has indicated that alterations in the levels of G proteins or 
adenylate cyclase may have occurred in DAT, while Chalmers et al. (1990) 
and Dewar et al. (1991) have observed changes in the levels of a number of 
different receptor proteins. This thesis builds on these results by using 
biochemical techniques to measure both the levels and functioning of a 
variety of different moieties involved in the signal transduction process.
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2. G protein coupled signal transduction.
2.1 Overview.
The elucidation of the processes by which the release of a transmitter 
substance (also referred to as hormones or agonists) by one cell causes a 
response in another is central to the understanding of how the central 
nervous system (CNS) functions at a molecular level. Typically this relies on 
the binding of the transmitter to a receptor molecule on the extracellular 
surface of the cell membrane. This binding event, or signal, must be 
communicated, or transduced, across the plasma membrane allowing the 
cell to respond in some way to the stimuli - hence signal transduction. In 
some cases the neurotransmitter binds directly to an ion channel causing it 
to open or close (ionotropic receptors), examples of this being the GABAa 
receptor (Sieghart, 1989), as well as several types of glutamate receptor 
(Farooqui & Horrocks, 1991). However in other cases the occupied receptor 
does not, in itself, cause any intracellular events to occur, but instead 
activates a second class of proteins termed heterotrimeric guanine 
nucleotide binding proteins (G proteins). These in turn modulate the 
activity of a range of enzymes and ion channels, the purpose of which are to 
cause some form of change within the cell. This multistep process possesses 
the potential for more varied, and finer, control than is possible for 
ionotropic receptors.
G proteins are part of a super family of guanine nucleotide binding 
proteins, which includes the initiation and elongation factors of protein 
synthesis, and the small GTP binding proteins such as the ras-related family 
of proto-oncogene products (Bourne et al., 1991). In view of their ability to 
bind guanine nucleotides, it is not surprising that the main feature of G 
protein coupled signal transduction systems is their requirement for GTP 
(Casey & Gilman, 1988). The first indications that such systems existed 
came from Rodbell et al. (1971) who demonstrated that the stimulation of 
adenylate cyclase by glucagon in liver was dependent upon GTP, a
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requirement which was subsequently found to be due to the presence of the 
adenylate cyclase stimulatory G protein, or Gs (Northup et al., 1980). A large 
number of other G proteins have subsequently been identified having 
functions such as the inhibition of adenylate cyclase (Hildebrandt et al., 
1983), the regulation of phospholipid metabolism (Birnbaumer et al., 1990) 
and the gating of ion channels (Sternweis & Pang, 1990). In addition the 
activity of G proteins can be modulated by a wide variety of receptors such 
as muscarinic, adrenergic and serotonergic (Birnbaumer et al., 1990).
2.2 Mechanism of G protein action.
Despite being able to associate with a wide range of receptors and 
effectors, all G proteins possess a similar heterotrimeric structure composed 
of a , 3 and y subunits (Lochrie & Simon, 1988). The a  subunits, of which 
many forms exist, confer receptor and effector specificity upon the G 
protein, whilst the 3 and y subunits are required for the expression of G 
protein activity (Kanaho et al., 1984; Florio & Sternweis, 1989), and are 
thought to be interchangeable between different a  subunits in a non 
discriminating manner (Birnbaumer et al., 1990). As well as their similarities 
in structure, each G protein appears to have a similar mechanism of action. 
Fundamental to this process is the ability of the a  subunit to bind GTP and 
subsequently hydrolyse it by means of an intrinsic GTPase activity 
(Pedersen & Ross, 1982). In its inactive state the a  subunit is bound to GDP 
and complexed to the 3 and y subunits (Figure 1). However when this 
trimeric structure interacts with an occupied receptor protein, GDP is 
exchanged for GTP, and the receptor-a-3l complex dissociates to give 
receptor, 3y subunits and free GTP-bound a  subunit (Taylor, 1990). The a  
subunit can then interact with specific effector proteins in the membrane, 
such as adenylate cyclase, and modulate their activity. Finally the GTPase 
activity of the a  subunit hydrolyses the bound GTP to GDP, causing the a  
subunit to reassociate with the 3y subunits, thereby returning the G protein
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to its inactive state. It is not certain at what stage the a  subunit actually 
becomes competent to modulate effector activity, since Codina et al. (1984) 
have demonstrated that, under certain conditions, a GTP-bound o <3y 
structure can be isolated. It is therefore possible that dissociation of the a  
subunits from the 3 and y subunits is not mandatory for G proteins to exert 
control over effectors; a feature which may allow a more rapid response to 
the binding of transmitter molecules. The mechanism of G protein action 
therefore takes the form of a cycle, which is activated by the presence of 
transmitter bound receptors, and "switched off" by the hydrolysis of GTP. 
This GTPase activity can easily be measured by virtue of the a-subunits 
possessing a higher affinity for GTP (low Km GTPase) than the other 
GTPases which are present in the cell (high Km GTPases) (Cassel & Selinger, 
1976). As might be expected, low Km GTPase activity is enhanced in the 
presence of certain agonists, a feature which has been useful in determining 
which receptors are coupled to G proteins (Cassel & Selinger, 1976; Franklin 
& Hoss, 1984). However low Km GTPase activity is also measurable in the 
absence of agonists, which indicates that there is a continuous basal rate of 
activation of G proteins. This feature may be important in determining the 
activity of effector proteins in the absence of external stimuli. The formation 
of active a  subunits can also be stimulated by the addition of non- 
hydrolysable analogues of GTP, such as guanyl-imido-diphosphate 
(GppNHp), which bind to the a  subunit and permanently activate it 
(Schramm & Rodbell, 1975). A similar action is also performed by 
fluoroaluminate (AIF^-), which also binds to and activates the a  subunit 
(Bigay et al., 1987). However this requires that the a  subunit is in its GDP- 
bound form, leading to the proposal that fluoroaluminate acts as a high 
affinity phosphate analogue, which binds next to the 3 phosphate of GDP 
mimicking a y phosphate group, hence converting the a  subunit to its active 
conformation (Bigay et al., 1987). One further feature of G protein coupled 
signal transduction is that the agonist bound receptor protein can exist in
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two different conformations, each of them possessing a different affinity for 
agonists (Iyenger et al., 1980; Rojas et al, 1985; Koo et al, 1983). The high 
affinity state is thought to be indicative of a receptor G protein complex, 
with the low affinity state representing free receptors (Taylor, 1990; 
Birnbaumer et a l, 1990). The addition of non-hydrolysable GTP analogues 
causes the conversion of high affinity to low affinity agonist binding, since it 
causes the formation of activated a  subunits, which then dissociate from the 
receptor (Figure 1).
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Figure L
The cyclical nature of G protein function.
A = Agonist, Rl and RH = Receptor, a, P and Y = G protein subunits, AC = 
Adenylate Cyclase.
When an agonist bound receptor protein interacts with an inactive 
trimeric G protein, the G protein a  subunit loses its bound GDP, and the 
receptor changes from its low (RL) to its high affinity state (RH). The a  
subunit then binds GTP causing the dissociation of the receptor/G protein 
complex into free a  subunit, Py subunits and receptor in its low affinity state. 
The a  subunit can now interact with, and modulate the activity of, effector 
proteins. In this case Gsa is shown activating adenylate cyclase. The cycle is 
terminated by the a  subunit hydrolysing its bound GTP, causing 
reassociation of the a  and Py subunits and returning the G protein to its 
inactive form.
2.3 Classification of G proteins.
As mentioned in Section 2.1, there exists a wide range of different 
enzymes and ion channels, the activity of which can be modulated by G 
proteins. In addition, many different a  subunits have been identified by the 
use of molecular cloning and protein purification. In many cases the specific 
function of the identified subunits is unclear. Conversely, many of the 
effector systems are still "seeking" a controlling G protein. It is therefore 
possible to classify G proteins in two ways; by characterised protein species 
and by the effector systems which are thought to be G protein controlled.
2.3.1 Physically identified G protein subunits.
The highly homologous nature of G protein subunits has meant that 
their purification to homogeneity by conventional means has proved 
difficult. However the use of molecular cloning has allowed the 
identification of numerous G protein encoding mRNAs and genes. The 
amino acid sequence deduced from these clones has allowed the preparation 
of highly specific anti-peptide antisera against individual G protein 
subunits, the use of which has proved invaluable in the process of 
elucidating the functions of these proteins. Such antisera will be used in this 
study to measure the levels of several G protein subunits. It is therefore 
important to examine the large variety of G proteins which have been 
identified in the CNS, before attempting to describe the specific functions of 
these proteins.
3 and 7 subunits.
The use of molecular cloning has identified two species of 3 subunit 
mRNAs termed 3i and p2 present in human and bovine brain (Fong et ai, 
1986; Fong et ai, 1987). These correspond to the two forms of 3 subunit 
protein which can be identified by SDS-PAGE (36kDa and 35kDa 
respectively; Stemweis et ai, 1981; Bimbaumer et al., 1990). In addition, a
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third form of J3 subunit mRNA has recently been cloned from bovine retina 
(Levine et al., 1990b), although a corresponding protein has not, as yet, been 
identified.
The G protein y subunits have not been fully characterised. They are 
much smaller than the 3 or a  subunits (approximately 8kD), and under 
normal circumstances are found tightly bound to the 3 subunit (Tamir et ai, 
1991). At least six forms of if subunits are known to exist, with three being 
present in bovine brain (Tamir et al., 1991). These can associate in any 
combination with the different 3 subunits (Birnbaumer et al, 1990), and 
while different tissues possess differing amounts of the 3 and y subtypes 
(Birnbaumer et al., 1990), no functional role is known for this heterogeneity.
a  subunits.
The a  subunits are a rapidly growing family of homologous proteins, 
possessing molecular weights ranging from 37 to 52 kDa, the amino acid 
sequences of which differ in the regions of the protein which confer receptor 
and effector specificity (Lochrie & Simon, 1988). A feature of the a  subunits 
which has proved useful in the elucidation of their function, is their 
susceptibility to ADP-ribosylation by bacterial toxins isolated from Bordetella 
pertussis (Pertussis toxin or PTX) and Vibrio cholera (Cholera toxin or CTX), 
which cause a change in the activity of the proteins that they modify (Cassel 
& Pfeuffer, 1978; Heyworth et al., 1984). Each toxin only modifies those 
proteins containing a specific amino acid sequence, which fortuitously are 
not present within every a  subunit. Hence discovering whether or not a 
process is susceptible to disruption by these toxins has helped to identify 
which G proteins are involved in each task. In addition, the use of 
radiolabelled substrate for the ADP-ribosylation reaction, allows partial 
quantification of the levels of cholera and pertussis toxin substrates, 
although the availability of highly specific anti-G protein antisera has 
reduced the need to use the toxins for this purpose.
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The major a  subunits which are known to exist in the CNS are as 
follows.
Gsa. Bray et al. (1986) have isolated four cDNA clones from human 
brain which correspond to Gsa. These are all derived from the same gene 
and arise from alternative splicing events (Kozasa et al., 1988 and Figure 2). 
The four mRNAs fall into two distinct groups - two species which encode 
the heavy form of Gsa, GsH, and those that encode the light form, GsL. 
GsH differs from GsL by containing a sequence of 14 or 15 additional amino 
acid residues, which corresponds to exon 3 of the Gsa gene (Kozasa et al., 
1988). Within each group, the proteins differ by a single amino acid residue, 
also caused by an alternative splicing reaction at the 5' end of exon 4 of the 
Gsa gene. This additional residue is a serine and may have some functional 
significance since it represents a potential phosphorylation site. All forms 
Gsa can be ADP ribosylated by cholera toxin, but not by pertussis toxin 
(Jones et al., 1990).
Gia. The use of cDNA cloning has revealed the presence of three 
homologous mRNAs, known as Gil, Gi2 and Gi3, which, unlike Gsa 
subtypes, are all derived from separate genes (Itoh et al., 1988). While Gil 
and Gi2 are prevalent species in brain, Gi3 is only found in very low 
concentrations in discrete brain regions such as the substantia nigra and 
hippocampus (Cortes et al., 1988). Newton & Klee (1990) have recently 
provided evidence for the existence of subspecies of Gi2 termed Gi2-A and 
Gi2-B. It is not known whether these derive from a difference in primary 
sequence or to post-translational modifications, but there are indications that 
they possess differences in function (Newton & Klee, 1990). In contrast to 
Gsa, Gia molecules can be ADP ribosylated by pertussis toxin but not by 
cholera toxin (Linder et al., 1990).
Goa. Two Goa cDNA clones, thought to derive from alternative 
splicing of one gene product, have been identified in mouse brain 
(Strathmann et al., 1990). The deduced amino acid sequence of Goa is
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similar to that of Gia (Lochrie & Simon, 1988), and can also be ADP 
ribosylated by pertussis toxin (Linder et al., 1990). Goa is found in large 
amounts within the CNS, where it comprises approximately 1% of total 
membrane protein (Gierschik et al., 1986). It has also been identified in other 
tissues such as heart and retina (Angus et al., 1986; VanDongen et al, 1988), 
but is thought to derive from the neuronal elements within these tissues. 
Various protein purification strategies have shown the existence of four 
Goa-like proteins in bovine brain, termed Go-1,2,3 and 4 (Inanobe et al, 
1990). Although these subspecies may all be due to differing post 
translational modifications, peptide mapping has suggested that two forms 
of Goa, each possessing a different amino acid sequence, exist in brain. 
Whether these correspond to the two cDNA clones which have been isolated 
is, at the moment, unclear. It also possible that other species of Goa await 
isolation, since the northern blot analysis of RNA purified from brain reveals 
the existence of several RNA species containing Goa like sequences, 
although this may be due to differences within the 3' untranslated regions of 
these mRNA species rather than within the coding region (Price et al, 1990).
Golfa. This a  subunit was cloned from a cDNA library derived from 
olfactory neurons (Jones & Reed, 1989), in which it is predominantly found. 
It is highly homologous to Gsa and can also be ADP-ribosylated by cholera 
toxin (Jones et ai, 1990).
Gza. This a  subunit, also known as Gxa, was originally cloned from 
bovine retina, but is also expressed in adrenal medulla and brain (Fong et al, 
1988; Casey et a i, 1990). It cannot be modified by either pertussis toxin or 
cholera toxin (Casey et al, 1990).
Gqa. This species, and the highly homologous a n ,  were cloned 
from mouse brain (Strathmann et al, 1989; Strathmann & Simon, 1990), and 
are expressed in many different tissues. Like Gza, neither protein can be 
ADP- ribosylated by pertussis toxin (Blank et ai, 1991).
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QsH (1) GsH (2)
Gly Qlu Ssr Glu
Gsa gene —
Exon 2 Exon 3 Exon 4
6AG TGAG
GsL (1) GsL (2)
GA T GAG
Asp Glu
GA &i:AQ T GAG
Asp Ssr Glu
Figure 2,
The four species of Gsa mRNA produced by alternative splicing reactions.
Exons 2, 3 and 4 of the Gsa gene are shown along with the nucleotide 
sequence adjacent to the splice points. The inclusion of the sequence 
encoded by exon 3 gives rise to GsH encoding mRNA, while its exclusion 
produces GsL mRNA. Furthermore, GsH (2) and GsL (2) mRNA, contain an 
additional codon (shaded) encoding a serine residue.
2.3.2 G protein coupled effector systems.
Adenylate cyclase.
The best characterised of the G protein controlled effector enzymes is 
adenylate cyclase. This is a membrane bound enzyme which catalyses the 
hydrolysis and cyclisation of ATP to form cyclic adenosine monophosphate 
(cAMP) (Rail et al., 1957; Rail & Sutherland, 1961). The cAMP formed then 
acts as a "second messenger" (the transmitter substance being the "first 
messenger") by diffusing into the cell's cytoplasm and activating a protein 
kinase, known either as protein kinase A or cAMP-dependent protein 
kinase. This in turn phosphorylates and alters the activity of a variety of 
cellular components including other enzymes (Martin, 1987), ion channels 
(Levitan, 1988), and cytoskeletal proteins (Nestler & Greengard, 1989). It has 
been known for many years that some transmitters can stimulate the activity 
of adenylate cyclase, for example adrenaline and dopamine, and that this 
can be altered by the action of cholera toxin (Cassel & Pfeufer, 1978). Since 
the only widely distributed cholera toxin substrate is Gsa, it was concluded 
that this protein was responsible for the coupling of these receptors to the 
stimulation of adenylate cyclase. This has subsequently been proved by 
reconstituting purified adenylate cyclase with purified Gsa (May et ai,
1985). More recently both GsH and GsL have been shown to be able to 
stimulate adenylate cyclase (Jones et ai, 1990).
There exists only one other a  subunit which is known to activate 
adenylate cyclase, this being Golfa. This G protein has been proposed to 
couple olfactory receptors to adenylate cyclase (Jones & Reed, 1989), 
although it is also able to couple |3-adrenergic receptors to the enzyme (Jones 
et ai, 1990). With this one exception, the hormonal stimulation of adenylate 
cyclase is thought to be mediated exclusively by Gsa.
Gsa was named because of its stimulatory effects on adenylate 
cyclase. Similarly, Gia subunits were thought to be involved in inhibitory 
processes. However, the exact mechanism by which receptors can cause the
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inhibition of the enzyme is unclear. Firstly, it is not known with which G 
protein inhibitory receptors interact. This is likely to be one of the Gia 
proteins, since the stimulation of low Km GTPase activity by opiate 
receptors (which inhibit adenylate cyclase), is blocked by anti-Gia antisera 
in NG-108 cells (McKenzie et al, 1988). Furthermore, the inhibition of 
adenylate cyclase by a-adrenergic agonists in platelets can be inhibited by 
anti-Gi2 antisera (Simonds et al, 1989), while the inhibition caused by non- 
hydrolysable GTP analogues in hepatocytes, can be blocked by the 
phosphorylation of Gi2 (Houslay, 1991). While these results indicate that 
Gi2 mediates the inhibition of adenylate cyclase, Katada et al (1986) have 
demonstrated that purified Gil is able to inhibit the enzyme which, along 
with other less direct evidence (Wang et al, 1990), suggests that the Gil is 
also able to fulfil this role. These results are not necessarily contradictory, 
since it is possible that different receptors may mediate the inhibition of 
adenylate cyclase via different G proteins.
The mechanism by which G proteins cause the inhibition of adenylate 
cyclase is also unclear. One possibility is that the enzyme is inhibited 
directly by the a  subunit of an inhibitory G protein, in an analogous manner 
to its stimulation by Gsa. This view is supported by the work of Katada et 
al (1986) who, as mentioned above, observed that Gil can directly inhibit 
adenylate cyclase. However similar experiments by others have failed to 
repeat this observation (Linder et al, 1989; Newton & Klee, 1990). 
Alternatively, the fact that (37 subunits can also cause inhibition of the 
enzyme (Hildebrandt & Kohnken, 1990), has lead to the suggestion that Py 
subunits released from an activated inhibitory G protein can combine with 
free Gsa molecules thereby preventing them from stimulating the enzyme. 
This implies that the activation of any G protein other than Gs could cause 
the inhibition of adenylate cyclase, since py subunits are thought to be 
interchangeable between a  subunits. However, titration of Gsa by Py 
subunits cannot be the sole mechanism by which Gi mediates inhibition of
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adenylate cyclase, since non-hydrolysable GTP analogues and inhibitory 
agonists can reduce the activity of adenylate cyclase in cells which totally 
lack any functional Gsa (Katada et al.f 1984a). As a compromise between the 
two possibilities, Hildebrandt & Kohnken (1990) have proposed that 
inhibition can occur by both mechanisms, with the release of Py subunits 
mediating "tonic" inhibition i.e. counteracting the effect of free Gsa 
molecules released under basal conditions (see Section 2.2), while actual 
transmitter-mediated inhibition is due to the direct effect of a Gia molecule 
upon adenylate cyclase.
Thus the term Gi is somewhat ambiguous. It can mean either a G 
protein which is capable of inhibiting adenylate cyclase, or the highly 
homologous family of cloned Gia proteins which, may, or may not, be the 
actual mediators of the agonist dependent inhibition of adenylate cyclase. In 
this text the terms Gia, Gil, Gi2 and Gi3, refer to the actual protein species, 
while the term Gi is used to mean a G protein through which receptors can 
cause the inhibition of adenylate cyclase.
Phospholipases.
The membrane-bound enzyme, inositol phopholipid-specific 
phospholipase C, serves to catalyse the breakdown of inositol phospholipids 
in the cell membrane to form inositol triphosphate (IP3) and diacylglycerol 
(DAG) (Fisher & Agranoff, 1987). The activity of the enzyme can be 
stimulated by a number of transmitter substances in a GTP dependent 
manner, indicating that it is a G protein coupled process (Kikuchi et al,
1986). The IP3 that is produced by phospholipase C diffuses into the 
cytoplasm, where it binds to specific receptors causing the release of calcium 
ions from intracellular stores (Berridge, 1990). This causes an increase in 
intracellular free calcium ion concentration, leading to a variety of effects 
including the activation of calcium/calmodulin dependent protein kinases, 
other phospholipases (Kennedy, 1989) and proteases (Melloni & Pontremoli,
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1989), as well as causing various cytoskeletal rearrangements (Forscher,
1989). The other product formed, DAG, acts in unison with calcium to 
activate protein kinase C (Huang, 1989), an enzyme of particular interest due 
it postulated role in the pathology of Alzheimers disease (Masliah et al., 
1991a, and references therein).
The identity of the G protein which stimulates phospholipase C, 
termed Gp, remains unclear. In some cases the stimulation of the enzyme 
can be inhibited by pertussis toxin, while in others it has no effect (Moriarty 
et al, 1989). This difference probably arises from the existence of 
isoenzymes of phospholipase C (Crooke & Bennet, 1989), which can 
presumably interact with different G proteins. In HL-60 cells the stimulation 
of phospholipase C is abolished by pertussis toxin treatment, but this can be 
overcome by the addition of purified Goa and Gia (Kikuchi et al, 1986). In 
addition, Moriarty et al (1990) have demonstrated that the addition of 
purified Goa but not Gil, Gi2 or Gi3, to Xenopus oocytes causes the opening 
of a calcium sensitive chloride channel, an effect which is accredited to the 
stimulation of phospholipase C. Although the limited tissue distribution of 
Goa makes it likely that other G protein species can activate phospholipase 
C, it seems that one role of Goa may be to modulate inositol phospholipid 
metabolism in brain.
The identity of the G protein which mediates the pertussis toxin- 
insensitive stimulation of phospholipase C has only recently become clearer. 
The two cloned a  subunits which are the best candidates for Gp, are Gza 
and Gqa (and a ll ) ,  both of which are insensitive to pertussis toxin. The 
experiments of Shenker et al (1991) have demonstrated that the stimulation 
of low Km GTPase activity in platelets by the thromboxane A2 receptor (a 
receptor which is coupled to the stimulation of phospholipase C), can be 
abolished by the addition of antibodies against Gqa but not Gza. This 
indicated that, in platelets at least, Gqa was associated with the modulation 
of phospholipase C activity. Confirmation of this has come from Smrcka et
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al. (1991), who have shown that both Gqa and a l l ,  purified from bovine 
brain, are able to stimulate phospholipase C, while Goa, Gil and Gi2 are 
not. Although it is as yet unknown with which receptors Gqa can interact, it 
is likely that this relatively unstudied G protein will prove to be important 
in neural function. Thus it appears that a range of different G proteins may 
serve to stimulate the activity of phospholipase C, each possibly interacting 
with different receptors and phospholipase C subtypes.
Although most is known about the G protein coupled control of 
phospholipase C, the activity of other phospholipases may also be 
modulated in this way. For example, phospholipase A2, which catalyses the 
breakdown of phospholipids to form arachidonic acid, appears in some 
circumstances to be stimulated by transmitters via a pertussis toxin sensitive 
G protein, termed Ga (Burch et al., 1986). In addition, the activity of 
phospholipase D in hepatocytes is also thought to be coupled to receptors by 
a G protein referred to as Gd (Bocckino et al., 1987), although other 
mechanisms involving protein phosphorylation or calcium ion concentration 
are also known to be involved (reviewed in Billah & Anthes, 1990). 
Phospholipase D may constitute an important part of the cell's signal 
transducing repertoire, since it catalyses the breakdown of phosphatidyl 
choline to form phosphatidic acid. This can be further degraded to DAG 
by the action of phosphatidic acid phosphohydrolase (Billah & Anthes,
1990). Since phosphatidyl choline is a much more abundant lipid than 
phosphatidyl inositol (Houslay & Stanley, 1984), it represents a much larger 
potential source of DAG, which as explained above, is required for the 
activation of protein kinase C. As it also appears that protein kinase C can 
in turn stimulate phospholipase D activity in astrocytoma cells (Martinson et 
al., 1989), there potentially exists a positive feedback mechanism between 
the two enzymes that could result in the persistent activation of protein 
kinase C. This may be of particular importance in the CNS, since protein 
kinase C is thought to play an important role in the formation and
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maintenance of long term potentiation (Malenka et al., 1989b), a process by 
which repeated stimulation of certain neurons gives rise to a lasting increase 
in their excitability. It is thought to be a mechanism by which information is 
stored in the brain i.e. memory (Barnes et al., 1990).
Ion channels.
The conductance of many types of ion channels can be altered by the 
action of kinases activated by the mechanisms described above (Levitan, 
1988). However, the use of the patch clamp technique for monitoring ion 
channel activity has shown that G proteins can directly interact with, and 
modulate the conductance of, several types of ion channel. This direct effect 
was initially investigated in heart in which a G protein, termed Gk and 
subsequently shown to be Gi3 (Codina et al., 1988), was able to control the 
opening of potassium channels (Codina et al., 1987). In addition, a Gia 
protein can activate ATP sensitive-potassium channels in rat RINm5F cells 
(Ribalet et al., 1989). Other G proteins are also involved in the regulation of 
ion channels. For example, Gsa can interact with sodium channels in guinea 
pig heart (Schubert et al., 1989), and dihydropyridine-sensitive calcium 
channels in guinea pig heart (Imoto et al., 1988) and rabbit muscle (Mattera et 
al., 1989). Although this facet of Gsa action has not been demonstrated in 
the CNS, it seems likely that it does occur. Thus Gsa may mediate a rapid 
response to a neurotransmitters via its direct effect on ion channels, which 
may then be consolidated by the phosphorylation of other ion channel 
proteins by protein kinase A, acting in response to increased cAMP levels. 
There exists two demonstrations of G protein control of neural ion channels. 
Firstly, Goa has been shown to enhance the conductance of four types of 
potassium channels in rat hippocampus (VanDongen et al., 1988). Secondly, 
the same protein can inhibit the opening of calcium ion channels in dorsal 
root ganglion cells (Ewald et al., 1988). Both these actions would be expected 
to have an inhibitory effect on the cell, which is somewhat at odds with the
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postulated role of Goa as an activator of phospholipase C; an action 
expected to increase the intracellular concentration of calcium ions. It is 
therefore likely that Goa does not mediate both effects within one cell, and 
raises the possibility that the different subtypes of Goa are functionally 
distinct.
2.4 G protein coupled receptors.
The preceding sections have concentrated mainly upon the 
relationship between different G protein and effector proteins. It has also 
been important to determine which receptors couple with which G protein 
linked pathways. This has been accomplished by monitoring the effect that 
receptor specific agonists have on the activity of the various effector 
proteins, reconstituting purified receptors and G proteins in phospholipid 
vesicles, and the use of anti-G protein antisera to block the actions of certain 
G proteins. A large number of G protein coupled receptors are known to 
exist in brain and some of the most important are listed in Table 1.
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Table 1.
Examples of G protein linked neurotransm itter receptors.
The table illustrates a range of neurotransm itters, and their receptors, 
that m odulate the activity of G protein coupled effector enzymes.
Abbreviations - AC = adenylate cyclase, PLC = phospholipase C, 
PLA2 = phospholipase A2 , PLD = phospholipase D, T or T indicates 
stim ulation or inhibition respectively, CRF = corticotrophin releasing factor.
References are -
(1) Bonner (1989)
(2) Peralta et al., (1988)
(3) Egan et al. (1986)
(4) Birn baumer et al. (1990)
(5) Cotecchia et al. (1990)
(6) Burch et al. (1986)
(7) Bocckino et al. (1987)
(8) Bowery (1989)
(9) Childers (1991)
(10) Hoyer and Schoeffter (1991)
Transmitter Receptor type Effector Reference
Acetyl Choline Ml tPLC (4)
t  AC (?) (2 )
4- K channel 0 )
M2 4 AC (1 )
t  K channel (3)
Adenosine Al 4. AC (4)
A2 t  AC (4)
Adrenaline 3i t  AC (4)
(Noradrenaline) T Ca channel (4)
02 tA C (4)
«1 tPLC (5)
tPL A 2 (6 )
tPL D (7)
°*2 4. AC (5)
Cholecystokinin tA C (4)
4-PLC (4)
CRF tA C (4)
Dopamine D1 tA C (4)
D2 4. AC (4)
GABA GABAb 4 AC (8 )
t  K channel (8 )
Histamine HI tPLC (4)
H2 tA C (4)
Opioid |i,K,S 4-AC (9)
tPLC (9)
Serotonin (5-HT) 5-HT1a 4, AC (1 0 )
5-HT1b 4. AC (1 0 )
5-HT1C tPLC (1 0 )
5-HT1D 4. AC (1 0 )
5-HT2 tPLC (1 0 )
5 -HT3 t  K channel (1 0 )
5-HT4 tA C (1 0 )
Somatostatin 4. AC (4)
t  K channel (4)
2.5 Summary.
It is evident that in some cases one neurotransmitter can bind to 
several different receptors, which in turn interact with different G proteins, 
which may themselves have more than one function. Additionally, the 
activity of G proteins may be dependent on the membrane potential of the 
cell (Cohen-Armon & Sokolovsky, 1991), thus offering the possibility that 
ionotropic receptors can also effect G protein coupled signal transduction. 
Furthermore, the functional activity of several receptors and G proteins can 
be altered by phosphorylation, and "cross talk" can occur between different 
effector systems e.g. protein kinase C, activated by the action of 
phospholipase C, can effect the control and activity of adenylate cyclase (Lo,
1988). Although all of these possibilities are unlikely to occur in every cell, it 
is apparent that a large variety of subtle interactions can exist between the 
various mechanisms responsible for transducing signals across the cell 
membrane. Thus, it is likely that even small alterations in the functioning of 
any of these components may have far reaching consequences for the 
assimilation and processing of intercellular messages, especially within the 
CNS.
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3. Changes in G protein coupled signal transduction associated with 
disease.
During the last decade it has become increasingly apparent that 
alterations in the mechanisms of signal transduction are associated with a 
wide range of diseases. This has already been mentioned with respect to the 
effect that some bacterial toxins have upon G proteins; however many more 
examples are known. In some cases the disruption of a signal transducing 
cascade is the primary cause of the ailment, while in others they may 
represent an adaptive response to the disease state. Probably the best 
studied example of the former is Albright's hereditary osteodystrophy 
(AHO). This is a rare genetic disorder characterised by numerous physical 
abnormalities including skeletal defects, short stature and obesity. Two 
forms of the disease exist in which the sufferers are either resistant to 
hormones which stimulate adenylate cyclase, such as parathyroid hormone, 
or show a normal response to these substances. These subclasses are termed 
pseudo-hypoparathyroidism (PHP) and pseudo-pseudo-hypopara­
thyroidism (PPHP) respectively (Weinstein et al., 1990). The majority, 
though not all, of those with the disease (both PHP and PPHP) demonstrate 
an approximately 50% deficiency in the levels of Gsa throughout the body 
(Levine et al., 1986; Levine et a l, 1988), with both GsH and GsL being 
affected (Carter et a l, 1987). The implication of this is that while a deficiency 
in Gsa contributes to the disease, other elements in the signal transduction 
cascade must also be altered in some way for the disease to develop. The 
use of molecular biological techniques has revealed that the Gsa deficiency 
can be caused by a variety of genetic defects. For example, in one patient 
Weinstein et al. (1990) observed a heterozygous splice junction mutation, 
which would presumably lead to abnormal RNA splicing and hence 
decreased levels of functional Gsa. In another patient however, the same 
authors found a heterozygous frameshift mutation within the coding region
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of the Gsa gene. In addition, a heterozygous mutation within the initiation 
codon of Gsa has been reported by Patten et a l (1990). Thus AHO is 
associated with a variety of dominant heterozygous abnormalities within 
the G sa gene.
As well as disease caused by too little functional Gsa being present, 
too much Gs activity would also appear to be detrimental. In some human 
pituitary tumours, the cancerous cells are characterised by high levels of 
intracellular cAMP (Vallar et al., 1987). This is due to the presence of a 
variety of point mutations within the Gsa gene, which prevents Gsa from 
hydrolysing GTP (Landis et al, 1989). The molecule therefore becomes 
constitutively active, leading to a high basal activity of adenylate cyclase. 
This bypasses the cell's normal requirement for trophic hormones and leads 
to uncontrolled cell division. Thus, Gsa can be thought of as a proto­
oncogene product, which is a potential source of tumours occurring in other 
tissues.
There are also a number of diseases where dysfunction of signal 
transduction is not the primary cause, but may contribute to the expression 
of the disease state. A well studied example of these, are disorders affecting 
the thyroid gland. In contrast to PHP in which parathyroid hormones are 
present but have reduced effect, these illnesses are characterised by either 
elevated (hyperthyroidism) or decreased (hypothyroidism) serum levels of 
thyroid hormones. One of the hallmarks of thyroid disorders is a change in 
the potency of those hormones which modulate the activity of adenylate 
cyclase. Thus hypothyroid rats display a decreased responsiveness to 
stimulatory hormones (Malbon & Gill, 1979), while hyperthyroidism is 
accompanied by a marked increase is this response (Guarnieri et a l, 1980). It 
might be expected from what is known about pseudo-hypoparathyroidism, 
that hypothyroidism will be associated with decreased Gsa levels, however 
this does not appear to occur (Levine et a l, 1990a). Rather the ailment is 
accompanied by the increased expression of Gia and Goa (Orford et a l,
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1991; Levine et a l, 1990a) and of G protein 3 subunits (Rapiejko et a l, 1989). 
This would presumably lead to a greater release of 3 l subunits from Gi 
under basal conditions, which would then compete with adenylate cyclase 
for free Gsa molecules, thereby reducing the response to stimulatory 
hormones. In contrast, the increased responsiveness to stimulatory 
hormones observed in hyperthyroidism is associated with decreased 
expression of G ia (Ros et a l, 1988), accompanied by slightly increased levels 
of Gsa as assessed by cholera toxin mediated ADP-ribosylation (Rapiejko & 
Malbon, 1987). Thus, at least one function of thyroid hormones is to regulate 
the effect that other hormones have on the cell, a feature which is mediated 
via their control of G protein levels. When dysfunction of the thyroid gland 
occurs, these effects are amplified, possibly contributing to the clinical 
symptoms associated with the disease. It is worthwhile noting at this point 
that other hormones can also alter the levels of G proteins. For example, the 
administration of glucocorticoid or sex steroid hormones results in increased 
levels of Gsa and decreased levels of Gia in rats (Saelo et a l, 1989; Riemer et 
a l, 1988). It would appear therefore, that the actions of a number of 
different hormones are mediated, in part, by affecting the functional 
characteristics of the adenylate cyclase transduction system. Furthermore, 
any disease which causes a change in the levels of such hormones, may 
produce physical symptoms via its effect upon this transduction system.
Considerable attention has also been given to the association between 
human heart disease and G protein function. A reduction in basal, 
GppNHp-stimulated and adrenergic receptor-stimulated adenylate cyclase 
activity has been reported to occur in failing heart. This is associated with 
increased levels of Gia and unaltered levels of Gsa (Bohm et a l, 1989; Bohm 
et a l, 1990), a situation which is reminiscent of that observed in 
hypothyroidism. In contrast however, no change in the levels of 3 subunits 
have been observed in heart disease (Bohm et a l, 1990). The decreased 
response of adenylate cyclase to adrenergic agonists may be accounted for
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by a reduction in the numbers of (3-adrenergic receptors present in failing 
heart (Bohm et al., 1990). However, it is difficult to explain the reduced 
stimulatory effect of GppNHp in heart disease, if one believes that inhibition 
of adenylate cyclase is mediated solely by (3? subunits. In addition, the 
reduction in stimulation can be removed by inactivating Gi with pertussis 
toxin (Feldman, 1991). The most logical explanation therefore is that Gia 
can have a direct inhibitory effect upon cardiac adenylate cyclase. Aside 
from the interest in this system for the testing of theoretical models of G 
protein function, the alterations observed may be of considerable 
physiological relevance, given that control over cardiac muscle contraction is 
mediated via the adenylate cyclase transduction system (Drummond et al., 
1979).
The study of animal models of diabetes has also demonstrated 
changes in the G proteins which control adenylate cyclase. This disorder is 
due to reduced levels of, or reduced effect of, insulin. The disease is 
associated with a wide range of metabolic aberrations, some of which are 
simply due to the primary loss of insulin effect upon glucose transport 
(Taylor & Agius, 1988). However the disease is also accompanied by 
alterations in the response of tissues to many other hormones. The 
development of an animal model of the disease, in which diabetes is 
induced in rats by the administration of streptozotocin, has proved 
invaluable in investigating the molecular basis for these "secondary" effects 
of diabetes. Using this model Gawler et al. (1987) have demonstrated a loss 
of G ia in hepatocytes of diabetic rats. In addition, the remaining Gi 
possesses decreased functional capacity (Bushfield et al., 1990b), an effect 
which appears to be mediated by the phosphorylation of Gi2. This effect is 
even more apparent in rat adipocytes, in which diabetes does not produce 
any change in the levels of Gia, but does reduce the ability of this G protein 
to inhibit adenylate cyclase (Strassheim et al., 1990). As well as providing a 
greater understanding of the disease, these studies have also been important
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in emphasising the need to consider the functioning, as well as the levels of, 
the components involved in signal transduction.
The study of affective disorders (mania and depression) has indicated 
that alterations in interneuronal communication occur in these extremely 
common illnesses. Various early studies of the disease suggested that 
depression is caused by a deficiency of monoamine neurotransmitters, 
especially noradrenaline, while mania is caused by an excess of these 
transmitters (reviewed in Malenka et a l, 1989a). However this hypothesis 
fails to explain many aspects of the diseases and their treatment. A more 
satisfactory molecular basis for the affective disorders has been proposed by 
Wachtel (1990), in which an imbalance occurs between the adenylate cyclase 
and phosphatidylinositol-specific phospholipase C signal transduction 
systems. Thus in depression, there is hypofunction of the adenylate cyclase 
system with a relative dominance of the inositol phospholipid system, while 
the opposite in proposed to occur in mania. This hypothesis offers a rational 
as to how various treatments for depression may operate. For example, a 
common therapy is the administration of lithium which has been shown to 
attenuate phosphoinositide turnover by inhibiting the resynthesis of inositol 
phospholipids. Lithium also inhibits the coupling of |3-adrenergic and 
muscarinic receptors to G proteins (Avissar et a l, 1991), although the length 
of time that lithium takes to exert a clinical effect suggests that its major role 
is in depressing phosphoinositide metabolism (Malenka et a l, 1989a). 
Additionally, two other treatments, tri-cyclic antidepressants and electro- 
convulsive treatment appear to increase the production of cAMP in rat 
brain, by enhancing the coupling between Gsa and adenylate cyclase 
(Ozawa & Rasenick, 1989; Ozawa & Rasenick, 1991). The molecular 
mechanism of this effect is unknown, but may be due to antidepressant 
treatment causing alterations in the "complexes" which are proposed to exist 
between Gs, Gi and the cytoskeleton. The suggestion that such 
interactions actually take place, derives from the apparent exchange of GTP
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between Gsa and Gia, and between G proteins and the cytoskeleton (Hatta 
et a l, 1986; Rasenick & Wang, 1988; Wang et al., 1990). After anti-depressant 
treatment, the exchange of nucleotides between Gsa and Gia appears to be 
increased (Ozawa & Rasenick, 1991). These studies, deriving from the 
investigation of disease, indicate that the proteins species involved in signal 
transduction may not simply move randomly in a "sea" of lipids, but may be 
assembled into functional units, held together by the cytoskeleton. There 
have been limited investigations of signal transduction mechanisms in the 
post mortem brains of manic-depressive human subjects, although Young et 
al (1991a) have very recently demonstrated an increase in the levels of Gsa 
post mortem, within the cortex of persons who had suffered from manic 
depression. It will be interesting to discover if the drug treatments given to 
such patients work in a similar way as that observed in animal models.
Finally, the functioning of signal transduction mechanisms is also 
changed by the chronic administration of certain drugs. For example, the 
treatment of NG-108 cells (a neural-glial hybrid cell line) with ethanol for 48 
hours causes a reduction in their response to agonists which stimulate 
adenylate cyclase. This was found to be due to a reduction in the levels of 
Gsa in the treated cells (Mochly-Rosen et al., 1988). Ethanol also uncouples 
receptors from the stimulation of phospholipase C in NG-108 cells, an effect 
which is once again attributed to its modulation of G protein activity 
(Simonsson et a l, 1991). The chronic administration of opiates also leads to 
alterations in G protein levels, with a decrease in Gia being reported in rat 
spinal cord neurons, resulting in the cells becoming desensitised to opiates 
(Attali & Vogel, 1989). Curiously, Nestler et a l (1989) have reported a small 
increase in the levels of Gia in rat locus coeruleus in response to opiate 
treatment. Despite this, desensitisation still takes place, suggesting that a 
decrease in receptor-Gi coupling has occurred.
Thus a growing number of disease states, or adaptive responses to 
external agents, are either caused by, or are manifested through, alterations
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in the functioning of signal transduction systems. In addition, the study of 
these mechanisms in disease provides an ideal opportunity to test current 
ideas of how such systems operate. As will be made clear in the next 
section, the investigation of signal transduction in dementia of the 
Alzheimer type has concentrated largely on neurotransmitters and their 
receptors, with little attention given to other components. Given the 
growing awareness that events distal to receptor activation are frequently 
affected by disease processes, it is imperative that such studies be carried 
out. Only by doing so can therapeutic strategies, which attempt to 
manipulate signal transduction, be designed with any confidence.
One general conclusion that can be drawn from the above examples, 
is the changes in the levels or activity of G proteins largely occur in response 
to chronic conditions. They can therefore be considered to be a means by 
which cells can respond to long term alterations in their environment. This 
makes them an ideal candidate for study in non-acute disorders such as 
dementia of the Alzheimer type.
4. The major features of Dementia of the Alzheimer Type.
4.1 Overview.
The combination of an increasing birth rate and decreasing mortality 
have led to a steady rise in the numbers of elderly persons. It is estimated 
that over the next ten years there will be a 25% increase in the numbers of 
individuals aged over 65 (Phelps, 1990). This has resulted in a heightened 
prevalence of the diseases of later life, among which are several neurological 
disorders collectively known as dementias. These are characterised by a loss 
of cognitive functions, impairment of memory, and a decreased ability to 
learn (Katzman, 1986). The most common form of dementia is Alzheimer's 
disease, first reported in 1907 by Alois Alzheimer (Alzheimer, 1907), in 
which the sufferers ability to reason is severely reduced. Alzheimer's 
disease was initially thought to be a pre-senile dementia since the case 
described by Alzheimer was of a 51 year old woman. However a very 
similar disease occurs in later life, the incidence of which increases with age 
(Evans et at., 1989). While the severity of the illness appears to be greater in 
the presenile compared to senile form (Mann et al., 1985), the only major 
difference between the two is age of onset. It is usual therefore to refer to 
any person whose brain displayed the pathological features of Alzheimer's 
disease, as having suffered from Dementia of the Alzheimer Type (DAT).
The disease has typically been investigated by one of two distinct 
strategies. The first has attempted to discover the cause of the disorder, with 
initial studies using mainly epidemiological approaches. Most recently, the 
application of powerful molecular genetics techniques has resulted in 
significant advances in our understanding of the disease's aetiology. A 
general conclusion of these studies has been that there is no single cause of 
DAT, but a variety of different risks factors exists including serious head 
trauma (Heyman et al., 1986), myocardial infarction (Aronson et al., 1990), 
aluminium intoxication (Crapper-McLachlan & Van Berkum, 1986), and a 
variety of possible genetic abnormalities (Weitkamp et al.,1983; Schellenberg
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et a l
et a l, 1991; Pericak-Vance^l991; Goate et a l, 1991; Chartier-Harlin, 1991). It 
is possible that the relative contributions of each factor will result in small 
differences in the pathological changes which take place within the DAT 
diseased brain. However, at autopsy, the brains of all DAT subjects possess 
a number of distinct pathological features. Macroscopically the brain shows 
significant atrophy, particularly of the frontal and temporal lobes, associated 
with narrowing of sulci, widening of gyri and ventricular enlargement 
(Perry, 1986b). There also exists in the literature, a large number of studies 
describing a range of neuropathological and neurochemical changes 
associated with DAT. The second research strategy employed has therefore 
been to characterise these changes and discover the mechanisms by which 
they occur. This review will be limited to (i) those neuropathological 
changes which allow DAT to be definitively diagnosed post mortem, an 
important consideration since it is not possible at present to unambiguously 
diagnose DAT before death, and (ii) neurochemical evidence that alterations 
in signal transduction systems may have occurred.
4.2 Neuropathological changes.
The classical features of DAT are characterised neuropathologically, 
these being the presence of neuritic plaques and neurofibrillary tangles 
within the association cortex and hippocampus. In addition, the disease 
exhibits loss of cells within particular populations of neurons, although the 
severity of loss in each area may differ between subjects. In general, it is the 
larger neurons that are lost, thus the large pyramidal neurons of the 
association cortex (especially in the frontal and temporal cortices) are 
severely affected, while smaller cells are relatively spared (Terry et a l, 1981). 
In addition, the pyramidal cells of the hippocampus (Hyman et a l, 1984), 
and cells in various subcortical nuclei, including the cholinergic nucleus 
basalis of Meynert (Whitehouse et a l, 1982), the adrenergic locus coeruleus 
and the serotonergic dorsal raphe (Mann et a l, 1984), are also affected by the
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disease. The death and dysfunction of these neurons is undoubtedly the 
physical basis for the cognitive decline observed in DAT. In contrast, other 
regions such as the brain stem, cerebellum and neostriatum are relatively 
unaffected by the disease (Pearson & Powell, 1989). The underlying cause of 
the selective vulnerability of certain cellular populations is unclear, but it is 
noticeable that they are within, or have connections with, the association 
cortex, suggesting that the disease is cortical in origin (Pearson & Powell,
1989). Quite why larger neurons are most effected is also unknown, but 
may be due to differences in the biochemical makeup of these cells, with the 
presence or absence of certain neurotransmitter receptors being a prime 
candidate (Phelps, 1990).
The quantification of neuritic plaques, which are present in large 
numbers within DAT diseased cortex, is commonly used to confirm the 
clinical diagnosis of DAT (Khachaturian, 1985). Plaques are most frequently 
composed of a core of amyloid protein surrounded by degenerating 
neuronal terminals, as well as microglia and astrocytes, although other 
forms do exist (reviewed in Probst et al., 1991). Most recently, several 
groups have identified a new form of plaque, known as amorphous or 
diffuse plaques, which are composed of non compacted deposits of amyloid 
protein (Joachim et a l, 1989). These are present in large numbers within 
DAT diseased brain, and most interestingly are found in areas which are 
thought to be relatively unaffected by the disease, such as the neostriatum 
and cerebellum, in addition to the cortex and hippocampus (Tagliavini et a l, 
1988; Yamaguchi et a l, 1988; Joachim et a l, 1989). Furthermore, it has been 
suggested that diffuse plaques are precursors of neuritic plaques (Motte & 
Williams, 1989). It is therefore of interest to determine what differences 
exists between, for example the cortex and cerebellum, such that diffuse 
plaques do not develop into neuritic plaques throughout the brain.
The composition of amyloid has been extensively studied, and is now 
known to be composed of a small 4kD protein known as (3-amyloid (Masters
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et a l, 1985). Although amyloid may merely serve to occupy the space left by 
dead neurons, there are indications that 3-amyloid has neurotoxic effects 
(Yankner et al., 1989). The use of protein sequencing and molecular cloning, 
has revealed that 3-amyloid is the proteolytic degradation product of a 
larger protein termed the amyloid precursor protein (APP) (Goldgaber et a l,
1987). The normal function of APP is unclear, but it is thought to exist in 
both membrane bound and secreted forms (Palmert et al., 1989). Molecular 
cloning has revealed the presence of three major species of APP, two forms 
of which contain a domain which is homologous to that of Kunitz serine 
protease inhibitors, with the other lacking this sequence (Ponte et al., 1988; 
Tanzi et al., 1988; Kitaguchi et al., 1988). The mRNAs are expressed in many 
tissues (Tanzi et al., 1988; Ponte et al., 1988), which agrees with the finding 
that APP is a typical housekeeping gene (Salbaum et al., 1988). The 
expression of APP mRNA is reported to be increased in DAT, with many, 
though not all, reports showing an increase in the mRNA containing the 
protease inhibitor domain (Konig et al., 1991 and references therein). This 
has led to speculation that altered expression of the different forms may 
alter the susceptibility of APP to proteolytic degradation, possibly increasing 
the amount of 3-amyloid that is formed. This is supported by the 
observation that deposits of 3-amyloid are formed in the brains of transgenic 
mice, in which APP mRNA containing the protease inhibitor domain was 
overexpressed (Quon et al., 1991).
An alternative explanation is that the proteolytic processing of APP is 
altered in DAT. In normal brain, APP is largely cleaved within the 3- 
amyloid region, thereby excluding the formation of the peptide (Tagawa et 
al., 1991). Thus in DAT an alternative pathway must occur which cleaves 
APP on either side of the 3-amyloid region. Indeed, Chartier-Harlin et al. 
(1991) have reported the presence of a mutated APP gene in some persons 
suffering from a form of DAT in which genetic factors are clearly involved 
(familial DAT). Such a defect may increase 3-amyloid formation by making
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APP a better substrate for the alternative pathway of processing. The recent 
purification and characterisation of proteases which can cleave APP 
(Tagawa et a l, 1991), makes it likely that the sequence of events which lead 
to the formation of 3-amyloid may soon be elucidated. The release of 
trophic factors by glia in response to neuronal death may also contribute to 
increased amyloid deposition, since nerve and epidermal growth factors 
cause the increased secretion of APP from PC12 cells (Refolo et al., 1989). In 
addition, it has been suggested that an alteration in the phosphorylation of 
APP in DAT may alter its proteolytic processing (Buxbaum et al., 1990).
The other main pathological feature observed in DAT diseased brain 
is neurofibrillary tangles (NFT). These are large, non-membrane bound 
filaments which occur in the neuronal cell body and often extend into the 
dendrites (Probst et a l, 1991). They are mainly found in the brain regions 
which experience the greatest cell loss (Bondareff et a l, 1989), leading to the 
conclusion that NFT occur within degenerating neurons. For this reason 
there has been great interest in how these structures are formed, since an 
understanding of this process may indicate a general mechanism for the 
cellular dysfunction that occurs in the disease.
NFT consist mainly of pairs of filaments twisted around each other 
(paired helical filaments or PHF), but straight filaments and vesicular 
materials are also found (Yagishita et a l, 1981; Wisniewski et a l, 1984). 
Although PHF were originally thought to be a form of normal 
neurofilaments, electron microscopy has demonstrated that PHF are not 
composed of filamentous structures (Wisniewski et a l, 1984), but of a chain 
of small globular units (Wischik & Crowther, 1986). Such a configuration is 
not typical of the other proteins which make up the normal neuronal 
cytoskeleton. Despite this, immunohistochemical studies using antibodies 
raised against various cytoskeletal elements, including the 150kD and 200kD 
neurofilament proteins (Anderton et a l, 1982; Sternberger et a l, 1985), MAP2 
(Yen et a l, 1987) and vimentin (Yen et a l, 1984), have demonstrated that PHF
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share common epitopes with these proteins, leading to the suggestion that 
PHF are composed of modified cytoskeletal proteins. Indeed the major, if 
not the only, component of PHF is thought to be a modified form of the 
microtubule accessory protein, tau (Goedert et a l, 1991). The normal role of 
tau is to promote tubulin polymerisation (Weingarten et a l, 1975), but in 
DAT it is found to be abnormally phosphorylated, as well as possessing an 
altered cellular localisation (Kowall & Kosik, 1987; Flament et a l, 1990). It 
has been proposed that the phosphorylation of tau, by as yet unidentified 
kinases, promotes its polymerisation into PHF (Mori & Ihara, 1991). The 
same authors have also suggested that this occurs as a consequence of 
changes in the functioning of one, or more, signal transduction systems. 
Thus, it is possible that aberrant kinase activity, possibly mediated by 
altered signal transduction mechanisms, may play a role in the formation of 
neurofibrillary tangles, as well as in amyloidogenesis.
4.3 Changes in the levels of neurotransmitters and receptors.
The measurement of the levels of neurotransmitters and their 
receptors, as well as the activity of enzymes involved in transmitter 
synthesis or breakdown, has revealed a wide variety of neurotransmitter 
abnormalities in DAT. In general these changes are thought to be due to the 
loss or dysfunction of specific neuronal types, although in the case of some 
neurotransmitter receptors, compensatory alterations in expression may 
occur. There follows a description of the effects that DAT has on the major 
neurotransmitter systems in the brain.
One of the most dramatic neurochemical changes that takes place in 
DAT diseased cortex is a reduction in the activity of choline acetyl 
transferase, the enzyme which catalyses the formation of acetyl choline 
(Procter et a l, 1988). In addition, levels of the M2 subtype of muscarinic 
receptors, which are thought to be located presynaptically, are decreased in 
DAT diseased cortex, although the postsynaptic Ml receptors are largely
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unchanged (Mash et a l, 1985). Since the major cholinergic projection into 
the cortex is from the nucleus basalis of Meynert (nbM), it was postulated 
that degeneration of this subcortical nuclei was the primary event in DAT, 
which in turn caused the dysfunction of the neurons in the cortex (Perry, 
1986a). This hypothesis was particularly appealing since Parkinson's 
disease appears to be caused by the death of neurons in the substantia 
nigra, which forms part of the brains dopaminergic system (Sourkes, 1989). 
It was therefore thought that DAT may be the cholinergic analogy of 
Parkinson's disease. However, marked cortical pathology can occur without 
severe cell loss from the nbM (Pearson et a l, 1983b). In addition, 
degeneration of neurons in the nbM has been observed to occur after cortical 
damage in human subjects, and in primates (Pearson et a l, 1983a). It is 
probable therefore that the primary damage in DAT occurs in the cortex, 
which causes damage to the projecting fibres and subsequent death of the 
neuronal cell body with the nbM. This seems likely since cell loss also 
occurs within other subcortical nuclei such as the locus coeruleus.
Although muscarinic receptors, being G protein coupled, are of most 
interest in the context of this study, the ionotropic nicotinic receptor has also 
been studied with conflicting results - Shimohama et al. (1986a) have 
reported no change in the levels of nicotinic receptors in DAT diseased 
cortex or hippocampus, while Flynn & Mash (1986) have demonstrated a 
65% decrease within the cortex.
Although, the cholinergic deficit is probably the most characteristic 
and robust neurochemical change which occurs in DAT, alterations also 
occur in a wide range of other neurotransmitter systems. For example, 
reductions in the levels of adrenalin have been reported to occur in post 
mortem DAT diseased brain (Adolfsson et a l, 1979), a not unexpected 
observation given the damage that occurs to the locus coeruleus in the 
disease. Shimohama and co-workers have demonstrated changes in the 
levels of adrenergic receptors in DAT, these being decreases in oq receptors
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in the hippocampus, a 2 receptors in the nucleus basalis and j3j receptors in 
the hippocampus and frontal cortex, but an increase in the levels of 
receptors in the hippocampus and frontal cortex (Shimohama et al., 1986b; 
Shimohama et a l, 1987).
In a similar way, the cellular loss found in the dorsal raphe indicates 
an involvement of the serotonergic neurons in the disease. This appears to 
be so, since Bowen et al (1983) have demonstrated a decrease in serotonin 
uptake in brain biopsies, while Cross et al. (1986) have reported large 
decreases in the levels of 5-HT2 , but not 5-HT1 , receptors in the cortex of 
DAT diseased subjects.
The lack of any substantial cell loss in the neostriatum or substantia 
nigra in DAT, would suggest that the brain’s dopaminergic system is 
relatively unaffected by the disease process. Cortical dopamine levels are 
largely unaltered in the disease, although low dopamine concentrations 
have been recorded in the neostriatum (Arai et a l, 1984), as well as 
reductions in the levels of Dj and D2 receptors (Cross et al., 1984b).
The levels of the peptide transmitter somatostatin are greatly reduced 
in the cortex and hippocampus, a change which correlates with impaired 
cognitive function (Tamminga et al., 1987). In addition, the number of 
somatostatin receptors are significantly reduced within these two regions 
(Beal et al., 1985). The levels of another peptide transmitter, corticotrophin 
releasing factor, are also decreased within DAT diseased cortex. However, 
this is accompanied by an increase in the levels of the receptor for this 
peptide, indicating that a compensatory response may have taken place in 
the postsynaptic neurons (De Souza et al., 1986). This observation is of some 
importance, since it indicates that despite widespread neuronal damage, 
some cells retain their capacity to respond to changes which occur in their 
extracellular environment.
Finally, the mainly ionotropic amino acid receptors will be 
considered, due to their postulated role in the pathological mechanism that
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takes place in DAT. There is considerable interest in the receptors of 
glutamate, since it putatively represents the major excitatory 
neurotransmitter of the large cortical pyramidal neurons which are 
preferentially lost in DAT (Fonnum et al., 1981). This, and the observation 
that there is a reduction in cortical glutamatergic terminals in DAT (Procter 
et al., 1986), has led some to suggest that the these neurons are damaged by 
a glutamate mediated excitotoxic mechanism. Glutamate acts via at least 
four receptor types, these being N-Methyl-D-Aspartate (NMDA) receptors, 
kainate receptors, and 2-amino-3-hydroxy-5-methyllisoxazole-4-propionic 
acid (AMPA) sensitive quisqualate receptors, all of which are thought to be 
ionotropic, and AMPA-insensitive quisqualate receptors, which are linked to 
the modulation of phospholipase C activity, presumably via Gp (Farooqui & 
Horrocks, 1991). The measurement of the levels of these receptors in DAT 
diseased brain has given rather inconclusive results. Chalmers et al. (1990) 
have reported an increase in the levels of cortical kainate receptors, a small 
decrease in NMDA receptors, and no change in the levels of AMPA sensitive 
quisqualate receptors. Greenamyre et al. (1987), and Jansen et al. (1990), have 
both demonstrated a large loss of NMDA receptors in the hippocampus, 
although Geddes et al. (1986) did not detect any change. The role of 
glutamatergic receptors in DAT therefore remains unclear. Most recently, 
and most relevantly to this study, a decrease in the numbers of hippocampal 
AMPA-insensitive quisqualate receptors has been observed (Dewar et al.,
1991).
The receptors of the inhibitory amino acid transmitter gamma 
aminobutyric acid (GABAa and GABAb) are also found to be decreased in 
DAT diseased cortex (Chu et al., 1987). In addition, Lowe et al. (1988) found 
a decrease in the cortical concentration of GABA determined post mortem 
in DAT diseased subjects.
5. Summary and objectives.
Recent advances in study of the molecular mechanisms responsible 
for the reception and processing of intercellular messages, have 
demonstrated the existence of a variety of complex interactions between the 
various components of such systems. This most likely derives from these 
mechanisms being involved in a large variety of different functions 
throughout the body. However, as described in Section 3, the potential for 
dysfunction of these processes is similarly great. With regard to dementia of 
the Alzheimer type, a large number of studies have demonstrated 
widespread changes in the levels of neurotransmitters and their respective 
receptors in DAT diseased brain, the most pronounced being to the 
cholinergic, serotonergic and somatostatinergic systems. However, little 
attention has been paid to the other components of signal transduction, such 
as G proteins and the various effector enzymes and ion channels. This 
situation is reminiscent of the investigation of affective disorders, which was 
initially confined to the determination of neurotransmitter levels. However 
the recent shift of emphasis onto the other components of the signal 
transduction cascade, has proved fruitful in unravelling the mechanisms 
associated with these illnesses. While the presence of widespread 
neuropathological features in DAT makes it somewhat different to that of 
affective disorders, it remains likely that the investigation of signal 
transduction mechanisms in DAT will prove to be similarly beneficial. Such 
knowledge is of particular importance to the design therapeutic strategies 
for the disease. For example, the observation that muscarinic M l receptors 
appear to be relatively unaffected by the disease, has prompted attempts to 
increase the stimulation of this receptor type, in the hope that this will ease 
the cognitive decline of sufferers. Various approaches have been used 
including the administration of drugs that raise the levels of acetyl choline in 
the brain (Dysken, 1987), or by the administration of muscarinic agonists 
(Read et al,  1990). Unfortunately, this form of treatment, known as
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cholinergic replacement therapy, has met with little or no success. While 
this may be due to increasing the stimulation of these receptors in a global 
manner, it could also be caused by dysfunction of the signal transduction 
mechanisms which are required for the activation of M l receptors to have 
any effect. For this reason, and the possibility that other neuropathological 
features such as NFT, may be in part due to changes having occurred in 
aspects of signal transduction, it is important to examine the functioning of 
these mechanisms in DAT diseased brain.
The specific objectives of this study will firstly be to examine the 
feasibility of examining the components of signal transduction in human 
post mortem brain tissue. There is a concern that during the inevitable delay 
between death and freezing of the brain tissue, proteins or RNA may be 
degraded by either chemical or enzymatic means, thereby reducing the 
reliability of any measurements performed in such tissue. Hence the effect 
that this delay has upon the integrity of G proteins, G protein encoding 
mRNA, and the activity of several enzymes, will initially be studied in rat 
brain. Should the results of these experiments indicate that measurement of 
these moieties in post mortem brain is worthwhile, then the same standard 
biochemical techniques will be used to examine the effects that dementia of 
the Alzheimer type has on the same components in human brain.
IL- METHODS
1. Materials.
1.1 Reagents.
All reagents used were of the highest grade commercially available and 
are listed according to source.
Tris, ethylenediaminetetraacetate (EDTA), sodium deoxycholate, tri­
chloroacetic acid, glycerol, ammonium persulphate, N,N,N',N'-tetramethylene- 
ethylenediamine (TEMED), tween-20, o-dianosidine, neutral chromatographic 
alumina, imazadole, sodium salt of cyclic 3-5' adenosine monophosphate 
(cAMP), sodium salt of adenosine triphosphate (ATP), creatine phosphate, 
creatine phospho kinase (from rabbit muscle), aluminium chloride, sodium 
fluoride, acetyl coenzyme A, acetonitrile, kalignost (sodium tetra phenyl boron), 
bovine serum albumin, diethyl pyrocarbonate, sodium N-lauryl sarcosine, 
phosphostigimine (eserine), 2-mercaptoethanol, 8-hydroxyquinoline, 
polyethyleneimine (PEI) cellulose, 3-[N-morpholino] propane sulphonic acid 
(MOPS), ficoll 400, polyvinyl pyrollidone, salmon testes DNA, methylene blue, 
comassie brilliant blue R, thimerosal, ouabain and bromophenol blue were 
purchased from Sigma Chemical Company Ltd., Poole, Dorset, U.K.. 
Dithiothreitol, phosphoenoylpyruvate, reduced nicotinamide . adenine* 
dinucleotide (NADH), pyruvate kinase (from rabbit muscle), lactate 
dehydrogenase (from hog muscle) and T4 polynucleotide kinase were 
purchased from Boehringer Mannheim Ltd., Lewes, Sussex, U.K.. Urea, 
glycine, hydrogen peroxide (30% v/v), magnesium chloride, potassium 
chloride, triton X-100, sodium hydrogen phosphate, sodium dihydrogen 
phosphate, potassium dihydrogen phosphate, sodium citrate, sodium acetate, 
chloroform, isoamylalcohol, sodium pyrophosphate, copper sulphate and 
sodium potassium tartrate were purchased from BDH Ltd., Glasgow, 
Lanarkshire, U.K.. Acrylamide, bis acrylamide, sodium hydroxide, sodium 
carbonate and formaldehyde were purchased from Fisons Ltd., Loughborough, 
Leicester, U.K.. Sodium dodecyl sulphate (SDS) and phenol were purchased
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from IBI Ltd., Cambridge, U.K.. Methanol, hydrochloric, acetic acid, 
isopropanol, ethanol were purchased from May and Baker Ltd., Dagenham, 
Essex, U.K.. Agarose, prestained protein molecular weight standards for 
western blotting and RNA molecular size markers for northern blotting were 
purchased from BRL Ltd., Uxbridge, Middlesex, U.K.. Fuji RX X-ray film and 
Saran wrap were purchased from Genetic Research Instrumentation Ltd., 
Dumow, Essex, U.K.. Dowex resin (AG50W-X4 200-400 mesh), mixed bed resin 
(AG501-X8 20-50 mesh) and poly prep columns were purchased from Biorad 
Laboratories Ltd., Hemel Hempstead, Hertfordshire, U.K.. Nitrocellulose 
(Schleicher and Schuel, 0.2 jjM) was purchased from Anderman and Co. Ltd., 
Surrey, U.K.. Guanidinium thiocyanate and formamide were purchased from 
Fluka Ltd., Bristol, U.K.. Ecoscint and POPOP (a toluene based scintillation 
fluid) were purchased from Packard Bell, Reading, Berkshire, U.K.. Hybond N, 
hybond N+, biotinylated anti-rabbit immunoglobulin G (IgG) antisera from 
donkey, streptavidin-linked horse radish peroxidase (HRP), 125I labelled anti­
rabbit IgG from donkey (5-20 pCi/jig protein), 8-3H cAMP (ammonium salt 1:1 
in ethanol; 30Ci/mmol), 14C-acetyl coenzyme A (60Ci/mmol), y-32P ATP 
(ammonium salt in 5mM 2-mercaptoethanol; 3000 Ci/mmol), a-32P ATP 
(ammonium salt in 5mM 2-mercaptoethanol; >400 Ci/mmol) were purchased 
from Amersham International PLC, Amersham, Buckinghamshire, U.K.. HRP 
linked anti-rabbit IgG was supplied free of charge from the Scottish Antibody 
Production Unit, Carluke, Lanarkshire, U.K..
1.2 Apparatus.
Vertical polyacrylamide gel and protein blotting apparatus were 
purchased from LKB Ltd., U.K.. Horizontal agarose gel apparatus was 
purchased from BRL Ltd., Uxbridge, Middlesex, U.K.. Intensifying screens 
were purchased from Sigma Chemical Company Ltd., Poole, Dorset, U.K.. 
Radioactive samples were counted in a Packard Bell Tri Carb 1900CA liquid 
scintillation counter.
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2. Brain tissue used.
Brains were obtained post mortem from nineteen subjects who had 
no neurological disorders (age 78 ± 3 years, (mean ± SE), delay between 
death and freezing the tissue 14 ± 3 hours), and ten subjects with a clinical 
diagnosis of dementia of the Alzheimer type (DAT), (age 84 ± 2 years, delay 
between death and freezing the tissue 7 ± 1 hours), as described in Table 2. 
The diagnosis of DAT was confirmed histopathologically after death 
according to the criteria of Khachaturian (1985). At autopsy, brains were cut 
into 1cm thick slices, dissected into different regions, frozen in isopentane 
(-40°C) and stored at -80°C. The freezer used for storage has a C 02 backup 
system as well as a high temperature alarm which is monitored 
continuously. Tissue blocks adjacent to those used in this study were fixed 
in 10% formalin, sectioned and used to determine regional densities of 
neuritic (senile) plaques. The DAT group had plaque densities of 42.5 ± 4.7 
plaques/m m 2 in the frontal cortex, and 7.2 ± 1 .4  plaques/m m 2 in the 
hippocampus, whilst the control group had plaque densities of 2.0 ±1.4  
plaques/m m 2 in the frontal cortex, and 0.5 ± 0.4 plaques/m m 2 in the 
hippocampus (Table 2). All manipulations involving undenatured human 
tissue were performed in a level 2 containment facility at the Wellcome 
Surgical Institute.
The rats used in the study were adult male Wistar rats which had a 
body weight of between 300 and 350g except in the case of experiments 
involving middle cerebral artery occlusion where male Sprague Dawley rats 
were used.
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Table 2.
The hum an subjects used in this study.
The subjects are listed according to their code number this being Cxx 
for controls or Axx for DAT subjects. PMD refers to the post mortem delay 
of the subject i.e. the time between death and freezing of the tissue. The 
drug treatment category lists any medication which was being administered 
to the subject before their death. Only drugs which are known to have 
effects on the CNS are listed. NK indicates that the cause of death and /o r 
drug treatment were not known. The neuritic plaque density in plaques/ 
mm2 of tissue blocks adjacent to those used in this study was derived as 
described in "Methods". The value given is the mean of the left and right 
hemisphere densities. The table also shows (as indicated by •) which 
patients were used in each of the major studies presented herein, these 
being:
(a) Measurement of G protein levels, adenylate cyclase etc. in the left 
frontal cortex.
(b) Measurement of G protein levels, adenylate cyclase etc. in the left 
hippocampus.
(c) Measurement of G protein mRNA levels in the right frontal cortex.
(d) Measurement of G protein mRNA levels in the right 
hippocampus.
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3. Preparation of crude membranes.
Tissue blocks were ground in liquid nitrogen before a portion was 
homogenised in 6 volumes of lOmM Tris/HCl, pH7.5, ImM EDTA for 30 
seconds in a polytron homogeniser at full speed. This and all further 
manipulations were carried out at 4°C. If required, a small aliquot was 
removed for the assay of choline acetyl transferase and stored at -80°C. The 
remainder of the homogenate was centrifuged at 1000gav for 15 minutes in a 
Beckmann TL-100 tabletop ultracentrifuge using a TL-100 rotor, or a 
Beckmann J2-21M/E ultracentrifuge using a JA21 rotor. The supernatant 
was removed and spun at 40,000gav for 15 minutes. The pellet was 
resuspended in lOmM Tris/HCl, pH 7.5, using a needle and syringe, before 
being spun at 40,000gav for 15 minutes. This pellet was then resuspended in 
lOmM T ris/H C l, pH 7.5, at an approximate concentration of 5mg protein/ 
ml. The preparation was then stored at -20°C until required.
4. Western blotting.
4.1 Antisera used.
The antisera used were provided by Dr. Graeme Milligan, 
Department of Biochemistry, Glasgow University. The antisera were raised 
against synthetic peptides corresponding to specific amino acid sequences 
predicted from cDNA sequences encoding the a  subunit of Gs, Gi and Go 
(Mullaney et al., 1988; Milligan & Unson, 1989). Briefly the peptides were 
linked to keyhole lympet haemocyanin and injected into New Zealand white 
rabbits. Blood was removed from the rabbits and sera separated by 
centrifugation. In brain tissue antisera OCl detects Goa, SG2 detects two 
forms of Gia, Gil and Gi2, and CS1 detects two forms of Gsa, GsH and GsL. 
Details of the sequences to which the antisera were raised are given in Table
3.
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Antisera Peptide Used G protein sequence Recognises Reference
OC1 ANNLRGCGLY Goa 345-354 Goa a)
SG2 KENLKDCGLF Transducin a  341-3501 Gil, Gi2 a)
CS1 RMHLRQYELL Gsa 385-394 GsH, GsL (2)
Table 3.
The anti-G protein antisera utilised in western blotting.
The peptide sequence against which the antisera used were raised 
(using one letter abbreviations), the position in the G protein that this 
corresponds to, and the subunits that the antisera recognises in brain are 
shown. References are: (1) Mullaney et al. (1988), (2) Milligan and Unson 
(1989).
1 - Transducin is a G protein, also known as Gt, which couples 
photoreceptors to guanylate cyclase. It is only present in the retina.
4.2 Preparation of membrane samples for electrophoresis.
Crude membranes were prepared for the electrophoretic analysis of 
proteins by precipitating with tri-chloroacetic acid as follows. An 
appropriate quantity of protein was made up to 1ml with distilled water in a 
micro centrifuge tube, and sodium deoxycholate was added to a 
concentration of 1%. After vortex-mixing the samples, ice cold tri­
chloroacetic acid was added to a concentration of 10% (w /v) to precipitate 
the proteins. The tubes were then left on ice for 30 minutes before the 
protein was pelleted by spinning briefly in a microcentrifuge. The 
supernatant was poured off and the tubes drained. The protein pellet was 
neutralised by the addition of 10 pi of 1M Tris, and then resuspended in 
denaturing buffer composed of 5% dithiothreitol, 5% sodium dodecyl 
sulphate (SDS), 5M urea and 0.1M Tris/HCl pH 8.0. A small volume of 
denaturing buffer containing 0.1% bromophenol blue was then added to 
each sample.
4.3 Polyacrylamide gel electrophoresis.
The denatured proteins were separated by discontinuous slab gel 
electrophoresis (Laemmli, 1970). A resolving gel, consisting of 12.5% 
acrylamide, 0.062% bisacrylamide, 0.38M Tris/HCl, pH 8.8, 0.1% SDS and 
4.2% glycerol, was poured between a former composed of 2 glass plates
1.5mm apart, to give a gel approximately 13cm in length. Polymerisation 
was initiated by the addition of TEMED and ammonium persulphate to final 
concentrations of 0.05% (v/v) and 0.04% respectively. While the gel was 
polymerising, the top surface of gel was covered with 0.1% SDS. After the 
resolving gel had polymerised, the 0.1% SDS was removed and a stacking 
gel, consisting of 3% acrylamide, 0.08% bisacrylamide, 0.38M Tris/HCl, 
pH6.8, and 0.1% SDS, was poured above the resolving gel, such that there 
was approximately 1.5cm of stacking gel between the bottom of each well 
and the resolving gel. Polymerisation was initiated in the same manner as
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for the resolving gel. After the stacking gel had polymerised, the 
electrophoresis apparatus was assembled and the denatured protein 
samples loaded onto the gel. When control and DAT subjects were being 
compared the two groups were loaded alternately onto the gel. Molecular 
weight markers were applied to at least one lane per gel. The markers used 
were prestained which allowed them to act as an indicator of protein 
transfer after blotting. However the bands produced by these markers were 
rather diffuse, and consequently only approximate molecular weights could 
be determined using them. The gels were run overnight at a constant 
current of 14mA per gel using an electrophoresis buffer composed of 190 
mM glycine, 25 mM Tris and 0.1% SDS. Electrophoresis was stopped when 
the bromophenol blue dye front reached the bottom of the gel.
4.4 Protein blotting.
After electrophoresis, the resolving gel was separated from the 
stacking gel and incubated in transfer buffer composed of 190mM glycine, 
25mM Tris and 20% methanol, for 15 minutes. The gel was removed from 
the buffer and a sheet of nitrocellulose was placed on top of it. After any air 
bubbles had been removed, the gel and nitrocellulose were sandwiched 
between sheets of wet Whatman 3MM paper, and immersed in transfer 
buffer in the blotting apparatus. Proteins were then transferred to the 
nitrocellulose at 70V for 3 hours. The extent of transfer and equity of protein 
loading on the gel, were then checked by staining the gel in a solution 
containing 0.05% comassie brilliant blue R, 50% methanol and 10% acetic 
acid, and destaining the gel in the same solution minus the comassie 
brilliant blue R.
4.5 Detection of G protein bands.
After transfer the nitrocellulose blot was incubated in TS buffer (0.5M 
sodium chloride, 20mM Tris/HCl, pH7.5) containing 3% fat free dried milk
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for 3 hours at room temperature to block non-specific binding sites. All 
incubations involving nitrocellulose sheets were carried out on an orbital 
shaker set at approximately 1 revolution per second. The nitrocellulose 
sheets were then rinsed twice with TS buffer and incubated overnight at 
room temperature in primary antisera diluted in TS buffer containing 1% 
dried milk and 0.01% thimerosal. The latter substance served to inhibit 
microbial growth. Antisera CS1 was normally used at a dilution of 1/200, 
SG2 at 1/200, and OC1 at 1/10000. The blots were then washed for 10 
minutes at room temperature in TS buffer containing 0.05% Tween 20, and 
then for 10 minutes at room temperature in TS buffer. Those blots which 
had been incubated with antisera OCl or SG2 were then incubated for 3 
hours at room temperature with horse radish peroxidase linked anti-rabbit 
IgG, used at a dilution of 1/200 in TS buffer containing 1% dried milk. The 
blots were then washed for 10 minutes at room temperature in TS buffer 
containing 0.05% Tween 20, and then for 10 minutes at room temperature in 
TS buffer. Immunoreactive bands were visualised by incubating with a 
buffer containing lOmM Tris/HCl, pH 7.5, 0.015% hydrogen peroxide and 
0.02% o-dianosidine. The colour reaction was terminated by rinsing the blot 
twice in distilled water. In a few experiments antisera CS1 was processed in 
the same manner as SG2 and OCl, however it emerged that more sensitive 
techniques were required for successful blotting with this antisera. In one 
experiment, after incubation with CS1 and subsequent washing, the blot was 
incubated for 2 hours at room temperature with biotinylated anti-rabbit IgG 
used at a dilution of 1/400 in TS buffer containing 1% dried milk. The blot 
was then washed for 3x5 minutes at room temperature in TS buffer 
containing 0.05% Tween 20, and then for 3x5 minutes at room temperature 
in TS buffer. After this the blot was incubated at room temperature with 
streptavidin linked horse radish peroxidase used at a dilution of 1/3000 in 
TS buffer containing 1% dried milk. The blot was then washed for 3x5 
minutes at room temperature in TS buffer containing 0.05% Tween 20, and
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then for 3x5 minutes at room temperature in TS buffer. Immunoreactive 
bands were then visualised by incubating with a buffer containing lOmM 
Tris/HCl, pH 7.5, 0.015% hydrogen peroxide and 0.06% o-dianosidine. The 
colour reaction was terminated by rinsing the blot twice in distilled water. 
For the majority of the experiments involving CS1, after incubation with the 
primary antisera and subsequent washing, the blot was incubated for 2 
hours at room temperature with 125I- labelled anti rabbit IgG, used at a 
concentration of 2-4pCi per 50 ml of TS buffer containing 1% dried milk. 
The blot was then washed for 2 x 10 minutes in TS buffer containing 0.05% 
Tween 20, before being dried, wrapped in Saran wrap, and exposed to Fuji 
RX X-ray film with "lightning fast" intensifying screens at -80°C for between 
2 and 5 days.
The blots were analysed using a Quantimet Image Analyser 970 
(Cambridge Instruments) by taking a number of spot densitometric readings 
along the width of the band which were then averaged to give the final 
measurement.
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5. Assay of adenylate cyclase activity.
The activity of adenylate cyclase was essentially assayed as described 
in Salomon et al. (1974) with some variations.
5.1 Preparation of chromatography columns.
An equal volume of water and Dowex AG50W-X4 200-400 mesh resin 
was mixed for 10 minutes, the resin allowed to settle out and the water 
removed. This was repeated until the water which had been mixed with the 
resin remained clear. A further volume of water was added to the resin and, 
whilst stirring rapidly, 2ml of the mixture was pipetted into a Biorad 
polyprep column to give a bed volume of 1ml. The columns were then 
washed once with 4ml of 1M NaOH, then with 4ml of 1M HC1, and finally 
the column was stoppered and a further 4ml of 1M HC1 added.
The alumina columns were prepared by mixing an equal volume of 
neutral chromatographic alumina and 0.1M imidazole/HCl, pH 7.3. While 
stirring rapidly, 2 ml of the mixture was pipetted into a Biorad polyprep 
column to give a bed volume of 1ml. The column was washed once with 4 
ml of 0.1M imidazole/HCl, pH 7.3, before the column was stoppered and a 
further 4 ml of 0.1M imidazole/HCl, pH 7.3, added.
Since the columns were to be used to separate ATP from cAMP, it 
was necessary to determine the elution profiles of the columns. A tube was 
prepared which was processed as per an assay blank (See Section 5.2) except 
that no 3H labelled cAMP was added. Another tube was prepared in a 
similar way except that no 32P labelled ATP was added. The contents of 
each tube were mixed with 0.6ml of water and applied to separate Dowex 
resin columns. The first 0.6 ml of eluate was collected in a scintillation vial. 
A series of additions of 0.5ml of water was then applied to each column and 
the eluate collected. After scintillation counting, the elution profiles of the 
columns were plotted (Figure 3). From this it was decided to wash the 
Dowex resin columns with 2 ml of water to elute most of the ATP, then with
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4 ml of water to elute the cAMP. The elution profiles of the alumina 
columns were derived by using the Dowex columns as determined above, 
and letting the 4ml water wash drip through onto, and through, the 
alumina columns. After this 0.5 ml volumes of 0.1 M imidazole/HCl, pH 7.3, 
were applied to the alumina columns, and the eluate collected and the 
radioactivity in each fraction determined by scintillation counting. The 
elution profiles for these columns (Figure 3) showed that most of the cAMP 
was eluted after l-5ml of 0.1M imidazole/HCl, pH 7.3, had been applied to 
the column. It was therefore decided to first wash the alumina columns 
with 1ml of 0.1M imidazole/HCl, pH 7.3, and then elute the cAMP with 4ml 
of 0.1M imidazole/HCl, pH 7.3.
63
(a)
(b)
of radioactivity 
applied to 
columns
50 n a  32 p
20 -
0
T 1TT T
Percentage 
of radioactivity 
applied to 
columns
50 
40 - 
30 - 
20 * 
10 -  
0 J
1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 
Elution Volume (ml)
a  32 p
• 3H
f
/  \
/  *
/  '
 A--------- A-------A -  A-------- f t r - O  ■c
■ 1 1--1   1 1 1 '-1 ■ 1-  1 ' 1
1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0
Elution Volume (ml)
f ig u re d
Elution profiles of Dowex resin and alumina columns,
Both 32P labelled ATP and 3H labelled cAMP were applied to Dowex 
resin or alumina columns as described in the text. Dowex resin columns (a) 
were washed with 0.5ml volumes of water, while alumina columns (b) were 
washed with 0.5ml volumes of 0.1M Imadazole/HCl, pH 7.3. The eluate 
was collected and the amount of 32P or 3H it contained determined by liquid 
scintillation counting. The results are expressed as the percentage of the 
quantity of radioactivity originally applied to the columns.
5.2 Formation of 32P labelled cAMP.
Aliquots of membrane protein preparations were diluted to lm g 
protein/m l with lOmM Tris/HCl, pH 7.5, and kept on ice before use. 
Adenylate cyclase activity was assayed by incubating 20pg of membrane 
protein in lOOpl of a buffer containing lOOmM Tris/HCl, pH 7.5, 50mM 
sodium chloride, 5mM magnesium chloride, ImM cAMP, 200pM ATP 
containing lpCi of oc-32P ATP, 20mM creatine phosphate and lOOU/ml of 
creatine phosphokinase. The incubations were carried out at 30°C for 15 
minutes, the linearity of the reaction having been confirmed. In some cases 
adenylate cyclase was assayed in the presence of lOpM aluminium chloride 
and 5mM sodium fluoride. Two tubes per assay were incubated with no 
membrane protein added to act as assay blanks. The reaction was 
terminated by the addition of 150|_il of stop solution containing 2% SDS, 
40mM ATP, 1.3mM cAMP and approximately 30,000 cpm of 3H labelled 
cAMP, before placing the tube in an ice bath. This was followed by boiling 
for 10 minutes. If required the assay tubes were frozen to -20°C and stored 
overnight. All preparations were assayed in duplicate.
5.3 Purification of 32P labelled cAMP.
32P labelled cAMP was purified from the much more abundant 32P
labelled ATP according to the method of Salomon (1974). The Dowex resin 
columns were prepared for use by draining them of the 4ml of 1M HC1 that 
they had been stored with, washing with 10ml of water and finally with 4ml 
of water. The alumina columns were simply drained of the 4ml of 0.1M 
imidazole/HCl, pH 7.3, that they had been stored with. To each assay tube 
was added 0.6ml of water and the entire contents of each tube applied to 
Dowex resin columns. After this had run into the column, the column was 
washed with 2ml of water and the eluate discarded. The Dowex resin 
columns were then placed above the alumina columns, and 4ml of water 
applied to the Dowex resin columns. The eluate from the Dowex resin
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columns was allowed to drip through the alumina columns, the eluate from 
the alumina columns being discarded. The alumina columns were then 
washed with 1ml of 0.1M imidazole/HCl, pH 7.3, and the eluate discarded. 
After this 4ml of 0.1M imidazole/HCl, pH 7.3, was added to the columns, 
the eluate being collected in scintillation vials filled with 16 ml of Ecoscint. 
The vials were shaken and counted, for four minutes per vial, in a liquid 
scintillation counter set to count 3H and 32P. The 3H counts were used to 
monitor the recovery of cAMP from each column, this being used to correct 
the 32P counts to give the total amount of 32P labelled cAMP produced in the 
reaction. Column recoveries of cAMP were in the order of 70 to 80%. The 
activity of adenylate cyclase in pmols cAMP form ed/m g protein/m inute 
was calculated by the following expression :
(32P recovered x 3H cAMP added (cpm)* x 20000 pmols **___
- assay blank) (cpm) 3H recovered (cpm) 32P added (cpm)***
x 1000 x ______1______
Protein (jig) Time (minutes)
* the amount of 3H cAMP solution added after the incubation to monitor 
recovery.
** the 20000 pmols refers to the amount of ATP in each assay tube.
*** the total amount of 32P labelled ATP added to each tube.
After each experiment the alumina columns were washed with 4ml of 
0.1M imidazole/HCl, pH 7.3, stoppered and a further 4ml of 0.1M 
imidazole/HCl, pH 7.3 added. The Dowex resin columns were recycled by 
washing them with 4ml of 1M NaOH, then with 4ml of 1M HC1. Finally the 
columns were stoppered and a further 4ml of 1M HC1 added.
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6. Assaying of sodium potassium-dependent ATPase activity.
Sodium potassium-dependent ATPase activity was assayed 
according to the method of Esmann (1988) with minor variations. The basis 
of the assay is the coupling of the hydrolysis of ATP to form ADP plus Pi, to 
the oxidation of NADH, an event which can be followed 
spectrophotometrically. The membrane preparations were diluted to lm g 
protein/m l with lOmM Tris/HCl, pH 7.5, and sodium deoxycholate was 
added to a final concentration of 0.2% and the mixture put on ice for 15 
minutes. 1ml of a buffer containing 30mM histidine, 3mM ATP, 20mM 
potassium chloride, 130mM sodium chloride, ImM phosphenolpyruvate, 
0.2mM NADH, lOU/ml pyruvate kinase and 30U/ml lactate dehydrogenase 
was pre-incubated in a cuvette for 90 seconds at 37°C. The reaction was 
then started by addition of 20pg of membrane protein. After 15 minutes at 
37°C, the A340nm of the incubation mix was measured to determine the 
amount of NADH oxidised and hence the amount of Pi produced. The 
linearity of the reaction had been confirmed previously. The non-specific 
ATPase activity of each sample was measured in the presence of ImM 
ouabain. Three cuvettes containing no membrane protein were processed 
per assay to act as blanks. All preparations were assayed in triplicate. The 
activity of sodium potassium-dependent ATPase in nmols Pi form ed/m g 
protein/m in was calculated as follows:
(A^onm assay blank x 1 x 1 x 1000__
'  A 340nm a t^er incubation) 0.00622* Time(mins) Protein (jig)
*the value of e(NADH) - e(NAD) in pM /cm  or nm ols/m l/cm . (The 
path length used was 1cm and the assay volume was 1ml).
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7. Assay of choline acetyl transferase activity.
Choline acetyl transferase activity was assayed according to the 
method of Fonnum (1975) with minor modifications. Tissue samples were 
homogenised in 6 or 10 volumes of ice cold lOmM Tris/HCl, pH 7.5, ImM 
EDTA and diluted 1:1 with 1% Triton X-100 in 20mM EDTA. The 
homogenates were kept on ice until ready to use. lOpl of each homogenate 
(containing 30-50pg of protein) was incubated for 20 minutes at 37°C in a 
buffer containing 300mM sodium chloride, 50mM sodium phosphate buffer, 
pH 7.4, 8mM choline bromide, 20mM EDTA, O.lmM physostigimine and 0.2 
mM acetyl CoA containing approximately 125,000 dpm of 14C labelled acetyl 
Co A. Three tubes which contained no protein were processed in each assay 
to act as blanks. All samples were assayed in triplicate. The microtube was 
then opened by cutting the top off and both pieces were put into a 
scintillation vial containing 5ml of 50mM sodium phosphate buffer, pH 7.4. 
The vial was then shaken for 30 seconds and 2ml of acetonitrile containing 
lOmg of kalignost added. Finally 10ml of a toluene based scintillation 
mixture (POPOP) was added to each vial. The vial was then shaken lightly 
for one minute and the two layers left to separate for 10 minutes. This 
procedure extracted the 14C acetyl choline formed during the incubation into 
the organic phase (which contains fluor), while leaving the acetyl CoA in the 
aqueous phase. The radioactivity in the organic phase was then determined 
by liquid scintillation counting. Choline acetyl transferase activity in nmols 
acetyl choline form ed/m g protein/hour, was calculated using the following 
expression -
(14C of sample x (5 nmols + contribution from 14C ACoA)
- assay blanks) (cpm) 14C added (cpm)
x 60 mins x 1000___
Time (mins) Protein (pg)
* the amount of acetyl CoA added to each assay tube
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8. Assaying of protein concentrations.
Proteins were assayed according to the method of Lowry et al. (1951) 
using bovine serum albumin as a standard.
9. Purification of total RNA.
All apparatus and solutions used in the purification and analysis of 
RNA were treated to remove any RNase contamination as described in 
Sambrook et al. (1989): glassware was oven baked at 200°C for 16 hours, or 
washed in chloroform before being autoclaved at 151b/inch2 for 20 minutes; 
plasticware was autoclaved for 20 minutes at 151b/inch2; aqueous solutions 
were treated, where appropriate with diethyl pyrocarbonate (DEPC) by 
adding DEPC to a concentration of 0.1%, shaking vigorously for 30 seconds, 
leaving the solution overnight and then autoclaving for 20 minutes at 151b/ 
inch2; certain articles of apparatus e.g electrophoresis kits, were steeped in 
3% hydrogen peroxide for 1 hour before being rinsed with DEPC treated 
water. In addition the water used to resuspend RNA was filtered through a 
sterile 0.2pm filter before being DEPC treated.
Total RNA was prepared, with minor variations, according to the 
method of Chomczynski & Sacchi (1987). Tissue which had been previously 
ground in liquid nitrogen was homogenised in 10 volumes of GIT buffer 
(4M guanidinium thiocyanate, 25mM sodium citrate, pH 7.0, 0.5% sodium 
sarcosine, 0.1M 2-mercaptoethanol; this solution was filtered through a 
0.8pm filter before use) using a teflon-glass homogeniser. The homogenate 
was then transferred to a 15 or 30ml glass centrifuge tube (Corex). To this 
was added sequentially; 0.1 volumes (relative to the homogenate volume) of 
2M sodium acetate, pH 4.0,1 volume of water saturated phenol containing 
approximately 0.1% 8-hydroxyquinoline, and 0.2 volumes of a 49:1 
chloroform, isoamyl alcohol mixture. The top of the centrifuge tube was 
sealed with para film, and the mixture shaken vigorously for 2 minutes
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before being left on ice for 15 minutes. It was then centrifuged at 3000gav for 
30 minutes at 4°C in a Mistral 5L centrifuge, or in some experiments at 
10,000gav for 20 minutes at 4°C in a Sorvall superspeed centrifuge. The 
upper aqueous phase was removed and mixed with an equal volume of cold 
(-20°C) isopropanol. This was then placed at -20°C overnight to precipitate 
RNA. The RNA was sedimented by centrifugation at 3000gav for 30 minutes 
at 4°C, or at 10,000gav for 15 minutes at 4°C, and the resulting pellet was 
resuspended in 3ml of GIT buffer and reprecipitated using isopropanol at - 
20°C for 1 hour. After centrifugation, the pellet was washed once with cold 
70% ethanol before being dried in a vacuum dessicator. The RNA was then 
resuspended in DEPC treated water, and the RNA concentration estimated 
by measuring the OD260 of the solution in triplicate (lOD unit = 40pg RNA/ 
ml; Sambrook et al., 1989). The purity of the RNA was assessed by 
measuring the OD260/O D 280 ratio of the solution. This purification 
procedure usually gave a ratio of above 1.90 and in all cases above 1.85. 
Pure RNA should give a ratio of 2.0 (Sambrook et a l, 1989).
10. Northern blotting.
10.1 Generation of oligonucleotide probes.
Oligonucleotides were synthesised using an Applied Biosystems 
DNA synthesiser, and are described fully in Table 4. Those which hybridise 
to G protein mRNA were designed by Prof. J.T. Knowler, Department of 
Biological Sciences, Glasgow Polytechnic. In summary, oligonucleotides 
were made with unique complementary to all four forms of rat Gsa mRNA, 
the two large forms of human Gsa mRNA, human G(31 and G(32 mRNA, rat 
Gil mRNA, rat Gi2 mRNA, human Gil mRNA, human Gi2 mRNA and 
human 28S rRNA. Oligonucleotides were 5' end labelled with y-32P labelled 
ATP by incubating lOOng of oligonucleotide in a buffer (final volume 50pl) 
containing lOmM magnesium chloride, lOOmM Tris/HCl, pH 7.6, 20mM 2- 
mercaptoethanol, lOOpCi y-32P ATP and 10 units T4 polynucleotide kinase.
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Incorporation of 32P into the oligonucleotide was monitored by thin layer 
chromatography on PEI cellulose plates using 0.5M potassium phosphate 
buffer, pH 3.5, as a running buffer. The plate was exposed to X-ray film to 
determine the position of the oligonucleotide, ATP and Pi. The plate was 
then cut up and Cherenekov counted to calculate the percentage 
incorporation of 32P into the oligonucleotide. This was typically between 
50% and 70%.
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Table 4.
The oligonucleotides utilised in northern blotting.
The sequences of the oligonucleotides are shown in the 5' to 3' 
direction. The amino acid sequence num bers represent the amino acids 
encoded by the mRNA to which the oligonucleotides are complimentary.
4 = the sequence given refers to the nucleotide number. RM = 
num ber of mismatches between oligonucleotide sequence and sequence in 
rat. HM = num ber of mismatches between oligonucleotide sequence and 
sequence in human. NK = not known.
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10.2 Electrophoresis and blotting of RNA.
The deionised formamide used in the following procedures was 
produced by mixing formamide with mixed bed resin (AG501-X8 (20-50 
mesh)) at 10ml formamide per gram of resin for 30 minutes. The formamide 
was then filtered to remove the resin, and stored at -20°C.
RNA (usually 20pg) was denatured at 65°C for 5 minutes in a buffer 
(final volume 25jnl) containing 2M formaldehyde, 50% deionised formamide 
(v/v) and lxMOPS (lxMOPS = 20mM MOPS, 5mM sodium acetate, ImM 
EDTA pH 8.0). To each tube was added 5|il of loading buffer containing 
50% glycerol and 0.4% bromophenol blue. This was then applied to a 1% 
agarose gel, of dimensions 1.2 cm deep and 14cm long, containing 2.2M 
formaldehyde and lxMOPS buffer. The gel was run overnight at a constant 
voltage of 24V, using lxMOPS as an electrophoresis buffer. In some cases 
RNA size markers were run in one lane per gel. After electrophoresis, RNA 
was transferred onto nylon membranes by capillary blotting according to 
Sambrook et al. (1989). The gel was inverted and placed on a piece of 3MM 
paper (Whatmann), the ends of which had been dipped into a reservoir of 
20xSSC (lxSSC = 150mM sodium chloride, 15mM sodium citrate pH 7.0). A 
piece of Hybond N or Hybond N+ was placed on top of the gel, and covered 
with two pieces of 3MM paper. On top of these was placed a 5cm pile of 
paper napkins. The whole sandwich was compressed with a 1kg weight, 
and transfer allowed to continue for 6 hours, with frequent changing of the 
paper napkins. After transfer, the RNA was fixed to the nylon membrane by 
exposing to short wavelength UV light for 1 minute (Hybond N), or placing 
the blot onto 3 pieces of 3MM paper soaked in 0.05M sodium hydroxide, 
leaving for 5 minutes and rinsing in 2xSSC (Hybond N+).
10.3 Detection of specific RNA species.
For the detection of Gsoc, Gil, Gi2 or GP mRNA the blots were 
prehybridised at 42°C for 4-6 hours in hybridisation solution (5xSSPE, 
(lxSSPE = 150mM sodium chloride, lOmM sodium dihydrogen phosphate, 
ImM EDTA, pH 7.4), 30% deionised formamide (v/v), 0.02% bovine serum 
albumin, 0.02% Ficoll 400, 0.02% polyvinylpyrrolidone, 0.02% denatured
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salmon testes DNA and 0.1% SDS) and then hybridised overnight in 
hybridisation buffer containing 3-5X106 cpm /m l of the appropriate labelled 
oligonucleotide. After hybridisation, the blots were rinsed twice in 2xSSPE, 
0.1% SDS at 42°C and then washed in 0.5xSSC, 0.1% SDS at 60°C for 15 
minutes. The 28S rRNA oligonucleotide was used in a similar way except 
that prehybridisation and hybridisation took place in a solution containing 
4xSSPE, 0.1% sodium pyrophophate, 0.2% SDS and 0.05% denatured salmon 
testes DNA. The blot was rinsed twice in 2xSSPE, 0.1% SDS, 0.1% sodium 
pyrophosphate, and then washed in the same solution for 30 minutes at 
37°C. This oligonucleotide was washed to a lower stringency than the G 
protein oligonucleotides due to its lower GC content and smaller size.
The location of bound oligonucleotide was visualised by exposure to 
Fuji RX X-ray film using "lightning plus" intensifying screens at -80°C. Blots 
which had been probed to show G protein mRNAs were exposed for 1 to 3 
days, while those probed to show 28S rRNA were exposed for 5 to 20 
minutes.
Densitometric analysis of the autoradiograms was carried out using a 
Quantimet Image analyser 970 (Cambridge Instruments). Spot 
densitometric readings were taken along the length of the band. The optical 
density reported is the highest OD within the length of the band. This is 
analogous to using peak heights on a scanning densitometer.
After hybridisation and autoradiography, total RNA was stained on 
the blots with methylene blue to show the position of 28S and 18S rRNA. 
The blot first immersed in 5% (v/v) acetic acid for 15 minutes, and then 
stained in a solution containing 500mM sodium acetate, pH 5.5, and 0.04% 
methylene blue, for 3 minutes. The blot was then washed in water until the 
background was destained.
The use of nylon membranes allowed the oligonucleotide probes to 
be stripped from the blot and the blot rehybridised to another probe. This 
was accomplished by immersing the blot in a solution of boiling 0.1% SDS 
and allowing it to cool to room temperature. Autoradiography was then 
used to check that the probe had been removed.
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11. Mid cerebral artery occlusion with 30 minutes of hypotension.
The following procedures were carried out by Dr. Kasumoto 
Kuramaji at the Wellcome Surgical Institute.
11.1 Preparation of animal.
The experiments were carried out on male Sprague-Dawley rats of 
body weight 250-300g. Anaesthesia was induced by placing the rat in a 
perspex box into which was fed 5% halothane in 30% 0 2 and 70% N20 . The 
animal was moved to an operating table where anaesthesia was maintained 
with 2% halothane in 30% 0 2 and 70% N20  delivered via a funnel placed 
over the animal's nose. The trachea was exposed and a tracheotomy tube 
inserted. Respiration was maintained using a Palmert small animal positive 
pressure respirator pump delivering 0.5% halothane, 30% 0 2, and 70% N20  
via the tracheotomy. Peripheral body temperature was recorded 
continuously by a rectal thermometer. Two femoral arteries and one 
femoral vein were cannulated with polyethylene catheters (internal diameter
0.58mm, external diameter 0.96mm). The arterial lines were used to obtain 
continuous, direct arterial blood pressure measurements using a Gould 
blood pressure transducer. They also served to withdraw arterial blood to 
induce haemorrhagic hypotension or perform intermittent arterial blood gas 
analysis using a Corning 168 pH /blood gas analyser. The venous line was 
used to deliver blood to return the animals blood pressure to normal after 
the period of hypotension.
11.2 Middle cerebral artery occlusion.
The occlusion of the middle cerebral artery was carried out exactly as 
described in Tamura et al. (1981). Briefly the left mid cerebral artery (MCA) 
was exposed by a small cranioectomy using a saline cooled dental drill. The 
skull was opened close to the foramen ovale. After the dura was opened 
with a fine needle, the middle cerebral artery was occluded by
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thermocoagulating and severing it between its cortical branch to the rhinal 
cortex and the lateral striate arteries. The cranioectomy was then covered by 
a small piece of gel foam. Sham operated animals were treated identically 
except that no MCA occlusion was performed.
11.3 Hypotension.
The blood pressure of the animal was lowered to a target value of 
55mm Hg for 15 minutes after MCA occlusion, and lasted for a period of 30 
minutes. This was performed as described in Osborne (1987). By 
continuous reference to the blood pressure trace (set on average) the animals 
blood pressure was lowered to the target value by withdrawing blood from 
the arterial line into a heparinised syringe. After transferring the syringe to 
the venous line and attaching another syringe to the arterial line, the blood 
pressure was maintained by withdrawal and administration of blood via the 
arterial and venous lines respectively. At the end of the thirty minute 
period, the blood pressure was restored to normal by slow reperfusion of 
blood through the venous line. Three hours after MCA occlusion the animal 
was killed by decapitation and the brain carefully removed. The region of 
the cortex fed by the middle cerebral artery (as described in Yamori et al. 
(1976)) was dissected from the left and right hemispheres, frozen in liquid 
nitrogen and stored at -80°C. The length of time between decapitation and 
freezing of the brain tissue was no more than 10 minutes.
74
12. Statistical methods.
The mean values of a variable measured in two groups were 
compared using a two tailed, unpaired Students test using pooled variance 
as described in Milton & Tsokos (1983). Each dataset was checked for any 
evidence of a non-normal distribution using a goodness of fit test (Milton & 
Tsokos, 1983). These two tests were usually carried out with the aid of the 
statistical package "Statworks" running on an Apple Macintosh 
microcomputer. In addition the assumption that the variances of both 
populations were equal was checked using a "F-test" (Milton & Tsokos, 1983) 
to compare sample standard deviations. The statistical significance of the 
result of a the test was either determined automatically by the Statworks 
program, or derived using Neave's (1983) tables. One way analysis of 
variance was accomplished manually as described in (Milton & Tsokos, 
1983).
The correlation between two variables was investigated using linear 
regressional analysis as described in Milton & Tsokos (1983). The statistical 
significance of the calculated regression coefficient was determined using 
Neave's (1983) tables.
The percentage difference between the mean value of two data sets, 
each possessing any given value of standard deviation, which was required 
to give a statistically significant result using a Students t-test was calculated 
as follows. A computer program was written that calculated the value of the 
t-statistic using the two datasets. If this was not statistically significant the 
mean value of one of the groups was changed by a small amount. The 
standard deviation of the data was also altered, such that the standard 
deviation as a proportion of the mean (the coefficient of variation) remained 
constant. The t-statistic was then recalculated. The program repeated this 
procedure until the value of the t-statistic became statistically significant, 
whereupon the percentage difference between the two means was reported. 
In this way the effect of different degrees of intersubject variability upon the 
likelihood of obtaining a statistically significant difference between two 
groups of data could be investigated.
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III. RESULTS
1. Characterisation of the procedures used to analyse human brain tissue.
The analysis of transduction systems in human brain required the use 
of various biochemical techniques. These procedures have previously been 
applied mainly in the investigation of animal and cell line systems. It was 
necessary therefore to check that the assays that were to be used would 
function correctly when used to analyse human brain tissue.
1.1 Western Blotting.
The measurement of the relative amounts of the a  subunits of Gs, Gi 
and Go was accomplished using western blotting utilising specific antisera. 
The antisera used were CS1 which detects Gsa, OCl which detects Goa, SG2 
which detects G ia (see "Methods").
The procedure that was employed to quantitate the relative amount 
of G proteins present on the western blots, was to measure the optical 
density of the G protein bands. For this to be successful it was necessary to 
ensure that a linear relationship exists between the amount of G protein 
present on the blot, and the optical density of the detected band. This was 
accomplished by loading an increasing quantity of membrane protein onto a 
gel, measuring the optical density of the resulting band(s), and determining 
over what range the two values are directly proportional to each other. 
Membranes prepared from rat brain were used to test antisera OCl and SG2 
due to the large amount of protein required for this procedure and the 
relative scarcity of the human tissue. Figure 4 shows a western blot of rat 
brain membrane proteins incubated with antisera OCl, the resulting 
immunocomplex being detected with a horse radish peroxidase (HRP) 
linked secondary antibody. The antisera detected one band, corresponding 
to Goa, which possessed an approximate molecular weight of 40kD. The 
optical density is directly proportional to the quantity of protein which was
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loaded onto the gel, within the range 0 to 150pg of protein. In all subsequent 
blots 50jig of protein was used. The procedure was also carried out for 
antisera SG2 (Figure 4), which detects two bands corresponding to two 
forms of Gia, Gil and Gi2, having approximate molecular weights of 39 and 
37kDa respectively. This antisera also gave a linear response up to 150pg of 
protein loaded for both Gil and Gi2; 50 or lOOpg of protein was used in 
subsequent experiments. Antisera SG2 also detected higher molecular 
weight proteins, which did not correspond to any known G protein species. 
However these were not present on all blots.
The use of antisera CS1, which detects Gsa, proved to be more 
problematical. The detection method used for OCl and SG2, namely a 
secondary anti-rabbit immunoglobulin antisera which had been linked to 
HRP, was too insensitive to detect Gsa protein in brain. When the antisera 
was used at a dilution of 1/200, even loading 400|ig of membrane protein 
onto the gel proved to be inadequate (data not shown). A more sensitive 
method was tried which employed a biotinylated secondary antibody with 
subsequent application of streptavidin-linked HRP. This procedure allowed 
the detection of bands which were the size of Gsa, but had the disadvantage 
that many other bands were also visible on the blot (data not shown). 
Another detection system was tried which used a 125I labelled anti-rabbit 
immunoglobulin antibody. When used with CS1 as the primary antibody, 
two major bands were visible on the resulting autoradiogram corresponding 
to the two forms of Gsa detected by CS1, GsH and GsL, possessing 
approximate molecular weights of 45 and 42 kDa respectively (Figure 5). 
The antisera gave a linear response up to lOOpg of protein loaded onto the 
gel for both GsH and GsL; 50|ig protein was used in subsequent 
experiments. A further three faint bands were also visible at molecular 
weights which do not correspond to any known variants of Gsa. They were 
not detected when the blot was incubated with secondary antibody alone, 
and are therefore not due to the detection system employed (data not
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shown). In addition these bands were present on some blots but not on 
others. However even when present, the higher molecular weight bands 
were barely discernible at the protein loadings which were routinely used.
To confirm that the same bands were being detected in both rat and 
human brain, membrane proteins prepared from both species were analysed 
by western blotting using the antisera OCl, SG2 and CS1 (Figure 6). The 
resulting blots show bands of the same molecular weight in rat and human 
brain, the only difference being that the band corresponding to GsH is wider 
in membrane proteins prepared from human brain, than from those 
prepared from rat brain. In addition the relative abundance of GsL 
compared to GsH is very low in membranes prepared from whole rat brain.
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Figure 4.
Relationship between the amount of protein loaded onto gels and the 
intensity of the Goa band detected with antisera OCl, and the G il and 
Gi2 bands detected with antisera SG2.
Crude membrane protein extracts were prepared from whole rat 
brain and analysed by western blotting as described in "Methods". A 
polyacrylamide gel was run overnight with each gel lane having been 
loaded with between 10 and 200pg of protein. After transfer of the proteins 
onto a nitrocellulose membrane, the blot was incubated with the antisera 
OCl, and then with HRP linked anti-rabbit IgG antisera. After 
development, a single band was visible on the blot (a), which was then 
analysed by densitometry (b) to show the relationship between the amount 
of protein loaded and the optical density of the resulting Goa band. A 
second polyacrylamide gel was loaded with between 25 and 250pg of 
protein per lane, run overnight and the proteins transferred onto a 
nitrocellulose membrane. The blot was incubated with the antisera SG2, and 
then with HRP linked anti-rabbit IgG antisera. After development, the blot 
(c) shows two bands which were then analysed by densitometry (d), to show 
the relationship between the amount of protein loaded and the optical 
density of the resulting Gia bands.
Molecular weight markers, run along with the membrane 
preparations, are shown alongside each blot.
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Figure 5.
Relationship between the amount of protein loaded onto the gel and the 
intensity of the GsH and GsL bands detected with antisera CS1.
Crude m em brane protein extracts were prepared from the right 
frontal cortex of subject C8 and analysed by western blotting as described in 
"Methods". The am ount of protein loaded onto the polyacrylamide gel 
ranged from 20 to 150pg. The gel was run overnight and the proteins 
transferred onto a nitrocellulose membrane. The blot was incubated with 
antisera CS1, and then with 125I linked anti-rabbit IgG antisera at a 
concentration of 3pCi/50ml. The immunocomplex was detected by 
exposure to X-ray film for 2 days. The resulting autoradiogram  (a) shows 
two bands of the correct molecular weight, which were then analysed by 
densitom etry (b) to show the relationship between the am ount of protein 
loaded and the optical density of the G sa bands.
Molecular weight markers, run along with the membrane 
preparations, are shown alongside the autoradiogram .
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Figure_6,
The detection of Gsa, Gia. and Goa proteins in human and rat brain.
Crude membranes were prepared from whole rat brain and from the 
left frontal cortex of subject C14 (a) and (c), or subject C20 (b). These were then 
analysed by western blotting as described in "Methods". For both rat and 
human samples, 50pg of protein was loaded per lane, the gels run overnight 
and the proteins transferred onto nitrocellulose membranes.
(a). One blot was incubated with antisera CS1, and then with 125I linked 
anti-rabbit IgG antisera at a concentration of 3pCi/50ml. The immunocomplex 
was detected by exposure to X-ray film for 3 days. RB = rat brain, HB = human 
brain.
(b). This blot was incubated with the antisera SG2, and then with HRP 
linked anti-rabbit IgG antisera.
(c). The blot was incubated with the antisera OCl, and then with HRP 
linked anti-rabbit IgG antisera.
1.2 Adenylate Cyclase assay.
Adenylate cyclase activity was assayed by monitoring the formation 
of 32P labelled cAMP usinga-32P labelled ATP as a substrate, and then 
separating the cAMP from the ATP using chromatography. The enzyme 
was assayed both under basal conditions, and stimulated in the presence of 
sodium fluoride and aluminium chloride (fluoroaluminate). To determine 
for how long the enzyme maintained a constant rate of reaction, and hence 
the number of samples that could be processed in one batch, a time course 
experiment was carried out using human membranes as the source of 
adenylate cyclase (Figure 7). It was evident that for both stimulated and 
basal activities that the initial rate of reaction was maintained for 20 minutes. 
In all subsequent assays the reaction was allowed to proceed for between 15 
and 17 minutes. Given that up to four assay tubes may be processed per 
minute, this allowed up to 68 tubes to be processed in one batch. This 
number was sufficient to allow all assays to be carried out in a single batch, 
thereby removing the possibility of inter-batch variation. Another 
experiment was performed to confirm that the amount of cAMP produced 
in the assay was directly proportional to the quantity of adenylate cyclase 
present. Figure 7 shows this to be true for both basal and stimulated 
activities up to at least 60pg of protein assayed. In addition the extent of 
stimulation by fluoroaluminate is independent of the amount of protein 
added to the assay (Figure 7).
The degree of stimulation of adenylate cyclase, when it is incubated 
in the presence of fluoroaluminate, is mainly dependent on the sodium 
fluoride concentration. Only small amounts of aluminium are required for 
stimulation to occur (Inoue et al. 1990), and in all assays performed the 
aluminium concentration was kept constant at 10pM. In both rat and 
human brain sodium fluoride caused an increase in the activity of adenylate 
cyclase (Figure 8), with maximal activity occurring at 5mM sodium fluoride 
after which stimulation decreased. This response to sodium fluoride is the 
same as that reported elsewhere (Inoue et al., 1990). A sodium fluoride 
concentration of 5mM was used in all subsequent assays.
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Figure 7.
The effect of time and protein concentration on adenylate cyclase activity
in hum an brain.
Crude m embranes were prepared from the left frontal cortex of 
subject C14 and assayed for adenylate cyclase activity under the conditions 
described in "Methods".
(a). Reactions were started by the addition of 20jng of m em brane 
protein and terminated after 5,10, 20, 30 or 40 m inutes at 30°C. The enzyme 
was assayed under basal conditions and in the presence of 10pM alum inium  
chloride and 5mM sodium  fluoride (fluoroaluminate). The am ount of cAMP 
formed during this period was calculated and and plotted against time, for 
both basal and fluoroalum inate stim ulated activity. The dotted line 
dem onstrates that the reaction rate is constant for the first 20 m inutes of the 
assay.
(b) and (c). Reactions were started by the addition of 5, 10, 20, 40 or 
60pg of membrane protein and term inated after 15 m inutes at 30°C. The 
rate of cAMP formation is shown plotted versus protein (b). For both basal 
and fluoroaluminate stim ulated activities a "best fit" line calculated by linear 
regressional analysis is shown. This give a regression coefficient of 0.998 for 
basal activity and 0.987 for stim ulated activity. Stimulated adenylate cyclase 
activity expressed as a percentage of basal activity is also show n (c).
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Figure 8.
The effect of sodium fluoride concentration on adenylate cyclase activity
in human and rat brain.
Membrane preparations were prepared from whole rat brain and 
from the left frontal cortex of human subject C14, and assayed for adenylate 
cyclase activity as described in "Methods". Reactions were carried out at 
30°C for 15 minutes. Each preparation was assayed in the presence of IOjiM 
aluminium chloride along with a range of sodium fluoride concentrations. 
The enzyme activity is expressed as a percentage of the basal activity which 
was determined in the same experiment. Basal activity was 61 pmols 
cA M P/m in/m g protein for human brain, and 52 pmols cA M P/m in/ mg 
protein for rat brain.
1.3 Sodium potassium-dependent ATPase.
The hydrolysis of ATP by sodium potassium dependent ATPase was 
assayed by coupling the formation of ADP by the enzyme to the oxidation of 
NADH, an event which can be followed spectrophotometrically. The assay 
as described in Esmann (1988) calls for continual monitoring of the A340nm of 
the assay mix during the reaction. However this method of working is 
somewhat impractical when large numbers of samples are to be assayed. 
The feasibility of measuring the A340nm of the assay mix after a fixed time 
interval was therefore considered. For this to be possible the initial rate of 
reaction must be maintained for a reasonable length of time. Figure 9 shows 
the time course of the reaction for various concentrations of membrane 
protein present in the assay. The reaction proceeds at a constant rate until 
approximately 200 pmols of Pi have been formed after which Pi 
accumulation appears to stop. When lower amounts of protein are used 
there is no change in the reaction rate over 30 minutes. The reaction stops 
when 200 nmols of Pi have been formed due to the supply of NADH being 
exhausted. At this point the A340nm of the assay mix is approximately 0.1. 
Based on the data illustrated in Figure 9, assays were routinely performed 
using 20fig of membrane protein over a 15 minute time course. However 
they were repeated using half the quantity of protein if the A340nm of the 
incubation mix had fallen below 0.2.
As well as sodium potassium-dependent ATPase there are other 
ATPases present in the membrane preparations. Since ouabain is a specific 
inhibitor of sodium potassium-dependent ATPase, the contribution of other 
non-specific ATPases can be measured by assaying ATPase activity in the 
presence of ouabain. The effect of ouabain concentration on ATPase activity 
in rat and human brain is shown in Figure 9. Both species show a similar 
sensitivity to ouabain, with maximal inhibition occurring between 0.1 and 
ImM. The latter concentration was routinely used to measure non-specific 
ATPase activity.
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Figure 9.
The effect of time, protein concentration and ouabain concentration on 
sodium potassium dependent ATPase activity in brain.
A crude m em brane preparation was prepared from the left frontal 
cortex of subject C19A and assayed for sodium  potassium  dependent 
ATPase activity under the conditions described in "Methods".
(a) Reactions were started by adding 10, 20, 40 or 60jag of protein to a 
cuvette containing assay mix which had been preincubated at 37°C for 90 
seconds. In one case the assay mix contained ImM  ouabain and in another 
no protein was added to act as a blank. After 2Vi m inutes the cuvette was 
removed from the water bath, the A340nm of the assay mix read, and the 
cuvette returned to the water bath. This was repeated after 5 ,10 ,15 , 20 and 
30 minutes. The change in A340nm was then converted to nmols Pi and 
plotted against time.
(b) Reactions were started by the addition of 5, 10, 20, 30, 40 or 60pg 
of membrane protein to a cuvette containing assay mix. Each protein 
concentration was assayed in duplicate. After 15 m inutes at 37°C the A340nm 
of the assay mix was m easured, allowing the enzym e activity to be 
calculated and plotted against the am ount of protein used. The activity 
shown is minus non specific ATPase activity, which was m easured at each 
protein concentration used by including Im M  ouabain in the assay.
(c) Total ATPase activity was determ ined in hum an and rat brain in 
the presence of a range of ouabain concentrations. The assay was carried 
out at 37°C for 15 minutes. The values plotted are the mean of duplicate 
determinations.
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1.4 Northern Blotting.
For some of the G protein mRNAs assayed in this study it was only 
possible to prepare oligonucleotides complimentary to one of the species 
studied - see Table 4. It was therefore necessary to be satisfied that the 
probes could be used to detect the relevant RNA species in both rat and 
human, and that cross reaction between different G protein mRNAs was not 
a problem. Each oligonucleotide probe was tested on RNA purified from 
the brain of a human subject and from fresh rat brain. The results of these 
hybridisations are shown in Figure 10. In all cases band smearing is 
observed in the human RNA, indicating that it is at least partially degraded.
The oligonucleotide which was used to detect mRNA encoding Gj3 
hybridises to two species of mRNA in human brain. These have an 
approximate molecular size of 3.0 kilobases (kb) and 1.4 kb (Figure 10). The 
molecular sizes of each of these RNA species are similar to those reported by 
others (Fong et ah, 1986; Fong et al.f 1987). The oligonucleotide hybridises 
to only one species in rat brain RNA. This has a molecular size slightly 
greater than that of the smaller human component (approximately 1.5 kb). It 
is assumed that this species was G|32, as the oligonucleotide hybridises to a 
second band the same size as human G(3l when the blot is washed at low 
stringency. This may indicate that rat G(3l is more divergent from its human 
counterpart than G(32 is, but it should be remembered that only a small 
region of the mRNA is being hybridised and that the variation may be 
confined to this area. A possible disadvantage of using the one 
oligonucleotide to detect both forms of GJ3 stems from the fact that G(3l 
mRNA can also be detected at a similar molecular weight to G)32. It is 
therefore possible that some of the hybridisation attributed to G(32 is actually 
to Gpl. However the abundance of the small form of Gj3l mRNA in brain is 
low compared to the large form (Fong et a l, 1987), and so this is unlikely to 
be a major problem. In any case this is only true for human RNA since 
washing rat RNA at high stringency abolishes the hybridisation of the probe
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to G(3l mRNA.
The oligonucleotide which should hybridise to all four species of Gsa 
mRNA detects only one major species in rat (Figure 10). However the band 
is rather elongated and has a molecular size ranging from 2.1 to 1.6 kb. This 
size and shape of Gs band has been observed by others (Harris on et al., 
1991a; Bray et al., 1986). When this oligonucleotide is hybridised to human 
RNA, four bands are visible. Two bands, of size 2.0 and 1.6kb, were within 
the range of sizes observed for rat. The doublet appearance of human Gsa 
mRNA has been observed before (Harris on et al., 1991a). The two species 
are too different in size to be the two major subgroups of Gsa mRNA 
reported by Bray et al. (1986). The third band detected with this probe has 
an approximate size of 1.2 kb. However when human RNA is hybridised to 
the Gs-52 oligonucleotide, which should only hybridise to the large forms of 
Gsa mRNA, this species is not detected. Instead a band of size 0.6 kb is 
visible. It is likely therefore that this band and the 1.2 kb band detected 
with the Gs oligonucleotide are degradation products. However the Gs-52 
oligonucleotide does hybridise to the 2.0 kb and 1.6 kb species detected by 
the Gs oligonucleotide. This confirms that the two bands are not derived 
from the large and small Gsa mRNA subgroups. For the purpose of 
estimating the amount of Gsa mRNA in human brain, the optical densities 
of these two bands were measured and the values averaged. An additional 
faint higher molecular size species (approximately 4.5kb) is also observed in 
rat and human RNA. This may be the aberrant form of Gsa mRNA 
produced using an alternative promoter that was reported by Ishikawa et al. 
(1990).
G ia mRNA was detected in rat brain RNA using oligonucleotides 
complimentary to Gil and Gi2 mRNA. The Gil oligonucleotide hybridises 
to a single species of approximate size 3.8 kb while the Gi2 oligonucleotide 
hybridises to a species of size 2.5 kb (Figure 10). Both these values are very 
similar to those reported by others (Nukada et al, 1986, Jones & Reed 1987).
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However due to the low abundance of Gioc mRNA, and the number of 
mismatches between both types of rat Gioc oligonucleotides and the region to 
which they hybridise to in human RNA (especially of Gil - see Table 4), 
separate oligonucleotides complimentary to the human Gioc mRNA species 
were made. The human Gil oligonucleotide hybridises very weakly to a 
species which is of a similar size to Gil mRNA in rat. The oligonucleotide 
also appears to hybridise to both 28S and 18S ribosomal RNA. Other human 
subjects had similarly low, or undetectable, amounts of Gil mRNA (data not 
shown). Due to this, the measurement of Gil mRNA in human brain was not 
pursued. A similar situation occurred with Gi2 mRNA in human brain. 
Despite there being one mismatch between the human Gi2 oligonucleotide 
and that of rat Gi2 mRNA, this oligonucleotide actually gave a stronger 
hybridisation signal for Gi2 mRNA in rat brain than in human brain. Again 
other human subjects contained a low abundance of Gi2 mRNA in RNA 
purified from brain, and no further attempts were made to measure Gi2 
mRNA.
The final oligonucleotide used was made complimentary to human 28S 
rRNA (Figure 10). This was intended to act as a control RNA species that 
would allow a normalisation of the amount G protein mRNA between 
different total RNA preparations. 28S rRNA was chosen in preference to the 
other common control RNA species, such as actin or GAPDH, since the 
hybridisation signal stays constant in a wide variety of circumstances (Leeuw 
et a l, 1989). The oligonucleotide hybridised more strongly to human 28S 
rRNA than to rat 28S rRNA. However there were a number of distinct lower 
molecular weight species detectable in human RNA not detectable in rat; 
these are most probably degradation products.
The suitability of using northern blots to quantitate G protein mRNA 
was previously confirmed by Dr. S. Griffiths, Department of Biochemistry, 
University of Glasgow. She demonstrated that the optical density of the G 
protein mRNA bands on the resulting autoradiogram is directly proportional 
to the amount of RNA loaded onto the gel, up to 40pg (S. Griffiths; personal 
communication).
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Figure 10.
Use of northern blotting to detect the mRNAs encoding G(3. Gsa. Gil. Gi2. 
and 28S rRNA in  hum an and rat brain.
RNA was purified from whole rat brain and from the right frontal 
cortex of hum an subject C34. The RNA was analysed by northern blotting 
as described in "Methods". An agarose gel was loaded with 20pg of 
denatured rat or hum an RNA per lane, and run overnight. After transfer of 
the RNA to Hybond N, the blot was cut into strips and hybridised to 
labelled oligonucleotides that were com plim entary to the mRNAs encoding 
(a and b) and G{32 mRNA (oligo GJ3), (c) all four forms of G sa (oligo Gs),
(d) the two large forms of G sa (oligo Gs-52), (e) rat G il (oligo Gil), 
(f) hum an Gil (oligo hGil), (g) rat Gi2 (oligo Gi2), (h) hum an Gi2 (oligo 
hGi2) and (i) 28S rRNA. The rat Gi oligonucleotides were hybridised to rat 
RNA only. The strip which had been hybridised to the G(3 oligonucleotide 
was first washed at low stringency (2xSSPE/0.1% SDS at 42°C for 15 
minutes) and exposed to X-ray film for 1 day (a). The blot was then washed 
to high stringency (0.5xSSC/0.1% SDS at 60°C for 15 m inutes) and exposed 
to X-ray film for 2 days (b). The strips that had been hybridised to oligo Gs, 
oligo Gs-52 and the Gi oligos were w ashed to a stringency of 0.5xSSC/ 
0.1%SDS at 60°C for 15 m inutes and exposed to X-ray film for 2 or 3 days. 
The strip which had been hybridised to the 28S rRNA oligonucleotide was 
washed to a stringency of 2xSSPE/0.1% SDS/0.1% sodium  pyrophosphate 
at 37°C for 30 m inutes and exposed to X-ray film for 10 minutes. The 
approximate molecular size (in kb) of each RNA species visible on the 
autoradiogram  is shown. These were estimated by com paring the bands 
migration to RNAs of know n size (4.4, 2.4 and 1.4 kb).
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2. The feasibility of studying signal transduction systems in human post 
mortem brain.
The study that was envisaged required the use of post mortem tissue. 
The time between death and freezing of the tissue was typically in the order of 
12 hours, this time interval being termed the post mortem delay or PMD. The 
following series of experiments attempted to discover the stability post 
mortem of G proteins, their mRNAs, adenylate cyclase or sodium potassium- 
dependent ATPase, in rat brain. No attempt was made to accurately model 
the cooling of the human brain post mortem; the experiments were designed 
merely to indicate the feasibility or otherwise of studying the forementioned 
substances in human post mortem brain tissue.
2.1 The effect of post mortem delay on G protein stability in rat brain.
Adult male Wistar rats were killed by cervical dislocation and stored at 
4°C for up to 72 hours, or at room temperature for 24 hours. After each time 
interval the brain was removed and ground in liquid nitrogen to yield a 
homogeneous powder, a proportion of which was used to prepare crude 
membranes. These preparations were then analysed by western blotting 
utilising antibodies to Gsa (Figure 11), Gia (Figure 12) and Goa (Figure 13). 
Since the abundance of GsL is very low in membrane preparations made from 
whole rat brain, no information about this protein was obtained.
In no case was a change in the molecular weight of any of the G 
protein bands observed nor were there any smaller size species apparent 
(there was a small amount of smearing of the Gia bands in the experiment 
conducted at room temperature, however this was also present in the zero 
time point preparations). In addition, there was no significant change (SL = 
0.05) in the optical density of any of the G protein bands with increasing time 
post mortem as tested by a one way ANOVA for the experiment conducted at 
4°C, or an unpaired Students t-test for that conducted at room temperature 
(data not shown). Thus these proteins appear to be very stable post mortem 
in rat brain, at least in respect to their mobility on polyacrylamide gels.
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Figure 11.
The effect of post mortem delay on the integrity of Gsa.
Fourteen male Wistar rats were sacrificed and kept at 4°C for up to 72 
hours before the brains were removed and stored at -80°C. In another 
experiment the animals were kept at room temperature (approximately 
20°C) for twenty four hours after death. Separate zero time point animals 
were used for the experiments conducted at room temperature (RT) and 
4°C. The brains were ground in liquid nitrogen and a portion used to 
prepare crude membranes as described in "Methods". 50jag of membrane 
protein was loaded per lane onto a polyacrylamide gel (except for the lane 
marked with * in which 150pg of protein was loaded) and the gel run 
overnight. After transferring the proteins onto a nitrocellulose membrane, 
antisera CS1 was used to show the position of the Gsa bands. The 
immunocomplex was detected by use of 125I labelled anti-rabbit IgG 
antibody used at 4pCi/50ml. The autoradiogram was exposed for 3 days.
Molecular weight markers, run along with the membrane 
preparations, are shown alongside the autoradiogram.
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Figure 12.
The effect of post mortem delay on the integrity of Gicx.
M embrane preparations were m ade from the brains of rats which had 
been kept at 4°C and at room tem perature (RT) after death, as described in 
the legend to the previous figure (Figure 11). lOOpg of m em brane protein 
was loaded per lane onto a polyacrylamide gel and the gel run overnight. 
After transfer of the proteins onto nitrocellulose, the blot was incubated with 
antisera SG2 and then with horse radish peroxidase linked anti-rabbit IgG 
antisera.
Molecular weight markers, run along with the m em brane 
preparations, are shown alongside each blot.
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Figure 13.
The effect of post mortem delay on the integrity of Gocx.
M embrane preparations were m ade from the brains of rats which had 
been kept at 4°C and at room tem perature (RT) after death, as described in 
the legend to Figure 11. 50pg of m em brane protein was loaded per lane 
onto a polyacrylamide gel and the gel run overnight. The proteins were 
then transferred onto a nitrocellulose membrane. Antisera OC1 was used to 
show the position of the G oa band, the immunocomplex being detected 
with horse radish peroxidase linked anti-rabbit IgG antisera.
Molecular weight markers, run along with the membrane 
preparations, are shown alongside each blot.
* - 150pg of protein was used in this lane.
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2.2 The effect of post mortem delay on adenylate cyclase activity in rat 
brain.
A subset of the membrane preparations which were used to assess the 
effect of post mortem on G protein integrity were used to examine its effect 
on adenylate cyclase activity. There was no significant change in either 
basal or fluoroaluminate stimulated activities during up to 48 hours at 4°C 
(Figure 14). There was a decrease in the order of 25% in both basal and 
fluoroaluminate stimulated activities after 24 hours at room temperature 
when compared with fresh tissue (Figure 14). This decrease approached, 
but did not reach, statistical significance. There was no change in 
fluoroaluminate stimulated adenylate cyclase activity when expressed as a 
proportion of basal activity. Since fluoroaluminate stimulates adenylate 
cyclase via its effect on G proteins, this parameter provides a measure of the 
ability of adenylate cyclase and G proteins to interact. It would therefore 
appear that adenylate cyclase is a fairly stable enzyme in rat brain, and is 
therefore a suitable candidate for study in post mortem human brain. In 
addition G proteins are still able to interact with adenylate cyclase in rat 
brain for at least 24 hours after death.
2.3 The effect of post mortem delay on sodium potassium-dependent 
ATPase activity in rat brain.
The effect of post mortem delay on the enzyme sodium potassium- 
dependent ATPase was examined using the same rat brain membrane 
preparations as those described for G proteins and adenylate cyclase 
(Sections 2.1 and 2.2). When compared to fresh brain tissue their was no 
statistically significant change observed in the activity of this enzyme in 
intact sacrificed rats which had been stored 48 hours at 4°C or 24 hours at 
room temperature, when compared to fresh tissue (Figure 14). This enzyme 
is therefore an ideal candidate for study in human post mortem tissue.
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Figure 14.
The effect of post mortem delay on the activity of adenylate cyclase and 
sodium potassium dependent ATPase.
Fourteen male Wistar rats were sacrificed and kept at 4°C for up to 72 
hours before the brains were removed and stored at -80°C. In another 
experiment the animals were kept at room tem perature (approximately 
20°C) for twenty four hours. Separate zero time point animals were used for 
the experiments conducted at room tem perature (RT) and 4°C. The brains 
were ground in liquid nitrogen and a portion used to prepare crude 
m embranes as described in "Methods". (Note that other aliquots were used 
to analyse G proteins - see Figures 11 to 13).
Adenylate cyclase activity was assayed (as described in "Methods") at 
30°C for 15 m inutes using 20pg of m em brane protein per tube, for both the 
animals which had been kept at 4°C, (a) and (c), and for those that had been 
kept at RT, (b) and (d). Both basal activity, (a) and (b), and fluoroalum inate 
stim ulated activity, (c) and (d), were m easured. In the latter case the 
concentrations of alum inium  chloride and sodium  fluoride were lOpM and 
5mM respectively. The activities shown are the m ean of duplicate analyses 
of two animals.
Sodium dependent ATPase activity was also assayed in these 
m em brane preparations, at 37°C for 15 m inutes using 20pg of m em brane 
protein per tube as described in "Methods". This is shown for the animals 
which had been stored at 4°C (e) and room tem perature (f). Non-specific 
ATPase activity was determ ined in the presence of Im M  ouabain.
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2.4 The effect of post mortem delay on RNA stability in rat brain.
The stability of RNA post mortem was studied in rat brain using the 
same animals as were used to study protein stability. RNA was purified 
from an aliquot of brain powder derived from each animal which had been 
stored at 4°C for up to 72 hours. The RNA was subsequently analysed by 
northern blotting using labelled oligonucleotides complimentary to Gsa 
and GJ3 mRNA, and to 28S rRNA (Figure 15). Each G protein mRNA 
showed little degradation after 72 hours post mortem, as witnessed by the 
small amount of band smearing and constant molecular size, relative to the 
zero time point animals. Of the band smearing that was apparent in the 
later time point preparations, it appears to be more marked for Gsa than G|3 
mRNA. Degradation of Gsa was most apparent after 48 hours where a 
weakly hybridising second band is visible. This band may be analogous to 
the 1.2 kb band detected in human Gsa mRNA (Figure 10). In the case of 
28S rRNA there was a gradual time dependent increase of low molecular 
weight 28S rRNA degradation products, of which there are three major 
species that hybridise to the oligonucleotide.
It appeared at this stage that G protein mRNA could be reliably 
measured in post mortem brain, and analysis of mRNA was conducted in 
parallel with those of G proteins (Section 3). During the course of these 
investigations however doubts emerged on the reliability of the 
measurement of G protein mRNA in human post mortem brain, and for this 
reason the data together with a further investigation of RNA degradation is 
presented in Section 5.
Figure 15.
The effect of post mortem delay on the integrity of G sa and GB mRNA,
and 28S rRNA.
Fourteen male Wistar rats were sacrificed and kept at 4°C for up to 72 
hours before the brains were removed and stored at -80°C. The brains were 
ground in liquid nitrogen and a portion used to purify RNA. The RNA was 
then analysed by northern blotting as described in "Methods". Three 
agarose gels were loaded with 20pg of RNA per lane and run overnight. 
The RNA was then transferred to Hybond N membranes. The blots were 
hybridised to a labelled oligonucleotide probe com plim entary to (a) G sa 
mRNA, (b) G|3 mRNA and (c) 28S rRNA. After washing, blots (a) and (b) 
were exposed to X-ray film for 2 days, while blot (c) was exposed for 25 
minutes. The arrow head on blot (a) indicates the position of the second 
band found at the longer time points using the G sa probe. The positions of 
18S and 28S rRNA are shown to indicate molecular size. The ribosomal 
bands were visualised by staining the entire blots with m ethylene blue stain 
after the autoradiogram s had been exposed.
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3. Analysis of G protein linked coupled transduction in demented and 
control subjects.
3.1 Comparison of choline acetyl transferase activity in control and DAT 
subjects.
A group of eleven subjects with a neuropathologically confirmed 
clinical diagnosis of DAT was compared to a group of fifteen age matched 
control subjects. From these, sixteen subjects (eight from each group) were 
chosen to study the effects of DAT on choline acetyl transferase (ChAT), G 
protein levels, adenylate cyclase and sodium potassium-dependent ATPase 
in the left frontal cortex. For experimental reasons a further different sixteen 
were employed to study the same parameters in the left hippocampus. 
Tissue from each subject was homogenised and a small aliquot was removed 
for the determination of ChAT activity. The remainder of the homogenate 
was used to make membrane preparations.
There was a large statistically significant decrease observed in the 
activity of ChAT in the frontal cortex and hippocampus of DAT subjects 
compared with that of controls (two-tailed Students t-test; P<0.002; Figure 
16). The mean ChAT activity in the frontal cortex of DAT subjects was 54% 
of that found in controls, while that observed in the hippocampus was 34% 
of that measured in controls.
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Figure 16t 
The activity of choline frcetyl transferase activity in-the frontal cortex and 
hippocampus of control and PA T subjects.
The left frontal cortex and left hippocampus from DAT and control 
subjects were powdered in liquid nitrogen and homogenised in six volumes 
of lOmM Tris/HCl, pH 7.5, ImM EDTA. A small aliquot was removed and 
assayed for choline acetyl transferase (ChAT) activity as described in 
"Methods". The assay was carried out at 37°C for 20 minutes using 30pg of 
protein. Eight control and eight DAT subjects were analysed for both the 
hippocampus and frontal cortex, although different sets of patients were 
used for each region. All assays were performed in triplicate. The 
distribution of ChAT activity within each group is shown for both regions. 
Bars indicate the mean enzyme activity of each group. *** indicates a 
statistically significant difference between control and DAT subjects (two 
tailed Students t-test; P<0.002). The ChAT activities measured in each 
subject are listed in Appendix Al.
3.2 comparison of G protein alpha subunit levels in control and DAT 
subjects.
The levels of the G protein subunits GsH, GsL, Gil, Gi2 and Goa 
were compared in the left frontal cortex and left hippocampus of DAT and 
control subjects, using membrane preparations which had been prepared 
from homogenates in which ChAT activity had been assayed (section 3.1). 
The levels of the various G protein alpha subunits were measured by 
western blotting using the antisera CS1, SG2 and OC1 (Figures 17 and 18).
No statistically significant difference was observed between control 
and DAT groups, as assessed using a two-tailed Students t-test (significance 
level = 0.05), in either region for any of the alpha subunits which were 
analysed. However a statistically significant decrease (28%) was observed 
(P<0.05) in the mean ratio of GsH to GsL found in the frontal cortex, but not 
the hippocampus, of DAT subjects compared with controls (Figure 19). This 
can occur since the ratio is determined for individual subjects, whilst G 
protein levels represent the overall value for each group of subjects. It 
would appear therefore that a small increase in the relative levels of GsL 
compared to GsH has taken place in DAT frontal cortex, although some 
caution should be exercised in the interpretation of this finding as a degree 
of overlap exists between the ratios obtained in the two groups.
Figure 17.
The levels of the alpha subunits of the G proteins Gs. Gi and Go in  the 
frontal cortex of control and DAT subjects.
C rude m em brane proteins were prepared from the left frontal cortex 
of eight control and eight DAT subjects, and analysed by western blotting as 
described in "Methods". A polyacrylam ide gel was loaded with 100|ng of 
protein per lane (to be used with antisera SG2), while another two gels were 
loaded with 50pg of protein per lane (to be used with antisera OC1 or CS1), 
and run overnight. After transfer of the proteins to nitrocellulose, one blot 
was incubated with antisera CS1, one with OC1 and the other with SG2. The 
blots were then incubated with either HRP linked anti-rabbit IgG antisera, or 
125I labelled anti rabbit IgG antisera at 3jiCi/50m l as appropriate. The latter
was then exposed to X-ray film for 3 days. The parts of the blots or 
autoradiogram  showing the G protein bands are shown in (a). The patient 
num ber is shown beneath each lane (C = Control, A = DAT, RB = rat brain). 
Subsequent densitometric analysis of these bands was used to determ ine the 
relative levels of each G proteins in the control and DAT groups. The 
distribution of band intensities in each group is shown for (b) G sa, and (c) 
G ia and Goa. Bars indicate the mean optical density in each group. The 
band intensity m easured for each G protein in each subject is listed in 
A ppendix A l.
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Figure 18.
The levels of the alpha subunits of the G proteins Gs. Gi and Go in the 
hippocampus of control and DAT subjects.
Crude membrane proteins were prepared from the left hippocam pus 
of eight control and eight DAT subjects, and analysed by western blotting as 
described in "Methods". Three polyacrylamide gels were prepared and run 
overnight. One gel was loaded with lOOpg of protein per lane (to be used 
with antisera SG2), while another two gels were loaded with 50pg of protein 
per lane (to be used with antisera OC1 or CS1). After transfer of the proteins 
to nitrocellulose, one blot was incubated with antisera CS1, one with OC1 
and the other with SG2. The blots were then incubated with either HRP 
linked anti-rabbit IgG antisera, or 125I labelled anti-rabbit IgG antisera at 
3pCi/50m l as appropriate. The latter was then exposed to X-ray film for 2 
days. The parts of the blots or autoradiogram  showing the G protein bands 
are shown in (a). The patient num ber is shown beneath each lane (C = 
Control, A = DAT, RB = rat brain). Subsequent densitometric analysis of 
these bands was used to determ ine the relative level of the G proteins in 
each the control and DAT groups. The distribution of band intensities in 
each group is shown for (b) Gsa, and (c) G ia and Goa. Bars indicate the 
mean optical density in each group. The band intensity measured for each 
G protein in each subject is listed in Appendix A l.
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Figure 12.
The ratio of GsH to GsL in the frontal cortex and hippocampus of control
and DAT subjects.
The distribution of the ratio GsH/GsL, derived from the data 
presented on Figures 17 and 18, is shown for control and DAT groups in 
each brain region. Bars indicate the mean of each group. * indicates P<0.05 
when the data was analysed using a two-tailed Students t-test.
3.3 The activity of adenylate cyclase in control and DAT subjects.
The activity of adenylate cyclase was assayed in crude membranes 
prepared from control and DAT left frontal cortex and hippocampus. The 
membrane preparations used were those in which the levels of G protein 
alpha subunits had previously been measured (section 3.2). The activity of 
adenylate cyclase was assayed under basal conditions and while stimulated 
by fluoroaluminate.
Both the basal and stimulated enzyme activities were found to be 
significantly decreased in the frontal cortex of DAT subjects (Figure 20), as 
assessed by a two-tailed Students t-test (p<0.01). The mean basal activity 
measured in DAT subjects was 56% of that determined in control subjects, 
while fluoroaluminate stimulated activity in DAT subjects was 53% of that 
found in controls. In contrast, no significant difference in adenylate cyclase 
activity was found between the control and DAT groups in the 
hippocampus. When fluoroaluminate stimulated adenylate cyclase activity 
was expressed as a percentage of basal activity in each subject, no significant 
difference was found between the control and DAT groups in either region 
(Figure 20).
Within the control group in the frontal cortex, two subjects (C15 and 
C22) gave values more akin to the DAT group. However these subjects had 
normal ChAT activities and normal neuritic plaque densities, and are 
therefore not incorrectly classified DAT cases.
An attempt was made to find a correlation between adenylate cyclase 
activity in DAT frontal cortex and two other measures which had been 
found to alter in DAT frontal cortex, namely neuritic plaque density and 
ChAT activity. There was no statistically significant linear correlation found 
between plaque density and both basal or stimulated adenylate cyclase 
activity (Figure 21; r = 0.152 and 0.091 respectively). However there was a 
significant linear correlation observed between basal adenylate cyclase 
activity and ChAT activity (Figure 21; r=0.770; p<0.05). The correlation 
between stimulated adenylate cyclase activity and ChAT activity 
approached, but did not reach, statistical significance (r = 0.675).
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Figure 20.
The activity of adenylate cyclase in  the frontal cortex and hippocampus of
control and DAT subjects.
Crude m em brane preparations were prepared from the left frontal 
cortex and left hippocam pus of subjects who had suffered from DAT, and 
from control subjects as described in "Methods". Eight control and eight 
DAT subjects were analysed for both the hippocam pus and frontal cortex, 
although for experimental reasons different sets of patients were used for 
each region. The preparations were assayed for adenylate cyclase activity as 
described in "Methods". Assays were carried out in duplicate at 30°C for 16 
minutes, using 20|_ig of protein per tube. Both the basal (a) and 
fluoroalum inate stim ulated (b) activities were m easured. The latter was 
determ ined by including 5mM sodium  fluoride and IOjhM alum inium  
chloride in the assay. Fluoroalum inate stim ulated activity is also shown 
expressed as a percentage of basal activity (c). Bars indicate the mean 
activity of each group. ** indicates a statistically significant difference 
between control and DAT subjects (Students t-test; P<0.01). The adenylate 
cyclase activities m easured in each subject are listed in Appendix A l.
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Figure 21.
A comparison of basai adenylate cyclase activity in  DAT frontal cortex, 
w ith choline acetyl transferase activity and neuritic plaque density.
Basal adenylate cyclase, assayed in the left frontal cortex of eight 
DAT subjects, is shown plotted against (a) the activity of choline acetyl 
transferase (ChAT), or (b) density of neuritic plaques. In each case linear 
regressional analysis was used to determ ine the "best fit" line. When 
adenylate cyclase activity is compared to ChAT activity a statistically 
significant linear correlation is present (P<0.05, r=0.770). In contrast no 
statistically significant linear correlation exists between basal adenylate 
cyclase activity and neuritic plaque density (r=0.091).
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3.4 The activity of sodium potassium-dependent ATPase in control and 
DAT subjects.
In the preceding sections a change in adenylate cyclase activity was 
described in DAT subjects which was not accompanied by any changes in 
the level of G protein alpha subunits. Another membrane bound enzyme, 
sodium potassium dependent ATPase, was assayed to act as a control 
against differences in membrane purity etc. having occurred between the 
two groups. Using the same membrane preparations that were assayed for 
adenylate cyclase activity (section 3.3), the activity of sodium potassium 
dependent ATPase was determined in the frontal cortex and hippocampus 
of control and DAT subjects. Although the mean activity of this enzyme 
was decreased by 20% in DAT frontal cortex compared to controls, this did 
not reach statistical significance. There was also no statistically significant 
difference in mean hippocampal activity between DAT and control groups 
(Figure 22).
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Figure 22.
The activity of sodium potassium dependent ATPase in the frontal cortex 
and hippocampus of control and DAT subjects.
Crude membrane preparations were prepared from the left frontal 
cortex and left hippocampus of subjects who had suffered from DAT, and 
from control subjects as described in "Methods". The preparations were 
assayed for sodium potassium dependent ATPase activity. Assays were 
carried out in triplicate at 37°C for 15 minutes, using 20jxg of protein per 
tube. Eight control and eight DAT subjects were analysed for both the 
frontal cortex and hippocampus, although different sets of patients were 
used for each region. The distribution of the enzyme activity for each region 
is shown above. Bars indicate the mean activity of each group. The activity 
of sodium potassium dependent ATPase measured in each subject is listed in 
Appendix Al.
4. The distribution of the proteins measured in this study in five regions 
of the human brain.
In section three little evidence was found that the levels of five G 
protein alpha subunits were altered in DAT. There were indications though 
that the proteins exhibited an uneven distribution within different regions of 
the the normal and diseased brain. In this section these indications are 
pursued.
4.1 Distribution of G proteins in five regions of the human brain.
The left frontal cortex, left hippocampus, right neostriatum (caudate/ 
putamen), left cerebellum and pons of three control subjects (C14, C19A and 
C34) were used to make crude membrane preparations. These were 
analysed by western blotting to determine the relative amounts of each G 
protein a  subunit in the different brain regions. The distribution of each 
subunit was broadly similar in each subject, the results being averaged to 
arrive at a final value. While it was possible to use a single antiserum to 
compare the relative amounts of individual G protein in different brain 
regions, it was not possible to compare the amounts of different G protein 
i.e. Gsa, G ia and Goa. This is because the different antisera are expected to 
vary in their affinities for their respective antigens.
Figure 23 shows the western blot analysis of Gsa in each subject. 
This shows the normal pattern of bands except in the neostriatum, where an 
extra band possessing an approximate molecular weight 43 kD is present. It 
is of low abundance relative to the Gsa bands but is clearly visible at longer 
exposures in C14 and C34. The band is just visible in C19A in which it is 
partially obscured by the GsL band. This 43 kD band is not an artefact of the 
secondary antibody since this did show any bands in either frontal cortex or 
neostriatum (Figure 23). It is therefore possible that this band represents a 
"Gsa-like" protein which is only present in the neostriatum (out of the five 
regions analysed). Of the levels of the known Gsa proteins, the cerebellum
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had the highest concentration of GsL within the five regions examined, 
followed (in descending order) by the pons, neostriatum, frontal cortex and 
hippocampus (Figure 23). The concentration of GsH was also highest in the 
cerebellum, but in this case was followed by the frontal cortex and 
hippocampus. The neostriatum and pons contained the lowest amounts of 
GsH. It is also clear from Figure 23 that in the frontal cortex and 
hippocampus GsH is the major species, while the reverse is true for the 
other three regions examined.
The relative concentrations of the two Gias were also examined 
(Figure 24). Of all the a  subunits measured, Gi2 has the least variable 
distribution within the regions analysed. It was highest in the frontal cortex 
followed by the hippocampus, neostriatum, cerebellum and pons. The 
distribution of Gil followed the same order as for Gi2, but was more 
variable between the different regions. The concentration of Gi2 was greater 
than that of Gil in all the regions examined (except in C14 frontal cortex), 
this being most pronounced in the neostriatum, cerebellum and pons.
Finally Goa was found to be distributed among regions in a similar 
manner to Gil and Gi2 (Figure 25), with the pons containing a very low 
concentration of Goa.
Figure 23.
The distribution of Gscx in  hum an brain.
Crude membranes were prepared from the frontal cortex, 
hippocampus, neostriatum, cerebellum and pons of subjects C14, C19A and 
C34, and analysed by western blotting as described in "Methods". A 
polyacrylamide gel was loaded with 50pg of protein per lane and run 
overnight. The proteins were then transferred onto a nitrocellulose 
membrane. The blot was incubated with antisera CS1, and then with 125I 
anti-rabbit IgG antisera at a concentration of 4p,Ci/50ml. A strip of 
nitrocellulose to which had been transferred samples of C14 frontal cortex 
and neostriatum was incubated in the secondary antisera alone. The blot 
was then exposed to X-ray film for 1 or 3 days (a). The longer exposure is 
shown to illustrate more clearly the position of the third band visible 
between GsH and GsL in human neostriatum. However the autoradiogram 
which had been exposed for 1 day was analysed densitometrically. Regions 
are indicated thus F = Frontal cortex, H = Hippocampus, N = Neostriatum, 
C = Cerebellum, P = Pons. RB = rat brain. Only the portion of the blot 
containing the G protein bands is shown.
The levels of GsH and GsL in each region are given in (b) and (c) 
respectively. The values shown are the mean of the three subjects; error bars 
indicate the SEM.
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Figure 24,
The distribution of G ia in human brain.
Crude membranes were prepared from the frontal cortex, 
hippocampus, neostriatum, cerebellum and pons of subjects C14, C19A and 
C34, and analysed by western blotting as described in "Methods". Each 
sample was loaded onto a polyacrylamide gel (lOOjug protein per lane) and 
the gel run overnight. After transfer of the proteins onto a nitrocellulose 
membrane, the blot was incubated with antisera SG2, and then with horse­
radish peroxidase linked anti-rabbit IgG antisera. The resulting blot is 
shown in (a) with regions indicated thus, F = Frontal cortex, 
H = Hippocampus, N = Neostriatum, C = Cerebellum, P = Pons. RB = rat 
brain. Only the portion of the blot that contained the G protein bands is 
shown.
The blot was then analysed densitometrically. The levels of Gil and 
Gi2 in each region are given in (b) and (c) respectively. The values shown 
are the mean of the three subjects; error bars indicate the SEM.
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Figure 25.
The distribution of Goa in human brain.
Crude membranes were prepared from the frontal cortex, 
hippocampus, neostriatum, cerebellum and pons of subjects C14, C19A and 
C34, and analysed by western blotting as described in "Methods". A 
polyacrylamide gel was loaded with 50pg of protein per lane and run 
overnight. The proteins were then transferred onto a nitrocellulose 
membrane and the blot incubated with antisera OC1, and then with horse 
radish peroxidase linked anti-rabbit IgG antisera. The resulting blot is 
shown in (a) with regions indicated thus, F = Frontal cortex, 
H = Hippocampus, N = Neostriatum, C= Cerebellum, P = Pons. RB = Rat 
Brain. Only the portion containing the Goa band is shown.
The blot was then analysed densitometrically. The level of Goa in 
each region is given in (b). The values shown are the mean of the three 
subjects; error bars indicate the SEM.
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4.2 Distribution of adenylate cyclase in human brain.
The activity of adenylate cyclase was determined in five brain regions 
of the subjects C14, C19A and C34, using the same membrane preparations 
that were used to analyse the G proteins (section 4.1). Once again the 
activities observed in each region were similar in each subject except in the 
neostriatum which gave basal activities of 37.9, 83.4 and 33.2 pmols cAMP/ 
m in/m g for C14, C19A and C34 respectively. The average value for basal 
adenylate cyclase activity in the neostriatum should therefore be viewed 
with some caution. Of the five regions basal activity was highest in the 
frontal cortex followed by the hippocampus, neostriatum, cerebellum and 
pons (Figure 26). The relationship between the distribution of adenylate 
cyclase and each G protein was investigated using linear regressional 
analysis (Table 5). Surprisingly neither GsH or GsL was significantly 
correlated with adenylate cyclase activity. The regional distribution of Goa 
was weakly, but significantly, correlated with activity while the best 
correlation was obtained with Gil and Gi2. This was investigated further by 
calculating the ratio between G protein levels and adenylate cyclase activity, 
both of which had been normalised to their values in the frontal cortex. If 
the two proteins possess the same relative abundance in each brain region, 
and hence could be said to possess a similar distribution, the normalised 
ratio between them should be unity. By using this approach, the 
distribution of adenylate cyclase activity in human brain appears to be most 
closely matched by that of Gil (Figure 27), although the analysis of more 
regions in a larger number of subjects would be needed to confirm this.
When adenylate cyclase was stimulated by fluoroaluminate the 
variation in activity between different regions was smaller than that 
observed for basal activity, since the extent of stimulation observed in the 
cerebellum and pons was greater than that of the other three regions (Figure 
26). Since fluoroaluminate acts via its effect on G proteins, the level of these 
proteins were compared with the observed stimulation of adenylate cyclase
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in each preparation. Adenylate cyclase stimulation was not significantly 
correlated with GsH levels (Table 5), and only weakly correlated that of GsL. 
However the ratio GsH/GsL was more strongly (negatively) correlated with 
adenylate cyclase stimulation, as were the levels of G il, Gi2 and Goa. The 
strongest correlation however was that observed between stimulation and 
the ratios G sa/G ia , and G sa/G oa.
Figure 26.
The distribution of adenylate cyclase activity in human brain.
Crude membranes were prepared from the frontal cortex, 
hippocampus, neostriatum, cerebellum and pons of subjects C14, C19A and 
C34, and assayed for adenylate cyclase activity as described in "Methods". 
Adenylate cyclase was assayed at 30°C for 16 minutes using 20jig of 
membrane protein per tube. Each sample was assayed in duplicate for both 
basal activity (a) and fluoroaluminate stimulated activity (b). The latter was 
carried out in the presence of 10pM aluminium chloride and 5mM sodium 
fluoride. Fluoroaluminate stimulated activity is also shown expressed as a 
percentage of basal activity for each region (c). Each region is indicated 
thus, F = Frontal cortex, H = Hippocampus, N = Neostriatum, C = 
Cerebellum, P = Pons. The values shown are the mean of the three subjects; 
error bars indicate the SEM.
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G protein level or ratio Versus Correlation coefficient
GsH Basal activity 0.503
GsL ff ff -0.138
Gil ff ff 0.710 **
Gi2 ff ff 0.787 **
Go ff ff 0.581 *
GsH Stimulation -0.174
GsL ff 0.525 *
GsH/GsL ff -0.616 4
Gil ff -0.746 **
Gi2 ff -0.789 **
Go ff -0.748 **
Total G sa/Total G ia ft 0.804 **
Total G sa/Total Goa ff 0.889 **
Table 5,
The relationship between G protein levels and basal adenylate cyclase 
activity, or its stimulation by fluoroaluminate.
The basal activity of adenylate cyclase, or its stimulation by 
fluoroaluminate relative to basal activity, in the frontal cortex, hippocampus, 
neostriatum, cerebellum or pons of subjects C14, C19A and C34 (Figure 26) 
was related to the levels of Gsa, Gia, Goa, or the ratio of Gsa to Goa, or G ia 
(Figures 23 to 25). This was accomplished by calculating Pearsons 
correlation coefficient to evaluate the strength of any linear relationship. 
Total Gs is the total of the optical densities of the bands corresponding to 
GsH and GsL on the western blot. Similarly total Gi is the sum of Gil and 
Gi2. The statistical significance of the observed regression coefficient is 
indicated thus, * = P<0.05, ** = P<0.01.
Figure 27.
Comparison of the distribution of basal adenylate cyclase activity in 
hum an brain to that of G protein alpha subunits.
The activity of adenylate cyclase and the levels of each G protein in 
each subject/region combination (Figures 23 to 26), were normalised to their 
value m easured in the frontal cortex of each subject. The normalised G 
protein levels were then divided by the normalised adenylate cyclase 
activities, and are shown as the m ean ratio of the three subjects, with bars 
showing the SEM. If the G protein possesses the same distribution as that 
of adenylate cyclase, the ratio between the two normalised values should be 
equal to unity in each region (shown by the dotted line). The num bers in 
brackets beneath are the average deviations from a ratio of one for each G 
protein. The ratio for the frontal cortex was not used for this calculation 
since this will always be equal to unity.
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4.4 Distribution of sodium potassium-dependent ATPase in the human
brain.
The activity of sodium potassium-dependent ATPase was 
determined in the same preparations used in Sections 4.1 and 4.2. As before 
all subjects gave similar results. The highest activity was observed in the 
cerebellum, followed by a similar activity in the frontal cortex and pons, the 
lowest activities being observed in the hippocampus and neostriatum 
(Figure 28). The activity of the enzyme was not significantly correlated with 
any other measurement performed with the exception of GsL (r=0.601; 
P<0.05). Thus the heterogeneous distribution throughout the brain of 
adenylate cyclase etc. is not due to differences in the purity of crude 
membranes prepared from different regions.
400
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Figme 28,
The distribution of sodium potassium dependent ATPase activity in
human brain.
Crude membranes were prepared from the frontal cortex, 
hippocampus, neostriatum, cerebellum and pons of subjects C14, C19A and 
C34, and assayed for sodium potassium dependent ATPase activity as 
described in methods "Methods". The enzyme was was assayed at 37°C for 
15 minutes using 20pg of membrane protein per tube. Each sample was 
assayed in triplicate. Non specific ATPase activity was measured in the 
presence of ImM ouabain. Each region is indicated thus, F = Frontal cortex, 
H = Hippocampus, N = Neostriatum, C = Cerebellum, P = Pons. The values 
shown are the mean of the three subjects; error bars indicate the SEM.
4.4 Distribution of G proteins, adenylate cyclase and sodium potassium- 
dependent ATPase in grey and white matter.
The right temporal cortex of subject C20 was dissected into grey 
matter, white matter and a mixture of both. Crude membrane preparations 
were made from all three and the levels of GsH, GsL, G il, Gi2 and Goa, and 
the activities of adenylate cyclase and sodium potassium-dependent ATPase 
measured. There was a marked difference in every parameter measured 
between grey and white matter (Table 6). In every case, except for Gil, the 
mixture of grey and white gave a value intermediate to that of substantially 
grey and substantially white matter. Except for GsLthe proteins were more 
abundant in grey matter than in white matter. However fluoroaluminate 
stimulated adenylate cyclase activity, expressed relative to basal activity, 
was approximately the same in grey and white matter.
Parameter Grey
Matter
Grey/White
Matter
White
Matter
GsH 0.207 0.186 (90%) 0.122 (59%)
GsL 0.058 0.111 (191%) 0.303 (522%)
GsH/GsL 3.57 1.68 (47%) 0.40 (11%)
Gil 0.027 0.033 (122%) 0.019 (70%)
Gi2 0.035 0.022 (63%) 0.018 (51%)
Goa 0.245 0.206 (84%) 0.156 (64%)
Basal adenylate 
cyclase activity
Fluoroaluminate 
stimulated adenylate 
cyclase activity -
68 62 (90%) 41 (60%)
(i) Absolute 251 221 (88%) 159 (67%)
(ii) Percent of basal 369 356 (96%) 389 (105%)
N a/K  dependent 
ATPase activity
349 202 (58%) 102 (29%)
Table JL
Levels of G proteins, adenylate cyclase and sodium  potassium -dependent 
ATPase in  temporal cortical grey and white matter.
The temporal cortex of subject C20 was thawed on ice and dissected 
into grey matter, white matter, and a mixture of grey and white matter. 
These were used to prepare crude membranes which were then analysed by 
western blotting to determine the levels of Gsa, Gia, and Goa, as well as 
being assayed for adenylate cyclase activity and sodium potassium- 
dependent ATPase activity as described in "Methods". Adenylate cyclase 
was assayed in duplicate at 30°C for 15 minutes, while sodium potassium 
dependent ATPase was assayed in triplicate 37°C for 15 minutes. G protein 
levels are given in optical density units, adenylate cyclase activity in pmols 
cA M P/m in/m g protein and sodium potassium-dependent ATPase activity 
in pmols P i/m in /m g  protein. The numbers in brackets indicate the 
percentage of that measured in grey matter.
5. RNA stability in human post mortem brain.
The results presented in Section 2.1 appeared to show that G protein 
mRNA levels could be reliably estimated in post mortem brain. As a result, 
experimental analyses of the effect of DAT on G protein levels were 
conducted in parallel with analyses of the level of G protein mRNAs. As 
will be seen however, the early indications that the mRNAs could be 
accurately measured in post mortem human brain proved to be unfounded, 
and data was generated that cast some doubt on other determination of 
mRNAs in post mortem brain that have been published by other 
laboratories. Because of this the investigation of human brain mRNA, 
together with supporting experiments with rat brain, are presented as a 
separate Section of the results.
5.1 Analysis of RNA prepared from human tissue.
RNA was prepared from human right frontal cortex and right 
hippocampus, using six control subjects and six DAT subjects in each case. 
To ensure that the purification procedure was not introducing any 
degradation, RNA was prepared in parallel from fresh rat brain. The RNA 
was then analysed by northern blotting using oligonucleotide probes 
complimentary to Gsa and G(3 mRNA, and to 28S rRNA. Autoradiograms 
derived from the analysis of the frontal cortex are shown in Figure 29, and 
that from the hippocampus is reproduced in Figure 31. The hybridisation 
pattern observed for each probe was similar in every human subject, and 
allowed the detection of the mRNAs encoding Gsa, G131 and G(32. The 
hybridisation pattern for each probe is described fully in Section 1.4. The 
frontal cortex blot which had been hybridised to the probe complimentary to 
Gsa mRNA (Figure 29), was reprobed with Gs-52 oligonucleotide which is 
complimentary to the large forms of Gsa (Figure 30). This did not hybridise 
to the lower molecular size (1.2kb) species observed using the probe 
complimentary to all four forms of Gsa mRNA, in any of the subjects
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analysed. This confirmed the view taken earlier (Section 1.4) that this band 
should not be included in any attempted quantification of Gsa mRNA. A 
visual inspection of the autoradiograms did not reveal any obvious 
difference in the intensity of the G protein mRNA bands in control and DAT 
subjects, however an attempt was made to quantify this using densitometry. 
Due to the smearing of the G protein mRNA bands and the large variability 
in signal intensity between subjects, densitometry proved difficult. 
However the values that were obtained are illustrated in Figure 32. There 
was no statistically significant difference in the relative amounts of Gj3l or 
GJ32 mRNA in the frontal cortex and hippocampus between control and 
DAT subjects, and no change in the relative amount of Gsa mRNA in the 
frontal cortex. (No numerical information was obtained about Gsa mRNA 
in the hippocampus since the hybridisation signal was too weak to allow 
densitometric analysis.) What is apparent is that the variability within each 
group is large (average standard deviation = 65% of mean). This high 
degree of variability is considered further in Section 5.3.
There was a significant degree of correlation observed between the 
amounts of each mRNA species measured in each subject. For example, Gsa 
versus G(32 mRNA in the frontal cortex gives a correlation coefficient of 0.90 
(Figure 33). This suggested either an error in gel loading or that another 
factor, such as RNA degradation, is acting equally on each mRNA species.
The northern blots showed a considerable degree of band smearing 
(especially that of Gsa mRNA) in the human RNA, which was not present in 
the rat brain controls. This indicates that the RNA was at least partially 
degraded. When the blots were re-hybridised with the 28S rRNA probe, a 
number of bands are visible in addition to the 28S rRNA band itself (Figures 
29 and 31). In many cases the intensity of the 28S rRNA band itself is low, 
and is accompanied by a relatively higher hybridisation to the lower 
molecular size species. This indicates that the larger species are being 
broken down to form the smaller ones. The pattern of bands was similar to
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that seen in the longer time points of the experiment used to assess the effect 
of delaying the freezing of the brain in rat (Section 2.3). They are therefore 
assumed to be degradation products of 28S rRNA. It is apparent that the 
extent of 28S rRNA breakdown differs between human subjects. In the two 
brain regions examined there was a marked correlation between the extent 
of 28S rRNA degradation, and the intensity of the G protein mRNA bands. 
Thus, where a tissue exhibited extensive degradation of 28S rRNA, in most 
cases the hybridisation signal of G protein mRNAs were also relatively weak 
and smeared. It therefore became clear that the degradation of 28S rRNA 
degradation was an excellent indicator of overall RNA degradation that 
could be used in further experiments designed to investigate RNA 
degradation. It should be noted that the 28S rRNA oligonucleotide 
hybridises less strongly to rat RNA than to human RNA, making it difficult 
to compare 28S rRNA degradation in rat and human RNA on the same blot 
by this method. However, the two can be compared on ethidium bromide- 
stained gels, or on the blots themselves using the RNA shadow method 
(Herrera & Shaw, 1989).
There was no evidence for increased RNA degradation in diseased 
brain compared to normal tissue. Neither was there a strong correlation 
between the degree of degradation and the time between death and freezing 
of the tissue. The effects of this variable, along with age and length of 
storage time, are considered further in subsequent sections.
Figure 29.
Analysis of RNA purified from the frontal cortex of control subjects and 
from those who had suffered from DAT.
RNA was purified from the right frontal cortex of six control subjects 
and six DAT subjects as described in "Methods". In parallel to these 
preparations, RNA was purified from fresh rat brain. The RNA was then 
analysed by northern blotting as described in "Methods". Two agarose gels 
were loaded with 20pg of denatured RNA per lane and run overnight. The 
RNA was then transferred to Hybond N membrane. One blot was 
hybridised to a labelled oligonucleotide com plimentary to G sa mRNA (a) 
and the other to an oligonucleotide complimentary to GJ3 mRNA (b). After 
washing, the blots were exposed to X-ray film for 3 days. Blot (b) was then 
stripped and rehybridised to an oligonucleotide com plimentary to 28S 
rRNA (c). This was then exposed to X-ray film for 20 minutes.
The subject num ber is shown beneath each lane (C = Control, A = 
DAT, RB = Rat Brain). PMD indicates the post m ortem delay of each subject 
in hours i.e. the time between death and freezing of the tissue. Each blot was 
stained with methylene blue stain to show the positions of 28S and 18S 
rRNA, which acted as molecular size markers.
I I I t I I I t I I I I I
Rat C14 A21 C16 A22 C18 A23 C19 A26 C23 A30 C34 A33 
PMD 0  11 6 17 6  19 15 7 2 4 4 6  8
Figure .31.
Analysis of RNA purified from the hippocampus of control subjects and 
from those who had suffered from DAT.
RNA was purified from the right hippocam pus of six control subjects 
and six DAT subjects as described in "Methods". In parallel to these 
preparations RNA was purified from fresh rat brain. The RNA was then 
analysed by northern blotting as described in "Methods". Two agarose gels 
were loaded with 20pg of denatured RNA per lane and run overnight. The 
RNA was then transferred to Hybond N+ membrane. One blot was 
hybridised to a labelled oligonucleotide com plimentary to G sa mRNA (a) 
and the other to an oligonucleotide complimentary to Gj3 mRNA (b). After 
washing the blots were exposed to X-ray film for 4 days. Blot (a) was then 
stripped and rehybridised to an oligonucleotide com plimentary to 28S 
rRNA (c). This was then exposed to X-ray film for 20 minutes.
The subject num ber is shown beneath each lane (C = Control, A = 
DAT, RB = Rat Brain). PMD indicates the post m ortem delay of each subject 
in hours i.e. the time between death and freezing of the tissue. Each blot was 
stained with methylene blue stain to show the positions of 28S and 18S 
rRNA, which acted as molecular size markers.
I t  I I  I I I I t I I  I I
Rat C24 A35 C34 A30 C14 A33 C28 A53 C20 A65 C33 A56 
PMD 0 3 3 6  4 11 8  12 8  15 11 23 16
Figure 32.
Densitometric analysis of northern blots in Figures 29 and 31.
The northern blots showing the analysis of RNA prepared from 
hum an frontal cortex and hippocam pus (Figures 29 and 31) were analysed 
by densitometry. The distribution of optical densities in each group are 
shown for (a) Gsa, (b) G$1 and (c) G|32 mRNA. No analysis is shown for 
G sa mRNA in the hippocam pus since the hybridisation signal was too weak 
to allow this. Bars indicate the m ean optical density in each group.
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Figure 33,
The relationship between the amounts of Gsa and GB2 mRNAs detected 
in each subject by northern blotting.
The northern blots in Figure 29 (human frontal cortex) were analysed 
densitometrically to give the relative amounts of each RNA species (Figure 
32). The graph opposite shows the relationship between the optical density 
of the Gsa bands and that of G$2. Filled circles indicate control subjects 
while open circles indicate DAT subjects. The line draw n through the points 
was determined by linear regression and has a correlation coefficient of 0.90.
5.2 The degradation of 28S rRNA in three regions of the human brain.
To explore the possibility that RNA degradation could differ in 
various brain regions, RNA was purified from the frontal cortex, 
hippocampus and cerebellum of three human subjects, all of whom had 
been used in the investigation of G protein mRNA (Figures 29 and 31). In 
two cases both hemispheres were examined. The subsequent analysis of 28S 
rRNA (Figure 34) shows that the extent of degradation is broadly similar in 
all the regions examined within each subject,.
I t t t t f 1 I t t  t t t I t
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C19A A65 C34
Figure 34.
The extent of 28S rRNA degradation in  different regions of three hum an
subjects.
RNA was purified from the frontal cortex, hippocam pus and 
cerebellum of subjects C19A, C34 and A65 as described in "Methods". In the 
latter two cases, both right and left hemispheres were used. The RNA was 
then analysed by northern blotting as described in "Methods". 20pg of RNA 
per lane was loaded onto two agarose gels and the gels ran overnight. After 
transfer of the RNA onto Hybond N+ membranes, the blots were hybridised 
to a labelled oligonucleotide complimentary to 28S rRNA. After washing, 
the blots were exposed to X-ray film for 20 minutes. The positions of 18S 
and 28S rRNA were visualised by methylene blue staining of the blot, and 
serve to indicate molecular size. F = Frontal cortex, H  = Hippocam pus, C = 
Cerebellum. These are preceded by L or R to indicate left or right 
hemisphere.
5.3 The inter subject variability of the parameters measured in human 
brain.
In view of the data in Section 5.1 indicating that RNA degradation 
could be substantial in human post mortem brain, it was decided to look 
further at some of the parameters that could be linked with macromolecular 
instability. The variability of RNA levels assayed was therefore compared 
with that of the other parameters measured and related to patient age, post 
mortem delay and the length of time for which the tissue had been stored.
The standard deviation of the data presented in the preceding 
Sections was calculated for all of the parameters measured in each of the 
regions examined. For each of the datasets the standard deviation in the 
control and DAT groups was compared using an F-test (see ’’Methods"). In 
no case was there any evidence to suggest that the variability of the data was 
greater in one group than the other (data not shown; these tests had been 
done previously to ensure the validity of using t-tests with pooled variance). 
To allow comparison of variance between the various measures employed 
all standard deviations were converted to coefficients of variation (CV) i.e. 
SD expressed as a percentage of the mean. The various datasets were 
arranged into groups and the average CV calculated for each category as 
shown in Table 7. For all of the categories which involved the measurement 
of protein levels or enzyme activities, the CV was in the order of 30%. The 
least variable measure was that of stimulated adenylate cyclase expressed as 
a percentage of basal activity which gave an average CV of 11%. The 
highest inter subject variability was observed in the measurement of G 
protein mRNA, which had a high average CV of 65%. This included the 
highest individual CV recorded in the entire study, this being 92% observed 
in the measurement of G(3l mRNA in the right frontal cortex of control 
subjects. For comparison to the human studies, the CV was calculated for 
the basal adenylate cyclase activities measured in rat brain in the study used 
to assess the effect that post mortem delay (at 4°C) had on this enzyme
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(Section 2.5). This study detected no change in activity over the period 
studied, and therefore the variance of this data can be used to estimate the 
extent of variability that is achievable using the techniques employed, this 
being a CV of 9%.
The effect of the various levels of variance in the data on the 
statistical methods employed in this study were examined using a form of 
post hoc power analysis. This allowed the smallest difference that could be 
detected between two groups, using an unpaired, two-tailed Students t-test, 
to be calculated. The results of this are listed in Table 7, and show that, for 
measures on proteins, a difference of 20-30% between mean values would be 
required to give statistically significant difference between control and DAT 
groups using a significance level of 0.05. In contrast the studies on RNA 
would require a difference of 70% between the groups for significance level 
of 0.05, and 107% for a significance level of 0.01.
The effect, upon the parameters measured, of post mortem delay, 
subject age, and the time the tissue had been kept in storage prior to use, 
was examined using linear regressional analysis. There was no significant 
linear correlation between post mortem delay or subject age, and any 
parameter measured in human tissue (Table 8). The length of time that the 
tissue had been stored at -80°C showed no significant correlation with any 
measurement except with that of sodium potassium dependent ATPase 
activity in the frontal cortex and hippocampus (r = 0.746 and 0.707 
respectively; p<0.01). Note that the correlation (illustrated in Figure 35) is 
positive i.e the longer the tissue has been stored the higher the activity of the 
enzyme.
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Parameter Sample
size
Average
CV(%)
Required 
difference (%)
P<0.05 P<0.01
G protein mRNA 6 65 71 107
G proteins (left hemisphere) 8 30 31 42
Basal adenylate cyclase 8 27 28 40
Stimulated adenylate cyclase - 
Absolute 8 29 30 42
Proportion of basal 8 11 12 18
N a/K  dependent ATPase 8 22 23 33
Choline acetyl transferase 8 32 33 46
Adenylate cyclase activity in rat 8 9 10 14
Table 7.
The inter-subject variability of the parameters measured in this study.
The standard deviation of each of the parameters measured in human 
tissue was expressed as a percentage of the mean value (the coefficient of 
variation or CV). The various CVs were arranged into the groupings given in 
the table and averaged to give a measure of the variability of that parameter. 
The sample size used for each study is also shown. The sample size and 
average inter-subject variability were used to calculate the smallest difference 
in the mean values of two groups e.g. control and DAT, that was required to 
give a statistically significant result using an unpaired, two tailed, Students t- 
test, assuming that the variability in the data is equal in both groups. The 
change required to a statistically significant difference is shown for 
significance levels of 0.05 and 0.01. The "adenylate cyclase in rat brain" 
category uses the variability of the values derived from the study to assess 
the effect of post mortem delay, at 4°C, on basal adenylate cyclase activity 
(Section 2.2).
Table 8.
Correlation of various parameters w ith the age, post mortem delay and 
length of tissue storage time of each subject.
The levels of G protein alpha subunits and the activities of several 
enzymes measured in the left frontal cortex (F. Cortex) and left 
hippocampus (Hipp.), together with the levels of G protein mRNAs 
measured in the right frontal cortex and right hippocampus, were related, 
using linear regressional analysis, to the post mortem delay, age, or length of 
time in storage. The correlation coefficient for each analysis is shown. 
Where there was no significant difference between control and DAT subjects 
for the parameter being examined, both groups were analysed together. 
Where a difference had been detected, the two groups were analysed 
separately the result of the correlation analysis being given as control, DAT. 
A statistically significant correlation of P<0.01 or P<0.001 is indicated by ** 
or *** respectively. The number of subjects used for the mRNA correlations 
was 12, while the protein studies employed 16 subjects, except in the case of 
correlations with subject age in the hippocampus where the size was 15, as 
the age of subject A35 was unknown. ND = not done.
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Figmre35t
Correlation between sodium potassium dependent ATPase activity in frontal 
cortex and hippocampus, and the length of tissue storage time.
The activities of sodium potassium dependent ATPase in the brains of 
eight control and eight DAT subjects (section 3.5), were compared to the length 
of time each brain had been stored at -80°C. This was accomplished using linear 
regressional analysis. The relationship between the two variables is shown for 
(a) the frontal cortex and (b) hippocampus. Filled circles indicate control 
subjects, and open circles represent DAT subjects.
5.4 Possible sources of RNA degradation modelled in rat brain.
The previous Sections have shown that, of all the parameters studied 
in human tissue, the measurement of mRNA levels show the largest inter 
subject variation. There were also indications that this variability might be 
due to different amounts of RNA degradation in each subject. These 
analyses failed however to relate the RNA degradation to subject age, post 
mortem delay, time of tissue storage or disease state. An attempt was 
therefore made to find conditions that reproduced this degradation in rat 
brain.
5.4.1 The effect of freeze/ thawing of rat brain on RNA integrity.
The brains of sacrificed adult male Wistar rats were rapidly removed, 
the cerebellum dissected away and the brain cut in half down the mid line. 
One hemisphere was left at 20°C for 15, 30 or 60 minutes, while the other 
was frozen to -80°C then left at 20°C for the same length of time. Figure 36 
shows the result of the northern blot analysis of RNA purified from each 
brain hemisphere. After fifteen minutes there was no detectable difference 
between control and freeze/thawed hemispheres, while at thirty minutes a 
small amount of degradation was apparent in the freeze/thawed tissue. 
However, after one hour there was no G protein mRNA detectable in the 
freeze/thawed tissue, this being accompanied by pronounced 28S rRNA 
degradation.
Figure 36.
The effect of freeze/thawing of tissue on the integrity of RNA in rat brain.
Male Wistar rats were sacrificed, and their brains removed and cut 
into two hemispheres. The right hemisphere was placed at 20°C for 15, 30 or 
60 minutes as indicated. The left hemisphere was frozen to -80°C and then 
left at 20°C for the same length of time, before RNA was purified as 
described in "Methods". L or R indicates the hemisphere used. The RNA 
was then analysed by northern blotting as described in "Methods". An 
agarose gel was loaded with 20pg of RNA per lane and ran overnight. The 
RNA was then transferred onto a Hybond N+ membrane and hybridised to 
labelled oligonucleotide probes complimentary to (a) Gsa mRNA, (b) G(3 
mRNA and (c) 28S rRNA. After washing, the blots were exposed to X-ray 
film for 2 days ((a) and (b)), or 10 minutes (c). The position of 18S and 28S 
rRNA was visualised by methylene blue staining of the blot, and serve to 
indicate molecular size.
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5.4.2 The effect of focal forebrain ischemia on RNA integrity in rat brain.
The human subjects from which the brains in the present study were 
derived, died from various causes but most common was pneumonia. In 
pneumonia, breathing difficulties may lead to tissue hypoxia well before 
death. Indeed it is possible that such an effect occurs, to varying degrees, in 
any persons who did not die suddenly. One effect of ante mortem hypoxia 
may be to cause increased RNase activity leading to greater RNA 
degradation (see "Discussion", Section 1.2.4). An attempt was therefore 
made to mimic this in rats by inducing focal forebrain ischemia.
The left middle cerebral arteries of five male Wistar rats were 
occluded as described in "Methods". Two sham operated animals were also 
produced. Blood was withdrawn from the animals to reduce the blood 
pressure to between 50 and 55 mm Hg for a period of thirty minutes. This 
period of hypotension has been shown to increase the volume of damaged 
tissue caused by mid cerebral artery occlusion ( Osborne 1987). The blood 
pressure of the animals was monitored throughout the experiment and is 
shown in Figure 37. The animals were sacrificed 3 hours after middle 
cerebral artery occlusion, the brains removed, and the right and left cortices 
dissected and stored at -80°C. RNA was subsequently purified from the 
tissue and analysed by northern blotting, using oligonucleotide probes 
complimentary to GJ3 mRNA and 28S rRNA (Figure 38). Unfortunately no 
information about Gsa mRNA was obtained since this oligonucleotide 
would no longer incorporate 32P. The G(3 oligonucleotide also exhibited 
very low incorporation of 32P (11%) and gave very high background 
hybridisation. The reason for the failure of the G protein oligonucleotides is 
unclear since they were stored under the same conditions as the 28S rRNA 
oligonucleotide. Despite this the GJ3 bands are still visible on the 
autoradiogram. There was no band smearing apparent in any of the RNA 
preparations, whether ischemic (left cortex) or control (right cortex). In 
addition the G(3 signal intensity is broadly similar in most preparations. The
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variability in signal intensity that did occur was mimicked by that of 28S 
rRNA hybridisation, indicating that this was due to errors in gel loading 
rather than to differences in RNA degradation in each preparation. Some 
28S rRNA degradation products were visible in each sample, however they 
were not consistently greater in abundance within the ischemic cortex than 
that observed within the control cortex, or in the sham operated animals.
Figure 37.
Time course of blood pressures during the three hour survival period 
following m iddle cerebral artery occlusion.
The blood pressures of the seven animals used to assess the effect of 
m iddle cerbral artery occlusion on RNA integrity (as described in the legend 
to Figure 38) are shown at several time points during the experiment. The 
values shown are the m ean of seven animals; bars indicate the SEM.
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Figure 33-
The effect of three hours of focal forebrain ischemia on RNA integrity in
rat brain.
Seven male Wistar rats were anaesthetised using halothane. Five of 
the animals were then subjected to left m iddle cerebral artery occlusion as 
described in "Methods". The other two rats, that acted as sham animals, 
were treated identically except that no occlusion was performed. Fifteen 
m inutes after occlusion, the animals blood pressure was reduced to between 
50 and 55 mm Hg by the removal of approximately 3 ml of blood. 
Hypotension was m aintained for 30 m inutes before blood was reinjected to 
bring the blood pressure back to normal (Figure 37). The animals were 
sacrificed 3 hours after occlusion, the brains removed and the left and right 
cortices carefully dissected. These were then frozen in liquid nitrogen and 
stored at -80°C. RNA was then purified from the tissue and analysed by 
northern blotting as described in "Methods". The agarose gel was loaded 
with 20pg of RNA per lane and run overnight. After transfer of the RNA to 
Hybond N+ membrane, the blot was hybridised to a labelled 
oligonucleotide complimentary to G(3 mRNA (a), washed and exposed to X- 
ray film for 3 days. The blot was then stripped and hybridised to a labelled 
oligonucleotide complimentary to 28S rRNA (b). This was exposed to X-ray 
film for 15 minutes. The positions of 18S and 28S rRNA were visualised by 
methylene blue staining of the blot, and serve to indicate molecular size. 
MCAO = mid cerebral artery occlusion, L or R indicates left (ischemic) or 
right (control) cortex, the subscript indicating which animal the RNA was 
prepared from.
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IV. DISCUSSION
1. The feasibility of biochemical analyses of human post mortem brain.
The breakdown of interneuronal communication in DAT which is 
central to the symptomology of the disease, is characterised by a variety of 
neurochemical alterations in the brain of the sufferer, not least of which are 
changes in aspects of cellular signal transduction. While some 
neurotransmitter systems appear to be severely effected by the disease, 
others remain relatively unscathed. The study of such systems has been 
mainly confined to what are essentially extracellular aspects of signal 
transduction, namely neurotransmitters and their respective receptors. 
However the events which occur subsequent to receptor activation are also 
of importance, possibly more so, since a variety of different receptors exert 
their effects through the same transduction mechanisms. It is possible 
therefore that neurotransmitters which appear to be relatively unaffected in 
DAT, may have impaired function due to damage having occurred to other 
parts of the signal transduction cascade. Alternatively the loss of 
neurotransmitters such as acetyl choline could be counteracted by a 
heightened response of post receptor elements. To address these 
possibilities, a systematic analysis is required of all the components which 
serve to carry signals across the cell membrane. The primary purpose of this 
study therefore was to examine the events that occur subsequent to receptor 
activation in DAT using a variety of established biochemical techniques. 
These included western and northern blotting to measure the levels of G 
proteins and their mRNAs, as well as enzyme assays to assess the functional 
integrity of some aspects of signal transduction in DAT. However, the use 
of human post mortem tissue presents potential difficulties, since the actual 
value of any parameter measured can be considered to be a combination of 
the effects of DAT, and that of other variables such as subject age, tissue 
storage time and the length of the delay between death and freezing of the
106
tissue (the post mortem delay). It is necessary to know the contribution of 
such factors in order to assess the feasibility of any study which is to use 
post mortem tissue. In essence one must ensure that any changes which 
occur due to the presence of DAT, are not exceeded, modified or negated by 
the action of other processes. Secondly such information allows groups of 
human subjects to be matched in such a way as to minimise the impact of 
variables other than that under investigation. Their importance can be 
assessed either by using animal models, or by attempting to correlate the 
variability observed between human subjects with a variety of factors such 
as post mortem delay, tissue storage time etc. A combination of both 
approaches was used in this investigation.
The determination of the average variance between human subjects 
for each technique used, allowed two general observations to be made. 
Firstly the inter subject variability of the parameters measured in human 
subjects was in all cases higher than that observed using rat brain. In 
addition, the variation in measurements of the levels or activities of proteins 
in human brain, was less than that observed in the analysis of mRNA. Due 
to the apparent difference between protein and RNA, the factors influencing 
the intersubject variability for each will be discussed separately.
1.1 Measurement of G protein levels and enzyme activities in human post 
mortem brain.
1.1.1 Statistical considerations.
Measurements of protein levels, or activities, typically gave a 
coefficient of variance (sd as percentage of mean) of approximately 30% 
compared to around 10% for measurements involving rats (Table 7). The 
effect that this level of variance has upon the likelihood of obtaining a 
significant change using Students t-test was determined, it being found that 
on average, using a sample size of eight and a significance level of 0.05, a 
31% difference in the mean of two groups of subjects could be detected, as
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opposed to 11% when rat brain was used. Thus, in the case of human brain, 
quite large neurochemical changes in DAT may not result in a statistically 
significant difference being detected. The possible causes of the variability 
observed therefore merit closer examination.
1.1.2 Methodological considerations.
Although it might be expected that studies of human brain would 
possess greater variation between subjects due to for example, genetic or 
environmental effects, it is also possible that variables such as post mortem 
delay contribute to the measurements performed in human brain. This of 
course assumes that there are no methodological differences between how 
the rat and human studies were performed, an assumption which is true 
except for one aspect, that of tissue sampling. In a complex tissue, such as 
the brain, it is important to ensure that exactly the same areas of tissue are 
used in each case. The rat studies involved the use of whole brains, thereby 
removing any problems of associated with sampling. The protocols which 
determines how the human brains are dissected into different regions are 
followed carefully, but since the dissections are carried out by a number of 
different persons, it is possible that small variations occur in the area of 
brain which is dissected.
One factor which may have a significant effect is the proportion of 
grey and white matter contained within each tissue block, since the levels of 
all the moieties measured in this study varied substantially between the two 
(Table 6). However, the variety of measurements carried out in the same 
preparations offers some safeguard against the possibility that differences in 
tissue sampling between groups of subjects are wrongly attributed to being 
due to the presence of DAT. Some investigators avoid this problem entirely 
by dissecting out grey matter from each block, a procedure which is most 
usefully carried out before the brain is frozen, but can be done afterwards. 
However, since in this study, grey matter was not dissected out before 
freezing of the tissue, it would have required that the tissue was thawed to
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allow dissection. Since at some stage RNA was to be purified from the same 
tissue blocks, there was a concern (later confirmed) that thawing the brain 
could effect RNA integrity.
The level of intersubject variability encountered in this study is not 
atypical when compared with that observed by others (for example, Cross et 
al., 1984a; D'Amato et al., 1987; Shapiro et al., 1991). In particular it is not 
noticeably higher than that observed in those studies in which grey matter 
was dissected out (Kalaria & Andorn, 1990), or those using in situ techniques 
which allow the same region of brain to be "sampled" in each subject (Dewar 
et al., 1990). In addition, if substantive differences were occurring in the 
relative amounts of grey and white matter used for each preparation, it 
might be expected that measurements in the cortex would possess greater 
variance than those in the hippocampus. There was however no indication 
that this had occurred. It seems likely therefore that other factors are acting 
on the tissue prior to its use.
1.1.3 The effect of post mortem delay.
One variable which might be expected to have a major effect on post 
mortem tissue, is the delay which occurs between death and freezing of the 
tissue. In the present study this ranged from two to twenty three hours. 
During this period, enzymatic degradation an d /o r protein denaturation 
may have an influence on parameters subsequently measured in the tissue. 
There exists in the literature many studies which assess the stability post 
mortem of a wide range of cellular constituents. A general conclusion that 
may be draw n from these investigations is that the stability of different 
cellular components is very variable. For example, the levels of some 
neurotransmitters change quickly after death (Sloviter & Conner, 1977; 
Spokes & Koch, 1978), while most enzymes are relatively unaffected by any 
delay in tissue freezing (Syapin et al., 1987; Spokes & Koch, 1978; Fahn & 
Cdte, 1976). Similarly, the stability of neurotransmitter receptors post 
mortem is very variable (Syapin et al., 1987; Whitehouse et al., 1984; Benwell
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& Balfour, 1985). It is therefore important to discover the stability post 
mortem of any moiety that is to be investigated.
The effect that post mortem delay has on brain, can be readily 
assessed using rats which have been stored for increasing lengths of time 
post mortem before being analysed. This offers an advantage over the 
alternative approach of using non-diseased human brains with a range of 
post mortem delays, since its effect can be studied in isolation in rat, whilst 
human subjects are likely to exhibit other sources of variation in addition to 
post mortem delay. However, differences have been found in the stability of 
benzodiazipine receptors between strains of rats, and even between males 
and females of the same strain (Syapin et a l, 1987). It would be prudent 
therefore to use the results of studies on the effect of post mortem delay in 
rats, merely as an indicator to the feasibility of studying a parameter in 
human tissue. Experiments were carried out to discover what effect 
delaying freezing of the brain after death has upon G proteins, G protein 
mRNA, adenylate cyclase and sodium potassium-dependent ATPase. Some 
investigators attempt to accurately model the cooling of the human brain 
which, due to its larger mass, cools more slowly than rat brain. However 
the simpler experiments presented here, which were carried out at either 
4°C or room temperature, proved to be a useful indicator of the effect that 
post mortem delay had on the same parameter in human brain.
The mobility of G proteins on polyacrylamide gels using membrane 
extracts prepared from rats which had been stored at 4°C for up to 72 hours, 
or at room temperature for 24 hours, was not significantly different from 
those prepared from fresh tissue (Figures 11 to 13). There was also no 
significant correlation between G protein levels and post mortem delay in 
the human subjects studied. Both these findings suggest that these proteins 
are relatively stable. This conclusion is supported by measurements of the 
in vivo half life of Goa measured in cell cultures, which varied from 28 hours 
in undifferentiated N1E-115 neuroblastoma cells to 154 hours in cerebellar 
granule cells (Brabet et a l, 1991). The apparent slow turnover of G proteins
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suggests that their levels will not change rapidly in response to stimuli, but 
rather represent a mechanism by which adaptations to long term changes in 
the cells environment may occur.
The influence that post mortem delay has on the activity of sodium 
potassium-dependent ATPase was also studied in rat brain. The results of 
this study were similar to those of Syapin et al. (1987) and Fahn & Cdte 
(1976), in that the enzyme was found to be stable post mortem under the 
conditions examined (Figure 14). In addition no significant correlation was 
found between human sodium potassium-dependent ATPase activity and 
post mortem delay. Adenylate cyclase proved to be slightly less stable, in 
that while its activity did not change in rat brain when the animals had been 
stored at 4°C, a small decrease was observed in animals which had been 
stored at room temperature for 24 hours (Figure 14). These results are in 
agreement with those of Nicol et al. (1981), who showed that adenylate 
cyclase activity was stable for at least 10 hours post mortem at room 
temperature in bovine striatum. As has previously been observed by Ohm 
et al., (1991), there was no correlation between post mortem delay and 
activity in human brain. The stability of the enzyme in brain is in contrast to 
that in heart, in which a rapid decrease in enzyme activity occurs after death 
(Vatner et al. 1990). It is unclear whether this is a consequence of the 
enzyme's cellular environment differing between brain and heart, or to 
different subtypes of the enzyme being present in the two tissues. The latter 
possibility seems most likely since cardiac adenylate cyclase has recently 
been shown to be inhibited by a rise in intracellular calcium ion 
concentration (Cooper, 1991), in contrast to neural adenylate cyclase which 
is stimulated (Harrison et a l, 1989). The degree of stimulation of adenylate 
cyclase by fluoroaluminate also remained unaltered with increasing post 
mortem delay. This would indicate that G proteins are still functionally 
active post mortem, at least with regard to their ability to interact with 
adenylate cyclase.
The stability of choline acetyl transferase (ChAT) post mortem was
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not investigated in rat brain, but has been shown to be stable by Spokes & 
Koch (1978). This was confirmed by the failure to find any significant 
correlation between ChAT activity and post mortem delay in human brain. 
Thus, it is evident that the proteins examined in this study may be reliably 
assayed in human brains possessing post mortem delays of up to at least 
twenty four hours. In addition, it is evident that the importance usually 
given to the matching of post mortem delays between different groups of 
subjects, perhaps at the expense of other factors, is not always justified, 
although it will continue to be a wise precaution.
1.1.4 The effect of subject age.
The failure to find that the post mortem delay had a major effect on 
any of the measured proteins studied led to other variables being 
considered, such as subject age. This was not significantly correlated with 
any measurement (Table 8), although caution should be exercised in the 
interpretation of this finding since the range of ages used was small. Indeed, 
the use of a larger age range by Young et al. (1991b), has demonstrated a 
statistically significant negative correlation between the levels of G ia and 
age in human frontal cortex, and a positive correlation between GsH levels 
and age. The apparent increase in the relative levels of stimulatory 
compared with inhibitory G proteins, may indicate the occurrence of age 
related changes in the activity of different neurotransmitter systems, or even 
that the levels of adenylate cyclase are reduced with age.
1.1.5 The effect of storage at -80°C.
The length of time which the brains had been stored at -80°C did not 
correlate with any measurement except with sodium potassium-dependent 
ATPase activity, where a positive correlation with storage time was 
observed (Figure 35). Since this occurred in both the frontal cortex and 
hippocampus, it is reasonable to assume that this is a real effect. It is 
unlikely that a single event such as freezer failure could account for this
112
observation since there is a continuous range of enzyme activities i.e. the 
activities do not fall into two distinct groups. The most likely explanation 
therefore is that long term storage damages a factor which has an inhibitory 
effect on the enzyme, whether this be another protein, or a domain within 
the enzyme itself. This phenomenon should have had little effect on the 
comparison of sodium potassium-dependent ATPase activities in control 
and DAT subjects, since no significant difference in the mean length of 
storage time existed between the groups of subjects used. However it does 
demonstrate that long term storage of brain tissue at -80°C can have a 
gradual effect on the integrity of some neural components. The time taken 
to assemble a sufficient number of brains which will allow useful analyses to 
be carried out, frequently means that there is a wide variation in the storage 
time of different subjects. Unfortunately this variable is usually given a low 
priority when attempting to match groups of subjects, and given these 
results and those of others (Burke et a l, 1991), this may be rather unwise.
Other factors such as the persons sex,
were also considered, but neither had any obvious effect. Thus, the 
source of the variability observed between human subjects is most likely due 
to a variety of factors which, by themselves, are not large enough to be 
readily detectable. Fortunately, the variability encountered was not of such 
a magnitude that it precluded a useful study of transduction system proteins 
in human brain.
1.2 The analysis of RNA in human post mortem brain.
1.2.1 A possible explanation for the high intersubject variability 
encountered.
The intersubject variability in the levels of G protein mRNAs, as 
measured by northern blotting, was much higher than that observed for that 
for the G proteins themselves when measured using western blotting (Table 
7). It is unlikely that the methodology used to measure RNA levels has an 
intrinsically greater scope for error, since multiple RNA preparations using 
rat brain did not normally give high levels of variability. A clue as to the 
source of this phenomenon was given by the observation that when the 
human RNA preparations were analysed by northern blotting, varying 
degrees of band smearing of each mRNA species was evident. This 
indicated that some RNA degradation had taken place, and it therefore 
seemed likely that different amounts of degradation in each subject could 
account for the variability in G protein mRNA levels.
1.2.2 Assessment of the degree of RNA degradation.
It was difficult to assess the extent of degradation from band 
smearing alone, not least because the smaller degradation products may 
have run off the end of the gel. However, when 28S rRNA degrades it gives 
clearly definable products since the secondary structure and normal 
association with protein leaves some parts of the molecule more vulnerable 
to RNase action than others. The extent of breakdown of 28S rRNA can be 
easily determined by visual inspection and provided a more rigorous 
assessment of degradation than band smearing per se. In most cases, the 
greater the degree of 28S rRNA degradation, the smaller the amount of Gsa 
or G(3 mRNA that was detected (Figures 29 and 31). This suggests that the 
amount of G protein mRNA detected in each subject is dependent, at least in 
part, on the extent of RNA degradation which has taken place in the tissue. 
The use of densitometric analysis of band smearing to provide an
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assessment of degradation has been used by Clark et al. (1989). A similar 
scheme to assess 28S rRNA degradation was not considered to be useful, as 
the intensity of each band depends not only on the extent of degradation but 
on the actual amount of RNA loaded onto the gel. Although the latter 
should be the same for each sample, small variations in the actual quantity 
loaded does occur. Indeed, it was to control for such variations that first 
prompted the use of the 28S rRNA probe. Furthermore, the similarity which 
was observed between 28S rRNA and G protein degradation may not be 
true for all mRNAs. Alternatively, if degradation is effecting most RNA 
species to the same extent, it would imply that normalising the levels of each 
RNA species under investigation to another control species would be 
advantageous. Indeed it was found that there was a high degree of 
correlation between the levels of Gsa and G(3 mRNA in each subject (Figure 
33). The problem associated with this is the choosing of a suitable control 
species. Common choices such as GAPDH or actin are known themselves to 
vary in their levels of expression (Leeuw et a l, 1989). One possible answer 
to this problem has been to use the hybridisation of polyT DNA to polyA+ 
RNA, thus detecting most mRNA species (Harrison et a l, 1991a). This is 
somewhat problematical for use with northern blotting, but can be 
advantageously utilised as a control for use with in situ hybridisation, or slot 
blotting. Whether the level of hybridisation of polyA+ RNA provides a good 
indicator of overall RNA integrity is unclear, since it has not been 
demonstrated that regions of poly A mRNA are degraded to a similar extent 
to the rest of the RNA molecule.
1.2.3 Statistical considerations.
The coefficient of variance (SD as percentage of mean) for the 
measurement of Gsa and G(3 mRNA levels ranged from 50% for G(32 mRNA 
in DAT hippocampus, to 93% for G(3l in control frontal cortex, with an 
average CV of 65%. This level of variability would only allow large
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differences between means, in the order of 80%, to be detected using 
Students t-test (Table7). Similarly, to detect, for example, a 40% difference 
between the DAT and control groups would require the use of over 40 
patients in each group. Thus, although there was no significant difference 
detected between the control and DAT groups, there is a strong possibility 
of a false negative conclusion. Alterations in response to the 
neurodegenerative process, are thus likely to be dwarfed by the interpatient 
variability as a consequence of RNA degradation. It is unlikely that variable 
degradation of RNA is peculiar to this study, or to G protein mRNA (and 
28S rRNA); published northern blots from human postmortem brain almost 
invariably displays some evidence of degradation in a diverse range of RNA 
species (e.g. Johnson et al., 1986; Clark et al., 1989; Iacopino & Christakos, 
1990; Crapper-McLauchlin et al., 1988; Goedert, 1987). In addition the ability 
of RNA extracted from the human brain to be translated in vitro is very 
variable (Perret et a l, 1988), again indicating varying degrees of degradation 
in different subjects. Harrison et al. (1991a) have also investigated Gsa 
mRNA in control and DAT diseased human brain. They found a similar 
level of intersubject variability to that reported here, but the use of large 
sample sizes allowed the detection of a large (300%) increase in Gsa mRNA 
expression in DAT diseased hippocampus compared to controls. The frontal 
cortex was not analysed, although no change was detected in the temporal 
cortex. Due to the low hybridisation signal of Gsa mRNA in the 
hippocampus, no quantitative data was obtained about its levels in control 
and DAT diseased subjects. However there was no subjective difference 
apparent between the control and DAT groups. The reason for the 
contrasting findings of the two studies may relate to the greater spatial 
resolution afforded by in situ hybridisation, although Harrison et al. (1991a) 
did detect alterations in Gsa mRNA expression throughout the 
hippocampus. As explained above, it not impossible that had larger sample 
sizes been used in this study, a change in Gs mRNA levels in DAT would
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have been detected.
As well as the risk of false negative conclusions being drawn, the 
large intersubject variability also heightens the likelihood of false positive 
conclusions. For example, in this study although there were no statistically 
significant changes in any of the mRNAs measured, in all cases the mean 
levels were decreased in the DAT group relative to controls. This was most 
likely due to the presence of a greater number of samples in the control 
group possessing modest amounts of RNA degradation. Such an effect was 
most clearly seen in the hippocampus, where of the two subjects which had 
the least RNA degradation, both were controls. Had this bias been any 
greater, and had no attempt been made to assess RNA degradation, it is 
possible that a statistically significant, but artefactual, difference would have 
been detected between the two groups.
1.2.4 The possible causes of RNA degradation in post mortem human 
brain.
The presence of varying degrees of RNA degradation in different 
subjects makes it especially important to determine what factors influence 
this RNA stability in the human CNS in order to identify criteria for 
matching groups of patients. There was no correlation between the extent of 
RNA degradation (or the amount of G protein mRNA detected), with either 
the diagnosis of DAT nor its histopathological severity. RNA degradation 
was not influenced by the age of the subjects or tissue storage time. Burke et 
al. (1991) also have examined the effect of storage time on RNA levels. 
These authors found a significant negative correlation between this variable 
and both actin and APP751 mRNAs, but not with the other mRNA species 
they examined. It is possible therefore that different RNA species possess 
different susceptibilities to long term freezer storage and, as suggested by 
Burke et al. (1991), that this variable may not possess an equal importance in 
each subjects.
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There was also no correlation between post mortem delay and G 
protein mRNA degradation in human brain. This result confirmed the 
experiment to assess the effects of PMD in rat brain which showed that even 
after 72 hours at 4°C, only small amounts of degradation of Gsa mRNA 
were observed, and practically none of GJ3 mRNA (Figure 15). Although 
there was a time dependent increase in 28S rRNA breakdown, the amount 
was small compared to the total amount of 28S rRNA and was much less 
than that observed in human brain. Most human subjects are not placed at 
4°C immediately after death, so greater opportunity for degradation in 
human tissue cannot be excluded. Nevertheless, the results of both the 
human and rat studies suggest that the delay in freezing the tissue after 
death is not the major influence on RNA stability (see also Johnson et al., 
1986 and Kobayashi et a l, 1990). In contrast, Burke et al. (1991) found the 
levels of actin and APP751 mRNA were negatively correlated with post 
mortem delay, although other mRNA species were not.
It has been suggested that mechanical damage to human tissue 
during dissection may increase RNA degradation (Johnson et a l, 1986). This 
seems unlikely since in the experiment which assessed the effect of freeze/ 
thawing on RNA stability, the control brains, which were removed from the 
skull and dissected, exhibited no detectable increase in RNA degradation. 
Only the freeze/thawing of the tissue greatly accelerated the rate of RNA 
degradation (Figure 36). It is highly unlikely that accidental thawing during 
storage could account for the RNA degradation observed in the human 
RNA for the following reasons. Firstly, the tissue was stored at -80°C in 
alarmed freezers with automatic solid C 0 2 backup. The experiments 
described here suggest that a complete thaw lasting at least 30 minutes is 
needed before significant degradation occurs. Secondly, there was no 
correlation between storage time and degradation. Thirdly, the RNA 
preparation method employed ensured that the tissue was ground up in 
liquid nitrogen and thawed into a buffer that instantly denatures RNase
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(Chomczynski & Sacchi, 1987). These precautions were taken because it has 
been reported that RNA extracted from human brain is especially vulnerable 
to degradation during RNA purification (Ilaria et al., 1985). It is highly 
unlikely that the methodology used herein was responsible for the RNA 
degradation observed, since separate RNA preparations made from the 
same tissue block displayed similar amounts of RNA degradation. For 
example, the extent of 28S rRNA degradation observed in subjects C19A, 
C34 and A65 in the experiment which compared degradation in different 
brain regions, was the same as that observed in previous preparations (e.g. 
compare Figures 29 and 31, to Figure 34).
The enhanced rate of RNA degradation observed after freeze/ 
thawing the tissue may provide a clue to the actual cause of the degradation 
observed in the human RNA. Rapid freezing of the tissue will cause 
damage to the membrane structures within the cell, most notably lysosomes. 
These organelles contain many hydrolytic enzymes, among which is a type 
of RNase (Koenig et al., 1964), known as acid RNase due its pH optima 
(Franzoni & Argiz, 1978). Under normal circumstances, acid RNase is 
confined within lysosomes and will have no effect on RNA present in the 
cytoplasm, but if the lysosomes are damaged, RNase can leak out. Although 
physiological pH is not the ideal condition for acid RNase activity, a large 
release of the enzyme may be enough to cause considerable RNA 
breakdown. The absence of lysosomal damage would provide an 
explanation as to why there is little RNA degradation observed over long 
post mortem intervals in rat brain. The non-lysosomal, cytoplasmic RNases 
which are responsible for the normal turnover of RNA may be relatively 
inactive after death due to cooling of the tissue, and because they are 
complexed with an inhibitor protein (Brockdorff and Knowler, 1987) . An 
explanation for the variable degree of RNA degradation in the brains used 
in the present study may reside in events immediately prior to death, such 
as the degree of ischemia or anoxia of the brain tissue caused by respiratory
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or circulatory malfunction (i.e. the "agonal state"). The degree of ischemia 
before death influences a variety of cellular components, most notably 
reductions in the activities of phosphofructokinase and glutamate 
decarboxylase (Perry et al., 1982). Animal models have shown that ischemia 
causes both tissue acidosis, due to lactate accumulation (Nemeto & Frinak, 
1981), and membrane damage caused by the action of phospholipases 
(Edgar et a l, 1982) and lipid peroxidation by free radicals (Kogure et al., 
1985). These events may lead to leakage of RNase from the lysosomes, 
(Maschoff et al., 1989), as well as providing more acidic conditions in which 
the enzyme can act. Indeed oxygen free radicals have been shown to cause 
the release of lysosomal enzymes in canine heart (Kalra et al., 1989). A recent 
study demonstrated that tissue acidity was significantly increased in those 
individuals who died agonally as opposed to those who died suddenly 
(Yates et a l, 1990), suggesting that ischemia or hypoxia was occurring in the 
former case. Unfortunately, although the cause of death of many subjects in 
this study was known, their agonal state was not adequately assessed. 
However, a study by Harrison et al. (1991b) found a relationship between 
the amount of M l muscarinic receptor RNA (but not total polyA+ mRNA) 
detected by in situ hybridisation and the agonal state of the subject. In 
addition, relatively undegraded RNA has been purified from subjects who 
had been oxygenated for several days prior to death, thus minimising the 
risk of antemortem hypoxia (Roses et a l, 1987).
It is known that the hippocampus is especially vulnerable to ischemic 
damage (Pulsinelli, 1985) and in view of the above observations it was 
expected that there would be increased RNA degradation observed in this 
region. However, when the extent of 28S rRNA breakdown was examined 
in the frontal cortex, hippocampus and cerebellum of three subjects, there 
was little difference observed between each region; although there were 
marked differences in degradation between the three patients (Figure 34). In 
an effort to gain greater understanding of the effects of ischemia/hypoxia on
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RNA stability in human brain, an attempt was made to model these events 
in rat brain. Permanent focal forebrain ischemia was induced in the rats by 
permanently occluding the left middle cerebral artery (Tamura et al., 1981). 
A series of preliminary experiments showed that dissection of the ischemic 
area only yielded 40 to 60mg of tissue. To increase the area of ischemic 
damage, the animals were made hypotensive for thirty minutes after 
occlusion (' O sborne, 1987). The restoration of normal blood pressure after 
the period of hypotension also facilitates some recirculation to take place in 
the tissue adjacent to the most severely ischemic areas. Having a degree of 
reflow is important, since during this period processes which cause 
additional tissue damage can occur (Halsey et a l, 1991). For example, 
during ischemia the rise in intracellular calcium levels increases the activity 
of phospholipase A2 leading to the production of arachidonic acid (Chan et 
al., 1985). Its subsequent metabolism to form leukotrienes, prostoglandins or 
thromboxanes, is thought to cause the production of superoxide radicles 
(Kuehl & Egan, 1980). This however requires the presence of molecular 
oxygen (Wolfe, 1989), and therefore during ischemia arachidonic acid 
accumulates. During reflow, the renewed availability of oxygen allows the 
rapid metabolism of accumulated arachidonic acid to take place, giving rise 
to a burst of free radicles which may lead to further lipid peroxidation and 
membrane damage (Chan et al., 1985).
The analysis of RNA purified from the ischemic areas did not show 
any marked increase in 28S rRNA degradation compared to controls (Figure 
38). In addition, Gj3 mRNA did not appear to be significantly degraded in 
the ischemic regions, although methodological problems hindered the 
assessment of mRNA integrity. The failure to find increased degradation 
after an ischemic insult may indicate that, despite much circumstantial 
evidence, antemortem ischemia is not the major cause of the degradation 
observed in the human subjects. Alternatively, it is possible that permanent 
focal forebrain ischemia does not provide an accurate model of what takes
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place during an agonal death. This is likely to involve short periods of 
partial ischemia or anoxia, followed by reflow, rather than one period of 
severe ischemia as provided by the model. Thus, a number of relatively 
small ischemic or anoxic events over a period of hours, may have a more 
pronounced effect on RNA integrity than one severe event. A useful 
development of the experiments already carried out, may therefore be to 
produce a number of short periods of global ischemia in the rat by reversibly 
occluding the carotid artery. In addition, the brains of elderly persons, as 
used in this study, may be particularly vulnerable to RNA degradation. A 
study carried out in the rat has shown that there is an age dependent 
increase in acid RNase activity, which may be due to to increased levels of 
the enzyme or to weakened lysosomes (Alberghina & Stella, 1988). 
Furthermore Goto et al. (1969) showed that the proportion of acid RNase 
activity recoverable in the "particulate" as opposed to the "cytosolic" cell 
fraction in mice liver was greater in aged compared to younger animals, 
indicating a decrease in lysosomal integrity with increasing age. It is 
possible therefore that the RNA present in the brain of elderly individuals is 
particularly vulnerable to degradation. Although no correlation exists 
between age and degradation was found, the range of ages used was small. 
It would be interesting therefore to compare the effects of ischemia, or post 
mortem delay, on RNA integrity in aged rats to that in younger animals. 
Alternatively the integrity of RNA extracted from younger human subjects 
may help to clarify this issue.
It seems likely that no single cause of RNA degradation observed in 
human brain exists, the phenomena being due to a combination of factors 
which may vary in their importance in each subjects, or for different RNA 
species. However the most important finding is that degradation occurs and 
its extent is variable. The small groups sizes frequently encountered in 
human studies make it possible that variable RNA degradation might give 
rise to incorrect conclusions. An assessment of the RNA degradation that
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has occurred in each subject is therefore highly advantageous, especially 
when using in situ hybridisation where unlike northern blotting, there is no 
indication of RNA integrity. Since RNA degradation was found to be 
similar in different regions of the brain, it may be possible to use a small part 
of the brain for the assessment of RNA degradation whilst the rest is used 
for in situ hybridisation studies. The finding that the measurement of G 
protein mRNA in post mortem human brain is unreliable, may lead one to 
question data on these species that was not accompanied by an assessment 
of stability.
In many ways it was unfortunate that the measurement of G protein 
mRNA levels proved so problematical, especially since there are reports of 
changes in the levels of G proteins mRNAs, independent of the actual 
protein levels, and vice versa (Granneman & Bannon, 1989; Klinz & Costa,
1990). Fortunately the high degree of stability possessed by G proteins 
themselves allowed them to be reliably measured in human post mortem 
brain.
2. The distribution of G proteins and adenylate cyclase in human brain.
2.1 Distribution of Gia and Goa.
It became evident from preliminary studies of G protein levels that 
these proteins were heterogeneously distributed throughout the brain. This 
presented an opportunity to discover in which regions G protein were most 
abundant, and to compare this to that of other signal transduction 
components. It was hoped that such information would facilitate the 
interpretation of data obtained in the analysis of DAT diseased brains. Of all 
the G proteins measured Gi2 had the least variable distribution throughout 
the five regions. However it possessed a similar regional distribution trend 
to that of Gil and Go with all three having their highest levels in the frontal 
cortex, hippocampus and neostriatum and their lowest levels in the 
cerebellum and pons (Figures 24 and 25). These findings are in broad 
agreement with that of Asano et al. (1990) who measured the levels of Gil, 
Gi2 and Go in rat brain. These authors reported however that Gil was 
substantially more abundant than Gi2 in all the regions they examined, 
while the present study suggests that both species have approximately the 
same levels of expression in human brain. The distribution of the mRNAs 
encoding G ia and Goa have also been examined (Brann et a l, 1987); both 
species having a similar level of expression in rat cortex, hippocampus and 
cerebellum. Curiously, these authors could detect no Gil or Gi2 mRNA in 
the neostriatum, although both proteins are present in human and rat 
neostriatum (Cooper et a l, 1990). This suggests that Gia levels in brain may 
be partly determined by post transcriptional mechanisms. The low levels of 
G oa and G ia that were found in the pons suggested that they were mainly 
expressed in grey matter, this being confirmed by the observation that 
cortical white matter contained low levels of these G proteins. Such a 
distribution is to be expected given the role of G proteins in signal 
transduction.
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2.2 The third Gsa-like immunoreactive species in human neostriatum.
The measurement of Gsa levels in the human brain produced a 
number of interesting results, including the detection of a third 
immunopositive band in the neostriatum, in addition to those of GsH and 
GsL (Figure23). While this may represent a breakdown product of GsH, the 
stability post mortem of this protein makes this unlikely. It is more 
plausible that the band represents a "Gsa-like" protein, the expression of 
which is limited to the neostriatum. One such species is Golfa which shares 
extensive amino acid homology with Gsa (88%). Although the sequence of 
human Golfa is not known, within the decapeptide sequence recognised by 
antisera CS1, an arginine residue in rat Gsa is replaced by a lysine residue in 
Golfa. Despite this, antisera CS1 is still able to detect Golfoc in rat (G. 
Milligan, personal communication). If a similar difference exists between 
the two species in humans, it is unlikely that the antisera will have the same 
affinity for Golfa and Gsa. Thus the abundance of the two proteins cannot 
be directly compared by western blotting using this antisera. The third band 
detected by CS1 is also of the correct molecular weight to be Golfa, as this 
protein contains two additional amino acids compared to GsL, and migrates 
just above GsL on denaturing polyacrylamide gels (Jones et al., 1990). As 
described in Section 2.3.1 of the Introduction, Golfa was originally cloned 
from olfactory sensory neurons. However Drinnan et al. (1991) have 
reported the presence of Golfa encoding mRNA throughout the basal 
ganglia in rat brain. These results may therefore suggest that human 
neostriatum contains, in addition to GsL and GsH, a third stimulatory G 
protein, Golfa. However Drinnan et al. (1991) failed to detect a third 
immunoreactive band in rat neostriatum and, since they also observed low 
levels of total Gsa mRNA compared to high levels of Golfa mRNA in this 
region, they concluded that what appeared, on western blots to be GsL, was 
in fact Golfa. This would imply that the major stimulatory G protein in the 
neostriatum is not G sa but Golfa. However these authors assumed that the
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low levels of Gsa mRNA present in the neostriatum implied low levels of 
Gsa protein. This may not be correct, since the levels of GsL mRNA in this 
region represents only a small proportion of the total Gsa mRNA present 
(16%) (Granneman & Bannon, 1991). Thus the degree of hybridisation of a 
probe complimentary to all forms of Gsa, will be mainly determined by the 
amount of GsH mRNA present, the abundance of GsL mRNA having only a 
minor effect. Hence the low levels of total Gsa mRNA detected by Drinnan 
et al. (1991) in rat neostriatum, may derive from the fact that this region 
contains a low abundance of GsH. Alternatively the possibility that G ia 
mRNA is translated with greater efficiency in the neostriatum i.e. normal 
protein levels associated with low mRNA levels, may also apply to Gsa, 
explaining the relatively low abundance of this mRNA species compared 
with that of Golfa mRNA. Furthermore, Jones et al. (1990) observed that S49 
eye cells could express Golfa less well than either GsL or GsH, possibly 
suggesting that Golfa mRNA is translated with lesser efficiency than that of 
Gsa. The failure of Drinnan et al. (1991) to find three immunopositive bands 
in rat neostriatum may simply be due to the difficulty in resolving GsL from 
Golfa on polyacrylamide gels (see subject C19A on Figure 23), and to the 
apparent low abundance of this protein although, as stated above, this may 
be due to antisera CS1 possessing a lower affinity for Golfa than for Gsa. 
Further experiments using Golfa specific antisera will be needed to confirm 
the presence of this G protein in human neostriatum, and to conclusively 
differentiate it from GsL. It is interesting however to speculate as to the role 
of Golfa in the neostriatum. It has been suggested that Golfa may couple 
D1 receptors to adenylate cyclase in the neostriatum (Drinnan et al., 1991). 
However Schiffmann et al. (1990) have reported that the mRNA encoding a 
putative G protein coupled receptor is present abundantly and exclusively 
in rat basal ganglia, perhaps indicating an association between this receptor 
and Golfa.
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2.3 Distribution of Gsa.
The distribution of Gsa throughout the brain, especially that of GsL, 
was somewhat different to that of Gil, Gi2 and Goa : the levels of both types 
of Gsa were highest in the cerebellum, while GsL exhibited an almost mirror 
image of Gia and Goa expression (Figure 23). In addition GsL appeared in 
general to be more highly expressed in those structures containing 
significant amounts of white matter. This was supported by the observation 
that GsL was present in relatively high amounts in cortical white matter, and 
in low quantities in grey matter (Table 6).
2.4 Distribution and stimulation of adenylate cyclase.
In an attempt to discover the reasons for the rather odd regional 
distribution of GsL, adenylate cyclase was assayed in the same membrane 
preparations (Figure 26). The basal enzyme activity exhibited significant 
correlations with the levels of Gil and Gi2, and to a lesser extent Goa, it 
having its highest activity in the frontal cortex and hippocampus with lower 
activities in the cerebellum and pons. Of the two G ia molecules, Gil most 
closely followed the distribution of adenylate cyclase (Figure 27), which 
offers some, albeit weak, evidence that Gil rather than Gi2 represents the 
predominant Gi activity in brain. In contrast, neither the levels of GsH or 
GsL were significantly correlated with adenylate cyclase activity (Table 5). 
This may suggest that Gsa is associating with other membrane components 
in addition to adenylate cyclase, such as the calcium and sodium ion 
channels that it interacts with in heart and muscle (see "Introduction", 
Section 2.3.2). However the high levels of GsL observed in white matter, 
makes it unlikely that it is concerned mainly with the modulation of ion 
channel activity. Another possible explanation lies in the existence in brain 
of at least two subtypes of adenylate cyclase, one of which can be stimulated 
by calcium (in association with calmodulin) while the other cannot (Mollner 
& Pfeuffer, 1988). Cooper et al. (1990) have suggested that GsL is
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preferentially associated with the calcium-insensitive form of the enzyme. 
Moreover, the distribution of the mRNA which encodes calcium sensitive- 
adenylate cyclase has recently been determined in rat brain (Xia et al., 1991); 
high levels of this mRNA were found in the cerebellum, high to moderate 
amounts in the cortex and hippocampus and none in the neostriatum and 
pons. Since this distribution is similar to that of GsH in human brain, it may 
suggest that an association exists between GsH and the calcium-sensitive 
form of adenylate cyclase. Confirmation of this awaits the co-expression of 
the different forms of adenylate cyclase and Gsa in cell cultures. If it is 
correct however, it would imply that white matter contained very little 
calcium- sensitive adenylate cyclase, a not unexpected situation given that 
this form of the enzyme has been implicated in the processes of learning and 
memory (Xia et a l, 1991).
The distribution of adenylate cyclase in brain has also been
investigated using the binding of 3H-forskolin to tissue sections. When
forskolin is used at concentrations in excess of 5-1 OpM, it causes the 
of
activationvadenylate cyclase activity (Seamon & Daly, 1981). This effect does 
not require the presence of Gs, and it has been suggested that forskolin 
interacts directly with adenylate cyclase (Seamon & Daly, 1981). However, 
at lower concentrations (50nM) forskolin does not stimulate the enzyme, but 
can potentiate the actions of stimulatory agonists (Seamon et a l, 1981). This 
has lead to the proposal that forskolin is binding to a G sa/adenylate cyclase 
dimer. The binding of forskolin to this so called high affinity site is therefore 
dependent on the presence of both Gsa and adenylate cyclase. However, 
since Gsa is present in much higher concentrations than adenylate cyclase 
( Alousi & a l, 1991), the level of forskolin binding should be mainly 
determined by the abundance of adenylate cyclase. High affinity forskolin 
binding to rat brain is highest in the neostriatum and the molecular layer of 
the cerebellum, with lower levels occurring in the cortex and hippocampus 
(Poat et a l, 1988), findings which do not concur with the activity of
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adenylate cyclase found in these regions of human brain. In the cerebellum 
this discrepancy is most probably due to the use of the whole cerebellum to 
measure adenylate cyclase activity rather than just cerebellar grey matter. It 
is unclear however as to why the neostriatum possesses such high levels of 
forskolin binding. While it is possible that differences exist in the levels of 
adenylate cyclase found in rat and human neostriatum, forskolin is also 
known to interact with moieties other than adenylate cyclase, such as ion 
channels and the glucose transporter (reviewed in Laurenza et a l, 1989). It is 
possible therefore that forskolin binding in the neostriatum is not all 
attributable to it binding to adenylate cyclase. Furthermore, Poat et al. (1988) 
have shown that differences in certain aspects of high affinity forskolin 
binding exists between the neostriatum and other brain regions. On the 
other hand, the affinity of the binding site for forskolin is the same in rat 
neostriatum, cerebellum and hippocampus (Poat et al., 1988), suggesting that 
the nature of the binding site is similar in each brain region. It is interesting 
to speculate that the postulated presence of Golfa in the neostriatum 
enhances forskolin binding, although the mechanism of such an action is 
unclear since, if anything, Golfa appears to be less efficiently coupled to 
adenylate cyclase than GsH or GsL (Jones et ah, 1990). Indeed, it seems 
unlikely that increased coupling between Gsa and adenylate cyclase could 
explain the high levels of forskolin binding in this region, since the ability of 
fluoroaluminate to stimulate the enzyme was similar in the hippocampus, 
cortex and neostriatum. Nevertheless, the stimulation of adenylate cyclase 
by fluoroaluminate was noticeably higher in the cerebellum and pons 
compared to other brain areas (Figure 26). There exists some, largely 
circumstantial, evidence to suggest that GsL is more efficaciously coupled to 
adenylate cyclase than GsH (Walseth et a l, 1989). In contrast, recent studies 
of GsH and GsL expressed in S49 eye cells, indicate that GsH is the slightly 
more potent of the pair (Jones et a l, 1990). The existence of a small but 
significant correlation between the degree of stimulation of adenylate
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cyclase in human brain, and the levels of GsL, or the ratio of GsL to GsH 
(Table 5), may indicate that GsL is better able to stimulate adenylate cyclase 
than GsH. However, despite cortical grey and white matter possessing the 
largest difference in the ratio of GsH to GsL (3.6 and 0.4 respectively), 
stimulation was similar in both, making it unlikely that the relative amounts 
of GsH and GsL determines the stimulatory ability of fluoroaluminate 
(Table 6). In cells which do not contain functional Gsa (Hildebrandt et a l, 
1983), or in situations where Gs is inaccessible (Inoue et a l, 1990), 
fluoroaluminate can inhibit adenylate cyclase. Since fluoroaluminate is able 
to activate Gi as well as Gs (Katada et a l, 1984b), it is probable that the final 
degree of stimulation of adenylate cyclase is a combination of the influences 
of stimulatory and inhibitory G proteins. Indeed a strong correlation was 
found between the ratio of Gia to Gsa and stimulation, although a similar 
correlation was also found between the ratio of Goa to Gsa and stimulation 
(Table 5). In both cases, fluoroaluminate stimulation may be being reduced 
by the release of (3y subunits, which have been shown to decrease 
fluoroaluminate stimulated activity in brain (Premont & Iyengar, 1989). 
Thus the stimulation of adenylate cyclase by fluoroaluminate may represent 
a simple means to assess the relative amounts of functional stimulatory and 
inhibitory G proteins present in different preparations.
3. Signal transduction in Dementia of the Alzheimer Type.
3.1 Choline acetyl transferase.
The subjects which were designated as having suffered from 
dementia of the Alzheimer type had both a clinical and neuropathologically 
confirmed diagnosis of the disease. The diagnosis was also confirmed by 
measuring the activity of choline acetyl transferase (ChAT) in each subject. 
This was found to be substantially reduced in the frontal cortex and 
hippocampus of DAT diseased subjects compared to that of controls, 
confirming that changes in neuronal communication had taken place in the 
DAT diseased brains which were used (Figure 16). A similar reduction in 
ChAT activity has been reported by a number of groups; for example 
Procter et al. (1988) observed a ChAT activity equal to 50% of controls in 
DAT diseased frontal cortex, and 44% in the hippocampus. Although the 
decrease in ChAT activity is a useful confirmation of the diagnosis of DAT, 
it is not possible to use it as an index of the severity of the disease, since no 
correlation has been observed between ChAT activity and the overall 
cognitive function of patients, using either cortical biopsies (Neary et al., 
1986), or in subjects whose cognitive abilities were tested before death 
(Perry, 1986a). However, the reduction in ChAT activity represents a severe, 
and accepted, neurochemical alteration in DAT with which other 
neurochemical measures may be usefully compared. In this respect, it offers 
an advantage over other markers of the disease, such as plaque density, 
since ChAT activity can be determined in the same preparations which are 
used to investigate other moieties.
3.2 Sodium potassium-dependent ATPase.
The use of biochemical techniques to investigate brain disorders 
usually necessitates the analysis of relatively large areas of tissue containing 
a heterogeneous population of cells. This leads to problems in interpreting 
the data obtained, since a significant change in the parameter being assayed
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may be due either to an up or down regulation of the moiety being 
measured, or to the loss of a particular cell type. It is therefore useful to 
measure other cellular components in parallel to the one of interest. The 
assay of several different G proteins in the same preparation, allowed each 
one to act as a control for the others. However, although adenylate cyclase 
activity was determined in the same preparations as those used to determine 
G protein levels, it was felt that the activity of another enzyme should also 
be measured. The ATP-dependent sodium potassium pump, or sodium 
potassium-dependent ATPase, which is responsible for the active transport 
of Na2+ and K+ ions, was chosen for this purpose as it located on the cell 
membrane and will be present in the same preparations as those used to 
measure the signal transduction components. The enzyme is important in 
its own right as it maintains the gradients of sodium and potassium ions 
necessary for nerve impulse conduction (Albers et a l, 1989). It is also 
estimated that it is responsible for 50% of the energy expenditure of the 
brain (Astrup et a l, 1981). In addition, the activity of sodium potassium- 
dependent ATPase can be stimulated by adrenergic or serotonergic agonists 
in synaptosomes (Albers et a l, 1989). Although the mechanism of such 
effects is unclear, it may involve phosphorylation of the enzyme by protein 
kinase C (Collins et a l, 1987; Hootman et a l, 1987), possibly acting via a G 
protein coupled mechanism (Danilenko et a l, 1991). Thus it appears that 
signal transduction mechanisms can modulate the activity of sodium 
potassium-dependent ATPase, which may in turn alter synaptic 
transmission by hyperpolarising the cell. The enzyme is also frequently 
used to control against differences in membrane purity, and therefore 
enzyme activity, that may arise during the preparation of membranes 
(Begin-Heick, 1990). It also offers the advantage of being similarly 
distributed between grey and white matter to G proteins and adenylate 
cyclase (Table 6). This offers a safeguard against the possibility that 
differences in the relative amounts of grey and white matter within each
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tissue block, may bias the resulting data in favour of the control or DAT 
diseased groups (see Section 1.1.2).
Previous investigations of sodium potassium-dependent ATPase 
levels in DAT have used the binding of 3H-ouabain to the enzyme to 
measure its abundance in human brain. Such studies have given conflicting 
results with Harik et al. (1989) reporting a decrease in 3H-ouabain binding to 
DAT diseased frontal cortex using in situ autoradiography, while Colvin et 
al. (1991) using 3H-ouabain binding in tissue homogenates found no change. 
The discrepancy between the two studies may arise from the use of different 
techniques to measure ouabain binding; autoradiography estimates the 
amount of binding per volume of tissue, while homogenate binding is 
usually expressed per weight of protein. Factors such as cell loss or atrophy 
may effect the former measure, while the latter might be expected to be less 
influenced by such changes. The measurement of the enzyme's activity in 
membrane preparations would therefore be expected to give similar results 
to that obtained using ouabain binding to tissue homogenates. In the 
present study, this is indeed the case since no significant difference in the 
activity of sodium potassium-dependent ATPase was detected between 
DAT and control subjects, in the hippocampus or frontal cortex (Figure 22). 
These results indicate that this important enzyme is largely unaltered in the 
disease, both in terms of activity, and possibly enzyme levels. Alternatively, 
if the results of Harik et al. (1989) do indeed mean that the abundance of the 
enzyme is lower in DAT diseased frontal cortex, the fact that its activity is 
unaltered may suggest that there exists a compensatory stimulation of the 
enzyme in DAT, possibly mediated by protein phosphorylation. It should 
be noted that the assay of 3H-ouabain binding and enzyme activity are not 
completely comparable measures. Of the a  and (3 subunits which comprise 
sodium potassium-dependent ATPase, ouabain is thought to bind to the a  
subunit. There are three forms of oc subunit present in brain, each differing 
in their affinity for ouabain. The low (<100nM) concentrations of ouabain
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used in binding studies will only bind to 0(2 and a3 subtypes, which have a 
Kd for ouabain in the order of 15nM (Colvin et al., 1991), compared to the a l  
subtype which possesses a Kd of 50pM (Marks & Seeds, 1978). Under the 
assay conditions used herein, it was observed that a ouabain concentration 
of lOOnM could only inhibit approximately 25% of enzyme activity. This 
suggests that the activity measured is mainly due to sodium potassium- 
dependent ATPase containing the a l  subunit. Studies using cell cultures 
have suggested that a l  is mainly present in astrocytes, and oc2 and a3 in 
neurons (Markwell et al., 1991). However, immunohistochemical 
investigations have demonstrated that there is no exclusively neuronal or 
glial forms of sodium potassium-dependent ATPase (McGrail et al., 1991), 
thus the enzymes activity cannot be assigned to any one cell type. Since G 
proteins are also thought to exist in both neurons and glial cells (Brabet et al., 
1988), sodium potassium-dependent ATPase represents a useful negative 
control with which the levels of other membrane proteins may be compared. 
The failure to find a difference between the control and DAT groups also 
indicates that the membrane purity of the preparations, or the amounts of 
grey and white matter in the tissue from which they were prepared, did not 
differ markedly between the two groups of patients.
3.3 G protein levels.
The first signal transduction components to be investigated in DAT 
diseased brains were the a  subunits of G proteins. This gave a similar result 
to that obtained with sodium potassium-dependent ATPase, namely that 
there was no significant change in the levels of Goa, Gil, Gi2, GsH and GsL 
in the frontal cortex and hippocampus of DAT subjects compared to controls 
(Figures 17 and 18). This suggests that G protein levels are relatively 
unaffected by the disease process. However a small, but statistically 
significant increase in the relative amount of GsL compared to GsH was 
observed in the frontal cortex of DAT subjects relative to controls. As
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discussed in Section 2.4, the functional significance of having two forms of 
Gsa is unclear, but an altered ratio of GsL to GsH, may indicate alterations 
in the stimulation of adenylate cyclase activity, or in the sensitivity of 
adenylate cyclase to intracellular calcium concentration; a possibility which 
is considered in more detail later.
Since this study was completed many other G protein a  subunits 
have been identified, the best characterised being G za and Gqa. Although 
both a  subunits are present in brain, the possibility that G qa can act to 
stimulate phospholipase C activity (see "Introduction", Section 2.3.2), and 
may represent a G protein through which muscarinic receptors can 
modulate inositol phospholipid metabolism, makes it of particular relevance 
to DAT. It cannot be ruled out that changes in the levels of G qa or other 
newly discovered a  subunits occur in DAT, and it would of interest to 
measure the levels of these a  subunits as, and when, antisera become 
available.
Although the results presented here suggest a maintenance of a  
subunit levels in DAT, it is possible that small cell-specific changes are 
occurring, which are masked by the use of areas of brain containing a 
heterogeneous population of cells. For example, a decline in G protein 
levels due to neuronal loss (Davies et a l, 1987) may be compensated by the 
proliferation of glial cells that occurs in the disease (Beach et a l, 1989). Both 
cell types are known to contain G proteins (Brabet et a l, 1988). The sub- 
cellular localisation of G proteins may also contribute to their robustness in 
the disease, since it appears that synaptic areas may be more severely 
affected than other parts of the cell (Hamos et a l, 1989). In particular the use 
of western blotting has demonstrated the partial loss of synaptophysin, a 
synaptic marker protein, in DAT diseased frontal cortex (Masliah et a l, 
1991b). Therefore, since Goa has been localised to areas of the cell outwith 
synaptic densities (Gabrion et a l, 1989), it may explain why no significant 
change in the levels of this protein was observed. Whether this is true for all
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G proteins is unclear, since ultrastructural studies of their intracellular 
localisation in neurons are unavailable. Clearly, an immunohistochemical 
study is required to resolve such questions. Unfortunately, the anti-G 
protein antisera which were available did not give immunopositive staining 
when used upon tissue sections, despite possessing excellent 
immunoreactivity against denatured proteins on western blots. This is most 
likely due to the antisera having been raised against small peptides; 
successful attempts to examine G protein expression by 
immunocytochemistry have used antisera raised against whole proteins.
3.4 G protein-receptor coupling.
Whilst G protein a  subunit levels appear to be maintained in DAT, 
there may exist some functional impairment of these proteins in the disease. 
For example the ability of somatostatin to inhibit adenylate cyclase is 
decreased in DAT diseased temporal cortex, but the number of somatostatin 
receptors are unchanged (Cowburn et al, 1991). A problem associated with 
such studies however is their inability to determine at what point in the 
transduction system a change has taken place. It is therefore advantageous 
to use techniques which examine specific events in the transduction cascade 
such as effector-G protein or receptor-G protein coupling. The latter event 
has been investigated by several groups, who have measured the ability of 
GTP analogues that cause the conversion of high affinity agonist binding 
sites (which are thought to represent receptor-G protein complexes), to low 
affinity sites (see "Introduction", Section 2.2). When applied to human brain, 
this and similar techniques, have demonstrated a substantial decrease in the 
relative amounts of high affinity agonist binding to M l and D1 receptors 
(Flynn et a l, 1991; De Keyser et a l, 1990), in the frontal cortex of DAT 
diseased subjects compared to controls. This may be due to a specific 
alteration of these receptors, possibly by phosphorylation, inhibiting their 
ability to interact with G proteins. Alternatively, a more generalised change
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in G protein-receptor coupling may have occurred in DAT diseased frontal 
cortex. This seems likely since the effect is observed with different receptors 
linked to several types of G proteins (D1 to Gs, and M l to Gq, Go or possibly 
Gs). It should be noted that high affinity binding to somatostatin receptors 
was found to be unchanged in DAT (Bergstrom et al., 1991). However since 
somatostatin causes the inhibition of adenylate cyclase (Schettini et a l, 1989), 
it is possible that Gi is not affected in the same manner as other G proteins. 
A possible explanation for reduced receptor-G protein coupling in DAT, 
may lie in the altered membrane composition that is reported to occur in the 
disease (Soderberg et a l, 1991). Alternatively, the interaction of G proteins 
with the cellS cytoskeleton may play a role. Tubulin, itself a GTP binding 
protein, can interact with G proteins (specifically Gi and Gs) and alter their 
activity (Rasenick & Wang, 1988; Wang et a l, 1990, and "Introduction", 
Section 3). There is strong evidence to suggest that there is a disruption of 
the cellS cytoskeleton in DAT, for example, the accumulation of 
neurofibrillary tangles, and the abnormal intracellular localisation and 
phosphorylation of the microtubule accessory protein tau (see 
"Introduction", Section 4). It is conceivable that such events may disrupt G 
protein function, leading to a decrease in their ability to interact with 
receptors. Indeed, work done in this laboratory has demonstrated a 
significant decrease in low Km GTPase activity in DAT diseased frontal 
cortex, suggesting that either not all of the a  subunits measured by western 
blotting are functional, or there is an overall change in G protein activity. A 
reduction in GTPase activity, or in receptor-G protein coupling, could also 
be due to a decrease in the levels of P or Y G protein subunits, since their 
presence is required for both GTPase activity and the interaction of G 
proteins with neurotransmitter receptors (Kanaho et a l, 1984; Florio & 
Sternweis, 1985; Florio & Sternweis, 1989). Although no significant change 
was found in the levels of GP mRNA, as discussed above, only large changes 
in mRNA levels would have been detectable. Thus the northern blot study
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cannot rule out that a small change in (3 subunit expression has occurred. 
Indeed, preliminary data obtained in this laboratory suggests that a decrease 
in the levels of (3 subunits has taken place in DAT diseased frontal cortex. 
Even a small change in (3 subunit expression, independent of that of a  
subunits, would have far reaching consequences for many aspects of signal 
transduction. Clearly this observation may be of great importance and 
experiments are underway to confirm or refute the preliminary data. 
Whatever the explanation for the apparent change of receptor-G protein 
coupling in DAT, it is unclear as to what the in vivo consequences of such 
events may be. However, a reduced ability of M l receptors to interact with 
G proteins may account for the failure of cholinergic replacement strategies 
to significantly improve memory or cognition in DAT patients.
3.5 G protein-effector coupling.
The discussion so far has concentrated on the functioning of G 
proteins in DAT with respect to their ability to interact with 
neurotransmitter receptors. To perform any useful function however, G 
proteins must also be able to couple to their various effector systems. The 
enzyme adenylate cyclase was chosen to examine the effect that DAT has on 
such interactions, as it has been well characterised with regard to its 
interactions with G proteins. As explained in Section 2.4, the ability of G 
proteins to interact with adenylate cyclase can be estimated by activating the 
enzyme with fluoroaluminate. The use of fluoroaluminate to stimulate 
adenylate cyclase activity offers an advantage over using agonists, in that it 
can be used to specifically assess G protein-effector coupling. The ability of 
agonists to stimulate the enzyme can however be additionally modified by 
changes in receptor number an d /o r receptor-G protein coupling.
Both basal and stimulated activities of adenylate cylase, assayed in 
membrane preparations in which G protein levels had been previously 
determined, were found to be substantially decreased in the DAT diseased
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frontal cortex, while no significant change was detected in the hippocampus 
(Figure 20). In contrast, the ratio of stimulated to basal adenylate cyclase 
activity was not significantly different between the DAT and control 
subjects, in either of the brain regions examined. This indicated that the 
presence of DAT has not adversely altered the ability of G proteins and 
adenylate cyclase to interact. It is therefore unlikely that any increase in the 
functional activity of inhibitory G proteins is responsible for the decrease in 
cortical adenylate cyclase activity observed, and that the disease has 
therefore affected adenylate cyclase itself. Decreased adenylate cyclase 
activity in DAT diseased frontal cortex may lead to a lowering of 
intracellular levels of cAMP, and hence decrease the in vivo activity of 
protein kinase A. Alterations in the phosphorylation of various cellular 
components have been reported to occur in DAT. For example, as well as 
changes in the phosphorylation of tau, the ability of synapsin 1 (a protein 
kinase A substrate) and GAP-43 to be phosphorylated in vitro is altered in 
DAT (Parks et a l, 1991; Florez et a l, 1991), and it has been suggested that 
phosphorylation of amyloid precursor protein by protein kinase C affects its 
metabolism (Buxbaum et a l, 1990). Furthermore, a lack of phosphorylation 
by protein kinase A may allow increased phosphorylation at competing sites 
by other kinases. Despite this, since no change was observed in the activity 
of hippocampal adenylate cyclase in DAT subjects, it would seem unlikely 
that the alterations observed in the frontal cortex play a fundamental role in 
the pathogenesis of the disease. They are therefore likely to be a 
consequence, rather than the cause of, other events.
3.6 Other studies of adenylate cyclase in DAT.
There exists in the literature several other investigations of adenylate 
cyclase in DAT diseased brain, giving mostly contradictory results. The 
results of these studies and that of the present investigation are summarised 
in Table 9. The study by Danielsson et a l (1988) claimed to have detected a
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significant increase in basal adenylate cyclase activity in DAT hippocampus. 
However, calculation of the t-statistic using the data given in the paper does 
not give a statistically significant change using a two-tailed test (P = 0.068). 
This discrepancy may be due to a misprint or to the manner in which the t- 
test was carried out. Even if the original data did give a significant change it 
is likely that it only just reached statistical significance. The actual enzyme 
activities recorded by Danielsson et al. (1988) are much lower than those 
quoted elsewhere, this being due to the enzyme being assayed in a 
homogenate which had been pelleted at 1650g, rather than a high speed 
membrane fraction. Given the non-standard methodology used for the 
Danielsson study, in addition to the questionable statistical analysis, it is not 
felt that the conclusions reached by these authors are reliable. The 
investigation by Ohm et al. (1991) detected a significant reduction in 
adenylate cyclase activity in the hippocampus of DAT diseased subjects. 
This data is in contrast to those of this study and that of Bergstrom et al. 
(1991). There are no obvious methodological reasons for the difference in 
findings of the studies, albeit that Ohm et al. (1991) did include the step of 
homogenising their tissue samples at 37°C in a buffer containing magnesium 
ions. Although any adverse effects of this treatment should be felt equally 
by control and DAT diseased groups, it is conceivable that different levels of 
proteases, or in the localisation of proteases in DAT diseased brain may 
account for a lower adenylate cyclase activity observed in this group of 
subjects. Bergstrom and collaborators also found no change in adenylate 
cyclase activity between control and DAT groups in the temporal cortex 
(Cowburn et al., 1991), cerebellum, caudate nucleus or frontal cortex 
(Bergstrom et al., 1991), this latter finding being in contrast with that of this 
study. However the data presented herein is in agreement with Dewar et al. 
(1990) who found a significant decrease in high affinity 3H-forskolin binding 
in the frontal cortex of DAT diseased subjects, but found no change in the 
hippocampus. In addition, there existed a significant correlation between
140
the activities of ChAT and adenylate cyclase in DAT diseased frontal cortex, 
further suggesting that the disease process is affecting adenylate cyclase in 
the frontal cortex of DAT diseased subjects. No correlation however was 
found between adenylate cyclase activity and the density of neuritic plaques 
in the frontal cortex. However plaques were counted in tissue adjacent to 
those used for the assaying of adenylate cyclase, and it is possible that local 
neuropathology differs between the two areas of brain. Even small 
differences would be enough to affect the strength of correlation due to the 
relatively low number of subjects used for the analysis. It should be noted 
though that the investigation of high affinity forskolin binding by Dewar et 
al. (1990), used subjects from the same population of patients as that used in 
the present investigation. It is possible therefore that there are 
pharmacological or aetiological reasons for the different findings reported 
by the various laboratories.
Region Study Control DAT Significance
Frontal Cortex a ) 50.1 ± 6.9 28.1 ± 2.3 P<0.01
(2) 85.6 ± 15.5 72.5 ± 10.9 NS
Temporal Cortex (3) 60.3 ± 11.8 47.4 ± 6.0 NS
Parietal Cortex (4) 14.5 ± 1.4 16.4 ± 3.1 NS
Hippocampus (1) 52.1 ± 3.6 54.1 ± 5.2 NS
(2) 42.7 ± 4.9 33.2 ±4.6 NS
(4) 9.8 ± 1.0 14.3 ±2.1 P<0.05 1
(5) 42.0 ± 3.0 22.3 ± 2.9 P<0.01
Caudate nucleus (2) 59.7 ± 5.9 57.5 ± 5.7 NS
Cerebellum (2) 82.7 ± 10.3 65.1 ± 7.9 NS
Table 9.
Comparision of basal adenylate cyclase activities in several studies of the 
enzyme in human post mortem brain.
The values quoted are derived from the following studies, and are 
quoted as mean basal activity (pmols cA M P/m in/m g protein) ± SEM.
(1) present study.
(2) Bergstrom et al., 1991.
(3) Cowburn et al., 1991.
(4) Danielsson et al., 1988
(5) Ohm et al., 1991.
In each case mean activity in control and DAT diseased subjects were 
compared using an unpaired, two-tailed, Students t-test, this being reported 
as a significance level (NS = not significant).
1 - the authors quote a signicance of P<0.05, however the data given in this 
paper does not give a statistically significant change.
3.7 Possible mechanisms leading to the loss of adenylate cyclase activity in 
DAT.
The obvious questions that must be addressed are by what 
mechanism is cortical adenylate cyclase activity decreased in DAT, and why 
this does not happen in the hippocampus. Since the activity of ChAT is 
decreased by a large amount in both the hippocampus and frontal cortex, it 
would suggest that the reason for the robustness of hippocampal adenylate 
cyclase in DAT, does not lie in this region being less severely effected by the 
disease than the frontal cortex. However, differences may exist in the 
localisation, nature, or control of the enzyme in the two regions. It is unclear 
whether the reduction in activity observed in the frontal cortex, is due to a 
decrease in the levels of the enzyme, or to a change in its functional capacity. 
The experiments of Wadman et al. (1991) have indicated that 
phosphorylation of adenylate cyclase may reduce the activity of the enzyme, 
while those of Yoshimasa et oX. (1987) strongly suggest that the enzyme can 
be phosphorylated by protein kinase C. While phosphorylation of adenylate 
cyclase may take place in DAT diseased frontal cortex, it is not known 
whether such a modification would be maintained over the post mortem 
delays encountered in the human tissue. Furthermore, as mentioned 
previously, Dewar et al. (1990) detected a 50% decrease in high affinity 
forskolin binding in DAT frontal cortex, suggesting a decrease in the actual 
levels of adenylate cyclase rather than a change in its activity. It is possible 
that adenylate cyclase, in the frontal cortex, is localised to parts of the cell, 
such as synapses, which are thought to be preferentially lost in DAT. 
However since the levels of Gs and Gi are unaltered (which would be 
expected to be colocalise with adenylate cyclase), it is perhaps more likely 
that there is a specific downregulation of the enzyme in the disease. This 
may simply be due to aberrant transcription of the adenylate cyclase gene in 
DAT. Alternatively a prolonged stimulation of the enzyme may have 
caused a compensatory decrease in its levels. If the enhanced stimulation
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was caused by mechanisms which were only active in vivo, or ceased shortly 
after death, the result would be a decreased activity when the enzyme was 
subsequently assayed in vitro. It is unlikely that increased stimulation by 
neurotransmitters would result in a downregulation of adenylate cyclase, 
since in other systems the mechanisms which compensate for such events 
either involve the phosphorylation and inactivation of specific receptors 
(Sibley et al., 1984), or decreased ability of Gs to stimulate adenylate cyclase 
(Hernandez-Sotomayor et a l, 1991). However it cannot be ruled out that the 
loss of specific receptors which cause the inhibition of adenylate cyclase e.g. 
somatostatin, results in a downregulation of the enzyme, especially since the 
stimulation of inhibitory opiate receptors in rat, results in increased 
adenylate cyclase activity (Duman et al., 1988). A potentially reversible 
increase in adenylate cyclase activity has been observed in frog erythrocytes 
after treatment with phorbol ester, a substance which activates protein 
kinase C (Yoshimasa et al., 1987). This effect is thought to be due to 
phosphorylation of adenylate cyclase. However in duck erythroctes, 
phorbol esters have the opposite effect, although this may not involve the 
direct modification of adenylate cyclase itself (Sibley et al., 1984). Increased 
adenylate cyclase activity can also arise from the removal of the inhibitory 
influence of Gi (Heyworth et al., 1984). In rat hepatocytes Gia is 
phosphorylated, probably by protein kinase C, leading to a stabilisation of 
the G protein trimer, and hence a loss of functional Gi (Bushfield et a l, 
1990a). Since the addition of phosphatase inhibitors results in a rapid 
increase in Gi phosphorylation (Bushfield et al., 1991), the 
dephosphorylation of Gi in hepatocytes appears to be a continuous process, 
a feature which would preclude its study in post mortem tissue. Of 
particular interest is the inactivation of rat adipocyte Gi2, which occurs in 
experimentally induced diabetes (Strassheim et al., 1990, and "Introduction" 
Section 3). This is accompanied by a large reduction in basal adenylate 
cyclase activity but without any change occurring in the levels of G il, Gi2 or
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Gsa. The loss of Gi function appears to be limited to its tonic inhibitory 
effect upon adenylate cyclase, rather than on receptor mediated inhibition. 
Although reduced adenylate cyclase activity in diabetic rat adipocytes could 
be mediated by a number of mechanisms, it is possible that the deactivation 
of Gi2 leads to an increase in basal adenylate cyclase activity and subsequent 
downregulation of the enzyme. Since the reduced activity of adenylate 
cyclase in DAT frontal cortex is also accompanied by a maintenance of G 
protein a  subunit levels, it is tempting to speculate that a mechanism similar 
to that in adipocytes occurs in brain. Although it is not known as to whether 
neural G ia can be phosphorylated, Sauvage et al. (1991) have recently shown 
that a protein kinase C-like enzyme is able to phosphorylate and inactivate a 
G protein, thought to be Gi, which had been purified from human brain. 
Hence if, as postulated by Masliah and collaborators (Van Huynh et al., 1989; 
Masliah et al., 1990; Masliah et al., 1991a), protein kinase C activity is altered 
in DAT, there exists the possibility that it catalyses the phosphorylation and 
inactivation of Gi in DAT diseased brain. Such an event would presumably 
lead to increased basal adenylate cyclase activity in vivo, and may 
subsequently elicit a compensatory reduction in the levels of the enzyme. 
Furthermore, the heterogeneous distribution of the various protein kinase C 
isotypes offers an explanation as to why such events take place in the frontal 
cortex, but not in the hippocampus (Nishizuka, 1988). It is possible that a 
change in protein kinase C activity could be mediated via a rise in 
intracellular calcium concentration, since calcium can stimulate the 
formation of diacylglycerol (which is also required for its activation), via its 
effects on phospholipase C (Kennedy, 1989), or on phospholipase D (Billah 
et a l, 1989).
Another possibility concerns the two subtypes of adenylate cyclase 
that exist in brain, namely the calcium-sensitive and insensitive enzymes. In 
cells which possess the calcium-sensitive form, a prolonged increase in 
intracellular calcium concentration, stimulating the cells adenylate cyclase
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activity, may lead to a down regulation of both types of adenylate cyclase, or 
of the calcium-sensitive enzyme in particular. The latter possibility is 
supported by the small increase in the levels of GsL compared to GsH 
detected in the frontal cortex of DAT subjects, since as described in Section 
2.4, GsL may be coexpressed with the calcium-insensitive form of the 
enzyme. In addition the possibility that a decrease in G protein (3 subunit 
levels has occurred in DAT diseased frontal cortex also supports this 
hypothesis, since the stimulation of adenylate cyclase by calcium can be 
inhibited by G protein (3y subunits (Katada et a l, 1987). Thus, a decrease in {3 
subunit levels may potentiate the stimulation of adenylate cyclase by 
calcium. There is much circumstantial evidence suggesting that intracellular 
calcium may be elevated in DAT diseased brain. For example, the 
application of excitatory amino acid neurotransmitters to rat cortex, (which 
leads to an increase in calcium levels), causes similar patterns of neuronal 
death to that observed in DAT (Maragos et al., 1987). In addition, increasing 
the intracellular calcium concentration of cultured rat hippocampal neurons, 
causes the formation of structures strongly resembling neurofibrillary 
tangles (Mattson, 1991). The use of primary cell cultures has also indicated 
that (3-amyloid can interfere with calcium homeostatis (Mattson et al., 1992). 
Furthermore, if the human hippocampus contains lower amounts of calcium 
sensitive adenylate cyclase, it could offer an explanation as to why adenylate 
cyclase activity is unaltered in the hippocampus. However, as described in 
Section 2.4, mRNA encoding this form of the enzyme possesses a similar 
abundance in rat hippocampus as that found in the cortex. The 
development of antisera to adenylate cyclase should allow the distribution 
of the two forms to be mapped in brain, as well as allowing any alterations 
that have occurred in DAT to be determined.
The possible mechanisms leading to down regulation of adenylate 
cyclase are summarised in Figure 39, which demonstrates that a decreased 
adenylate cyclase activity in DAT diseased brain is not incompatible with a
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rise in intracellular calcium concentration having occurred, possibly due to 
the excitotoxic effects of glutamate.
3.8 Closing comments.
The effect that DAT has on cortical adenylate cyclase activity could 
have important consequences for potential therapeutic strategies which act 
through this enzyme. For example, the failure of cholinergic replacement 
therapies may lead to attempts to increase the levels of other transmitters 
which are reduced in DAT, for example somatostatin. Although such a 
strategy would apparently worsen a deficit in adenylate cyclase as discussed 
above, it is not certain whether decreased activity occurs in vivo. More 
generally, the data presented here demonstrate that significant alterations in 
signal transduction can occur in the DAT. It is therefore necessary to 
develop the investigation of the disease to include other effector systems 
such as phospholipase C. This particular enzyme is one of the major routes 
of cholinergic signal transduction, and has recently been 
immunohistochemically localised to neuritic plaques (Shimohama et al.,
1991). It would be of interest therefore to determine its activity in the brains 
of control and DAT subjects, especially since the receptor for the second 
messenger it produces, IP3, has been found to be lowered in DAT diseased 
brains (Young et a l, 1988). Similarly, another phospholipid metabolising 
enzyme phospholipase A2, may possess increased activity in the disease as 
an increased abundance of its metabolites are detected in DAT diseased 
frontal cortex (Blusztajn et a l, 1990). Thus, much work needs to be done to 
gain a full understanding of the mechanisms leading to the breakdown of 
intercellular communication in DAT. Once completed such studies will 
allow a more realistic assessment of whether any strategies designed to treat 
the disease once cognitive dysfunction has occurred, will ever prove 
successful. This will also provide insights into the pathological mechanisms 
involved in the disease process.
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Figure 39.
Downregulation of adenylate cyclase in DAT.
(a) Under normal circumstances adenylate cyclase activity is 
controlled by stimulatory receptors (Rs) acting via Gs, and inhibitory 
receptors (Ri) acting via Gi. Although it is not certain, it is likely that Gi in 
brain can be inactivated in brain by phosphorylation (Gi-P) by protein 
kinase C (PKC) (activated by diacylglycerol (DAG) and Ca2+), an effect 
which is reversed by phosphatases (phosph.). In addition, adenylate cyclase 
can also be stimulated by a rise in intracellular calcium ion concentration.
(b) In DAT (line thickness and size of characters indicates the relative 
effect of each feature) a decline in inhibitory G protein activity, whether due 
to loss of inhibitory receptors e.g. somatostatin, or increased 
phosphorylation of Gi by protein kinase C, may lead to a rise in basal cAMP 
levels. Similarly, elevated intracellular calcium concentration would also be 
exspected to raise cAMP levels. These events may in turn lead to a 
compensatory downregulation of adenylate cyclase itself. Note though that, 
with the exception of the loss of inhibitory receptors, the other changes 
would only be apparent either, in vivo (rise in calcium concentration), or 
would be reversed soon after death (phosphorylation of Gi). Thus the net 
result would be decreased adenylate cyclase activity when the enzyme was 
assayed in vitro.
(a)
Rs Phosphollpases
PKC
CaGs
Phosph.
AC
(b)
Phosphollpases
PKC
Gi-® Ca
Phosph.
O (D ow n  
-regu lation )
1 [CAMP]
APPENDIX A1
The values of the parameters measured in each human subject used 
in the analysis of the frontal cortex and hippocampus ("Results", Section 3), 
are listed in Table 10.
Table 10.
G proteins levels and enzyme activities of each human subject.
The values of the parameters measured in each human subject, as 
described in Section 3 of "Results", are shown. GsH, GsL, Gil, Gi2 and Go 
refer to the G protein a  subunits, and are quoted in optical density units. 
Bas. AC and Stim. AC refer to basal and fluoroaluminate stimulated 
adenylate cyclase activity respectively, and are quoted in pmols cAMP/ 
m in/m g protein. ATPase refers to sodium potassium-dependent ATPase 
activity and is quoted in nmols P i/m in /m g  protein. ChAT refers to the 
activity of choline acetyl transferase, and is given as nmols acetyl choline/ 
hour/m g protein.
FRONTAL CORTEX
Subject GsH GsL Gil Gi2 Go Bas. AC Stim. AC ATPase ChAT
C14 0.112 0.040 0.101 0.104 0.162 68 182 337 3.5
C15 0.133 0.099 0.055 0.074 0.069 26 70 180 4 3
C16 0.243 0.124 0.097 0.121 0.177 55 175 308 3.2
C19A 0.187 0.094 0.087 0.107 0.190 82 211 251 4.2
C21 0.153 0.081 0.053 0.083 0.128 50 108 198 2.0
C22 0.165 0.070 0.058 0.078 0.129 24 556 149 4.0
C25 0.160 0.057 0.063 0.091 0.157 53 127 210 27
C35 0.210 0.087 0.087 0.096 0.172 43 118 185 4.0
A23 0.175 0.086 0.076 0.109 0.124 31 87 210 1.9
A30 0.123 0.106 0.042 0.065 0.140 30 68 210 1.7
A33 0.132 0.153 0.046 0.107 0.138 19 59 281 14
A53 0.148 0.093 0.045 0.069 0.061 26 49 181 1.5
A54 0.199 0.088 0.060 0.094 0.189 29 82 174 20
A55 0.163 0.087 0.075 0.110 0.159 41 103 177 3.5
A56 0.202 0.117 0.051 0.086 0.088 26 65 149 0.9
A63 0.094 0.080 0.067 0.744 0.020 23 49 110 22
HIPPOCAMPUS
Subject GsH GsL Gil Gi2 Go Bas. AC Stim. AC ATPase ChAT
C8 0.079 0.060 0.039 0.037 0334 52 187 194 13
C16 0.104 0.174 0.063 0.065 0387 39 131 235 13
C19A 0.132 0.221 0.027 0.034 0350 69 244 208 23
C20 0.162 0.160 0.023 0.032 0332 52 158 182 33
C28 0.163 0.201 0.062 0.038 0339 45 127 172 23
C33 0.124 0.161 0.057 0.030 0.243 60 167 193 43
C34 0.122 0.085 0.052 0.025 0.248 57 172 142 4.7
C37 0.176 0.093 0.073 0.047 0315 40 146 155 1.7
A17 0.140 0.081 0.041 0.047 0.275 76. 218 207 1.0
A18 0.174 0.125 0.030 0.051 0331 39 134 216 1.1
A29 0.221 0.170 0.019 0.034 0302 50 153 165 0.9
A30 0.160 0.149 0.021 0.024 0.250 43 141 220 0.7
A33 0201 0.140 0.056 0.039 0.257 57 213 168 03
A35 0.161 0.102 0.059 0.033 0.260 63 206 180 03
A53 0.085 0.084 0.046 0.024 0.201 35 108 125 0.9
A54 0.093 0.052 0.070 0.047 0312 67 208 176 13
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